var title_f39_10_40096="Urethrocutaneous fistula";
var content_f39_10_40096=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F50774&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F50774&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Urethrocutaneous fistula",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 325px; height: 360px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Urethrocutaneous fistula caused by circumcision.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Dr. Laurence Baskin.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_10_40096=[""].join("\n");
var outline_f39_10_40096=null;
var title_f39_10_40097="Patient information: Meniere disease (The Basics)";
var content_f39_10_40097=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?42/26/43425\">",
"         Patient information: Tinnitus (ringing in the ears) (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?40/59/41905\">",
"         Patient information: Vertigo (a type of dizziness) (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?40/31/41460\">",
"         Patient information: Dizziness and vertigo (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?17/42/18082\">",
"         Patient information: Tinnitus (ringing in the ears) (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Meniere disease (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/meniere-disease-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H14147825\">",
"      <span class=\"h1\">",
"       What is Meniere disease?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Meniere disease is a condition that causes problems with balance and hearing. It is sometimes called Meniere&rsquo;s disease.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H14147840\">",
"      <span class=\"h1\">",
"       What causes Meniere disease?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Doctors think Meniere disease is caused by a build-up of fluid in the inside of the ear.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H14147855\">",
"      <span class=\"h1\">",
"       What are the symptoms of Meniere disease?",
"      </span>",
"      &nbsp;&mdash;&nbsp;People with Meniere disease have these 3 symptoms: &nbsp;",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Feeling dizzy and like they are spinning, swaying, or tilting. They might also feel like the room is moving around them. Some people feel sick (nausea) and throw up. These symptoms are known as &ldquo;vertigo.&rdquo;",
"       </li>",
"       <li>",
"        Hearing a buzzing, ringing, or hissing noise in one or both ears, called &ldquo;tinnitus.&rdquo; People with Meniere disease often say the noise sounds like listening to machinery or the inside of a seashell.",
"       </li>",
"       <li>",
"        Hearing loss &ndash; This symptom happens slowly, often over a period of 8 to 10 years.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H14147870\">",
"      <span class=\"h1\">",
"       Is there a test for Meniere disease?",
"      </span>",
"      &nbsp;&mdash;&nbsp;No. There is no test. But your doctor or nurse should be able to tell if you have it by learning about your symptoms and doing an exam.",
"     </p>",
"     <p>",
"      Your doctor might do tests to make sure you do not have a different problem. These tests might include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Balance testing &ndash; For one of these tests, you will have small devices called &ldquo;electrodes&rdquo; put near your eyes to measure your eye movements while you move your head and eyes. For other tests, you sit in a special chair that spins, or you stand on a platform that moves. Special devices measure how your body responds to the movements.",
"       </li>",
"       <li>",
"        A hearing test (also called &ldquo;audiometry&rdquo;)",
"       </li>",
"       <li>",
"        Blood tests",
"       </li>",
"       <li>",
"        An MRI of the head &ndash; This is an imaging test that allows the doctor to see parts of your brain.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H14147885\">",
"      <span class=\"h1\">",
"       Is there anything I can do on my own to feel better?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. You might feel better if you avoid eating and drinking things that make your symptoms worse. These things can include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Salt and salty foods",
"       </li>",
"       <li>",
"        Monosodium glutamate (also called &ldquo;MSG&rdquo;) &ndash; This is a substance sometimes added to certain foods (such as Chinese food and packaged foods) to make them taste better.",
"       </li>",
"       <li>",
"        Coffee, tea, sodas, or other drinks that have caffeine in them",
"       </li>",
"       <li>",
"        Alcohol",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      You should also stop smoking, if you smoke.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H14147900\">",
"      <span class=\"h1\">",
"       How is Meniere disease treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Treatments include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Medicines to treat dizziness and nausea",
"       </li>",
"       <li>",
"        Medicines to help with fluid or swelling in the ear",
"       </li>",
"       <li>",
"        A hearing aid",
"       </li>",
"       <li>",
"        Special exercises to help with your balance &ndash; Your doctor might refer to you to a physical therapist (exercise expert) to teach you these exercises.",
"       </li>",
"       <li>",
"        Medicines that go into your ear &ndash; These are given as an injection (shot). Your doctor might recommend these if medicines taken in pill form do not work. &nbsp;",
"       </li>",
"       <li>",
"        Surgery &ndash; Your doctor might recommend surgery if your symptoms are so bad that you are not able to drive, work, or do active things you used to be able to do. But surgery might make your hearing worse.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Some patients say that they feel better taking special vitamins or herbal treatments. But there are no studies that prove these treatments are helpful, and some may be costly.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H14147915\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?40/59/41905?source=see_link\">",
"       Patient information: Vertigo (a type of dizziness) (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?42/26/43425?source=see_link\">",
"       Patient information: Tinnitus (ringing in the ears) (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?17/42/18082?source=see_link\">",
"       Patient information: Tinnitus (ringing in the ears) (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?40/31/41460?source=see_link\">",
"       Patient information: Dizziness and vertigo (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"mobipreview.htm?39/10/40097?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 83065 Version 2.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-122.72.80.101-9C98E7F444-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_10_40097=[""].join("\n");
var outline_f39_10_40097=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14147825\">",
"      What is Meniere disease?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14147840\">",
"      What causes Meniere disease?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14147855\">",
"      What are the symptoms of Meniere disease?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14147870\">",
"      Is there a test for Meniere disease?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14147885\">",
"      Is there anything I can do on my own to feel better?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14147900\">",
"      How is Meniere disease treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14147915\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?40/31/41460?source=related_link\">",
"      Patient information: Dizziness and vertigo (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?17/42/18082?source=related_link\">",
"      Patient information: Tinnitus (ringing in the ears) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?42/26/43425?source=related_link\">",
"      Patient information: Tinnitus (ringing in the ears) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?40/59/41905?source=related_link\">",
"      Patient information: Vertigo (a type of dizziness) (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f39_10_40098="Three types of TSHR antibodies";
var content_f39_10_40098=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F71144&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F71144&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 493px\">",
"   <div class=\"ttl\">",
"    Three types of TSH receptor antibodies",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 473px; height: 284px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This figure illustrates the three types of TSHR antibodies present in autoimmune thyroid disease: stimulating, blocking, and neutral.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Latif R, Morshed SA, Zaidi M, Davies TF. The thyroid-stimulating hormone receptor: impact of thyroid-stimulating hormone and thyroid-stimulating hormone receptor antibodies on multimerization, cleavage, and signaling. Endocrinol Metab Clin North Am. 2009; 38:319.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_10_40098=[""].join("\n");
var outline_f39_10_40098=null;
var title_f39_10_40099="MRA of cerebral AVM";
var content_f39_10_40099=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F75369&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F75369&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Magnetic resonance angiogram of a frontotemporal arteriovenous malformation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 281px; height: 364px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <p>",
"     Magnetic resonance angiogram in a thirteen-year-old girl with hemiparesis showing a large right frontotemporal arteriovenous malformation with arterial feeders and nidus (upper arrows) and the large venous drainer (lower arrows).",
"    </p>",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_10_40099=[""].join("\n");
var outline_f39_10_40099=null;
var title_f39_10_40100="Pre post exstrophy";
var content_f39_10_40100=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F68809&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F68809&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 574px\">",
"   <div class=\"ttl\">",
"    Preoperative and postoperative pictures of a male infant with bladder exstrophy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 554px; height: 374px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Photographs showing frontal view of a male infant with bladder exstrophy prior to repair as a newborn and several weeks following complete primary repair of bladder exstrophy.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of: Dr. Joseph Borer.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_10_40100=[""].join("\n");
var outline_f39_10_40100=null;
var title_f39_10_40101="Steroidogenic pathways";
var content_f39_10_40101=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F79609&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F79609&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Adrenal steroidogenesis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 402px; height: 626px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     <strong>",
"      CYP11A:",
"     </strong>",
"     cholesterol side chain cleavage enzyme P450scc; 20-hydroxylase, 22-hydroxylase, and 20,22-lyase.",
"     <br>",
"      <strong>",
"       CYP17:",
"      </strong>",
"      P450c17; 17-alpha-hydroxylase and 17,20-lyase.",
"      <br>",
"       <strong>",
"        3",
"        <sub>",
"         &beta;",
"        </sub>",
"        HSD:",
"       </strong>",
"       3 beta-hydroxysteroid dehydrogenase.",
"       <br>",
"        <strong>",
"         CYP21:",
"        </strong>",
"        P450c21; 21-hydroxylase.",
"        <br>",
"         <strong>",
"          CYP11B1:",
"         </strong>",
"         P450c11; 11 beta-hydroxylase.",
"         <br>",
"          <strong>",
"           CYP11B2:",
"          </strong>",
"          P450aldo (aldosterone synthase); 18-hydroxylase (corticosterone methyl oxidase I, CMOI) and 18-dehydrogenase (CMOII).",
"         </br>",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_10_40101=[""].join("\n");
var outline_f39_10_40101=null;
var title_f39_10_40102="Kanamycin: Drug information";
var content_f39_10_40102=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"15\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Kanamycin: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?35/13/36051?source=see_link\">",
"    see \"Kanamycin: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708960\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F185648\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antibiotic, Aminoglycoside",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F185622\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Dosing should be based on ideal body weight",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Susceptible systemic infections:",
"     </b>",
"     I.M., I.V.: 5-7.5 mg/kg/dose in divided doses every 8-12 hours (&lt;15 mg/kg/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Following surgical contamination, peritonitis:",
"     </b>",
"     Intraperitoneal: 500 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Irrigating solution:",
"     </b>",
"     0.25%; maximum 1.5 g/day (via all administration routes)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Aerosol:",
"     </b>",
"     250 mg 2-4 times/day",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F185638\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Dosing should be based on ideal body weight",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Infections: I.M., I.V.: 15 mg/kg/day in divided doses every 8-12 hours",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F185623\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     I.M., I.V.: Initial dose should be 5-7.5 mg/kg based on ideal body weight (except in obese patients); maintenance dose and interval should be adjusted for estimated renal function; dosing interval in most older patients is every 12-24 hours (see Dosing in Renal Impairment).",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F185624\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Adults: I.V.: The following adjustments have been recommended (Aronoff, 2007).",
"     <b>",
"      Note:",
"     </b>",
"     Renally adjusted dose recommendations are based on a dose of 7.5 mg/kg every 12 hours.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &gt;50 mL/minute: Administer every 12-24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     10-50 mL/minute: Administer every 24-72 hours; monitor levels.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;10 mL/minute: Administer every 48-72 hours; monitor levels.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Intermittent hemodialysis (IHD): One-half the dose administered after hemodialysis on dialysis days.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Peritoneal dialysis (PD): Administration via PD fluid: 15-20 mg/L/day of PD fluid",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Continuous renal replacement therapy (CRRT): Administer every 24-72 hours; monitor levels.",
"     <b>",
"      Note:",
"     </b>",
"     Drug clearance is highly dependent on the method of renal replacement, filter type, and flow rate. Appropriate dosing requires close monitoring of pharmacologic response, signs of adverse reactions due to drug accumulation, as well as drug concentrations in relation to target trough (if appropriate).",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F16144918\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F185597\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, as sulfate: 1 g/3 mL (3 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F185582\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F185601\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     I.M.: Administer deeply in upper outer quadrant of the gluteal muscle.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     I.V.: Infuse over 30-60 minutes.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Some penicillins (eg, carbenicillin, ticarcillin and piperacillin) have been shown to inactivate aminoglycosides",
"     <i>",
"      in vitro",
"     </i>",
"     . This has been observed to a greater extent with tobramycin and gentamicin, while amikacin has shown greater stability against inactivation. Concurrent use of these agents may pose a risk of reduced antibacterial efficacy",
"     <i>",
"      in vivo",
"     </i>",
"     , particularly in the setting of profound renal impairment. However, definitive clinical evidence is lacking. If combination penicillin/aminoglycoside therapy is desired in a patient with renal dysfunction, separation of doses (if feasible), and routine monitoring of aminoglycoside levels, CBC, and clinical response should be considered.",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F185654\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     W, D",
"     <sub>",
"      10",
"     </sub>",
"     W, LR, NS.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Cyclophosphamide, cyclosporine, heparin, heparin with hydrocortisone sodium succinate, hydromorphone, magnesium sulfate, meperidine, morphine, oxytocin, potassium chloride, vitamin B complex with C.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Furosemide.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Compatible:",
"     </b>",
"     Penicillin G sodium.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Ampicillin, heparin.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Cloxacillin.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F185600\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of serious infections caused by susceptible strains of",
"     <i>",
"      E. coli",
"     </i>",
"     ,",
"     <i>",
"      Proteus",
"     </i>",
"     species,",
"     <i>",
"      Enterobacter aerogenes",
"     </i>",
"     ,",
"     <i>",
"      Klebsiella pneumoniae",
"     </i>",
"     ,",
"     <i>",
"      Serratia marcescens",
"     </i>",
"     , and",
"     <i>",
"      Acinetobacter",
"     </i>",
"     species; second-line treatment of",
"     <i>",
"      Mycobacterium tuberculosis",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F185656\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Kanamycin may be confused with Garamycin&reg;, gentamicin",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F185646\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Edema",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Neurotoxicity, drowsiness, headache, pseudomotor cerebri",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Skin itching, redness, rash, photosensitivity, erythema",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Nausea, vomiting, diarrhea, malabsorption syndrome (with prolonged and high-dose therapy of hepatic coma), anorexia, weight loss, salivation increased, enterocolitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Granulocytopenia, agranulocytosis, thrombocytopenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Burning, stinging",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Weakness, tremor, muscle cramps",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Otic: Ototoxicity (auditory), ototoxicity (vestibular)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: Nephrotoxicity",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Dyspnea",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F185604\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to kanamycin, any component of the formulation, or other aminoglycosides; pregnancy",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F185586\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Nephrotoxicity:",
"     <b>",
"      [U.S. Boxed Warning]: May cause nephrotoxicity;",
"     </b>",
"     usual risk factors include pre-existing renal impairment, concomitant nephrotoxic medications, advanced age, and dehydration. Discontinue treatment if signs of nephrotoxicity occur; renal damage is usually reversible.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Neuromuscular blockade and respiratory paralysis: May cause neuromuscular blockade and respiratory paralysis, especially when given soon after anesthesia or muscle relaxants.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Neurotoxicity:",
"     <b>",
"      [U.S. Boxed Warning]: May cause neurotoxicity;",
"     </b>",
"     usual risk factors include pre-existing renal impairment, concomitant neuro-/nephrotoxic medications, advanced age, and dehydration. Ototoxicity is proportional to the amount of drug given and the duration of treatment. Tinnitus or vertigo may be indications of vestibular injury and impending bilateral irreversible damage.  Discontinue treatment if signs of ototoxicity occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Superinfection: Prolonged use may result in fungal or bacterial superinfection, including",
"     <i>",
"      C. difficile",
"     </i>",
"     -associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hearing impairment: Use with caution in patients with pre-existing vertigo, tinnitus, or hearing loss.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypocalcemia: Use with caution in patients with hypocalcemia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Neuromuscular disorders: Use with caution in patients with neuromuscular disorders, including myasthenia gravis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with pre-existing renal insufficiency; dosage modification required.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Long-term use: Not intended for long-term therapy due to toxic hazards associated with extended administration.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299553\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F185591\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AbobotulinumtoxinA: Aminoglycosides may enhance the neuromuscular-blocking effect of AbobotulinumtoxinA.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphotericin B: May enhance the nephrotoxic effect of Aminoglycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Antibiotics may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bisphosphonate Derivatives: Aminoglycosides may enhance the hypocalcemic effect of Bisphosphonate Derivatives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Capreomycin: May enhance the neuromuscular-blocking effect of Aminoglycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CARBOplatin: Aminoglycosides may enhance the ototoxic effect of CARBOplatin. Especially with higher doses of carboplatin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiac Glycosides: Aminoglycosides may decrease the serum concentration of Cardiac Glycosides. This effect has only been demonstrated with oral aminoglycoside administration.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cephalosporins (2nd Generation): May enhance the nephrotoxic effect of Aminoglycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cephalosporins (3rd Generation): May enhance the nephrotoxic effect of Aminoglycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cephalosporins (4th Generation): May enhance the nephrotoxic effect of Aminoglycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CISplatin: May enhance the nephrotoxic effect of Aminoglycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Colistimethate: Aminoglycosides may enhance the nephrotoxic effect of Colistimethate. Aminoglycosides may enhance the neuromuscular-blocking effect of Colistimethate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): Aminoglycosides may enhance the nephrotoxic effect of CycloSPORINE (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gallium Nitrate: Aminoglycosides may enhance the nephrotoxic effect of Gallium Nitrate.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Loop Diuretics: May enhance the adverse/toxic effect of Aminoglycosides. Specifically, nephrotoxicity and ototoxicity.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Neuromuscular-Blocking Agents: Aminoglycosides may enhance the respiratory depressant effect of Neuromuscular-Blocking Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: May decrease the excretion of Aminoglycosides. Data only in premature infants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     OnabotulinumtoxinA: Aminoglycosides may enhance the neuromuscular-blocking effect of OnabotulinumtoxinA.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Penicillins: May decrease the serum concentration of Aminoglycosides. Primarily associated with extended spectrum penicillins, and patients with renal dysfunction.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Amoxicillin; Ampicillin; Cloxacillin; Dicloxacillin; Nafcillin; Oxacillin; Penicillin G (Parenteral/Aqueous); Penicillin G Benzathine; Penicillin G Procaine; Penicillin V Potassium.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RimabotulinumtoxinB: Aminoglycosides may enhance the neuromuscular-blocking effect of RimabotulinumtoxinB.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents.  Use of this vaccine should be postponed until at least 24 hours after cessation of antibacterial agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vancomycin: May enhance the nephrotoxic effect of Aminoglycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F185593\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F185607\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hearing impairment in the offspring was observed following maternal use of kanamycin in animal studies; teratogenic events were not reported. Kanamycin crosses the placenta and produces detectable serum levels in the fetus. Because of several reports of total irreversible bilateral congenital deafness in children whose mothers received another aminoglycoside (streptomycin) during pregnancy, kanamycin has been classified by the manufacturer as pregnancy risk category D. There is also one case report of hearing impairment in a child with prenatal exposure to kanamycin.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F185627\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/not recommended (AAP rates \"compatible\"; AAP 2001 update pending)",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F185608\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Kanamycin is excreted into breast milk in minute amounts and breast-feeding is not recommended by the manufacturer; however, kanamycin is not well absorbed when taken orally. This limited oral absorption may minimize exposure to the nursing infant. Nondose-related effects could include modification of bowel flora.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F185595\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Serum creatinine and BUN every 2-3 days; peak and trough concentrations; hearing",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Some penicillin derivatives may accelerate the degradation of aminoglycosides",
"     <i>",
"      in vitro",
"     </i>",
"     . This may be clinically-significant for certain penicillin (ticarcillin, piperacillin, carbenicillin) and aminoglycoside (gentamicin, tobramycin) combination therapy in patients with significant renal impairment. Close monitoring of aminoglycoside levels is warranted.",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F185598\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Therapeutic: Peak: 15-30 mcg/mL; Trough: 5-10 mcg/mL; Toxic: Peak: &gt;35 mcg/mL; Trough: &gt;10 mcg/mL",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F185609\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Cristalomicina (AR);",
"     </li>",
"     <li>",
"      Kamycine (FR);",
"     </li>",
"     <li>",
"      Kan-Ophtal (DE);",
"     </li>",
"     <li>",
"      Kana-Stulln (DE);",
"     </li>",
"     <li>",
"      Kanacet (IT);",
"     </li>",
"     <li>",
"      Kanacin (KP);",
"     </li>",
"     <li>",
"      Kanacolirio (ES);",
"     </li>",
"     <li>",
"      Kanacyn (BE, LU, PK);",
"     </li>",
"     <li>",
"      Kanafil (IT);",
"     </li>",
"     <li>",
"      Kanafluid (ES);",
"     </li>",
"     <li>",
"      Kanahidro (ES);",
"     </li>",
"     <li>",
"      Kanamicin (HR);",
"     </li>",
"     <li>",
"      Kanamicina Firma (IT);",
"     </li>",
"     <li>",
"      Kanamycin Capsules Meiji (TH);",
"     </li>",
"     <li>",
"      Kanamycin Meiji (HK, PH, TW);",
"     </li>",
"     <li>",
"      Kanamycin Sanbe (ID);",
"     </li>",
"     <li>",
"      Kanamycin-POS (DE);",
"     </li>",
"     <li>",
"      Kanamytrex (DE);",
"     </li>",
"     <li>",
"      Kananovo (ES);",
"     </li>",
"     <li>",
"      Kanapiam Orale (IT);",
"     </li>",
"     <li>",
"      Kanaplus (ES);",
"     </li>",
"     <li>",
"      Kanaqua (ES);",
"     </li>",
"     <li>",
"      Kanarco (ID);",
"     </li>",
"     <li>",
"      Kanasig (AU);",
"     </li>",
"     <li>",
"      Kanatrol (IT);",
"     </li>",
"     <li>",
"      Kancin (IN, MY, PH, TH);",
"     </li>",
"     <li>",
"      Kancin-L (SG);",
"     </li>",
"     <li>",
"      Kanescin (ES);",
"     </li>",
"     <li>",
"      Kannasyn (GB, IE);",
"     </li>",
"     <li>",
"      Kano (IT);",
"     </li>",
"     <li>",
"      Kantrex (BF, BJ, CI, ES, ET, GH, GM, GN, KE, LR, MA, ML, MR, MU, MW, MX, NE, NG, PE, SC, SD, SL, SN, TN, TZ, UG, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      Keimicina (IT);",
"     </li>",
"     <li>",
"      Visiokan (IT)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F185585\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Interferes with protein synthesis in bacterial cell by binding to ribosomal subunit",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F185603\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.M.: Rapid",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral: Minimal",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : ~0.3 L/kg:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Relative diffusion from blood into CSF: Good only with inflammation (exceeds usual MICs)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     CSF:blood level ratio: Normal meninges: Nil; Inflamed meninges: 43%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 0%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 2-4 hours; Anuria: 80 hours; End-stage renal disease: 40-96 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, serum: I.M.: 1-2 hours (decreased in burn patients)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (as unchanged drug)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics Committee on Drugs, \"Transfer of Drugs and Other Chemicals Into Human Milk,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2001, 108(3):776-89.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/10/40102/abstract-text/11533352/pubmed\" id=\"11533352\" target=\"_blank\">",
"        11533352",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Begg EJ and Barclay ML, &ldquo;Aminoglycosides - 50 Years On,&rdquo;",
"      <i>",
"       Br J Clin Pharmacol",
"      </i>",
"      , 1995, 39(6):597-603.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/10/40102/abstract-text/7654476/pubmed\" id=\"7654476\" target=\"_blank\">",
"        7654476",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chow MS, Quintiliani R, and Nightingale CH, &rdquo;",
"      <i>",
"       In Vivo",
"      </i>",
"      Inactivation of Tobramycin by Ticarcillin. A Case Report,\"",
"      <i>",
"       JAMA",
"      </i>",
"      , 1982, 247(5):658-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/10/40102/abstract-text/6798229/pubmed\" id=\"6798229\" target=\"_blank\">",
"        6798229",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cunha BA, &ldquo;Aminoglycosides: Current Role in Antimicrobial Therapy,&rdquo;",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 1988, 8(6):334-50.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/10/40102/abstract-text/3146747/pubmed\" id=\"3146747\" target=\"_blank\">",
"        3146747",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Daly JS, Dodge RA, Glew RH, et al, &ldquo;Effect of Time and Temperature on Inactivation of Aminoglycosides by Ampicillin at Neonatal Dosages,&rdquo;",
"      <i>",
"       J Perinatol",
"      </i>",
"      , 1997, 17(1):42-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/10/40102/abstract-text/9069064/pubmed\" id=\"9069064\" target=\"_blank\">",
"        9069064",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dowell JA, Korth-Bradley J, Milisci M, et al, &ldquo;Evaluating Possible Pharmacokinetic Interactions Between Tobramycin, Piperacillin, and a Combination of Piperacillin and Tazobactam in Patients With Various Degrees of Renal Impairment,&rdquo;",
"      <i>",
"       J Clin Pharmacol",
"      </i>",
"      , 2001, 41(9):979-86.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/10/40102/abstract-text/11549103/pubmed\" id=\"11549103\" target=\"_blank\">",
"        11549103",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Drugs for Tuberculosis,&rdquo;",
"      <i>",
"       Med Lett Drugs Ther",
"      </i>",
"      , 1993, 35(908):99-101.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/10/40102/abstract-text/8412982/pubmed\" id=\"8412982\" target=\"_blank\">",
"        8412982",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Edson RS and Terrell CL, &ldquo;The Aminoglycosides,&rdquo;",
"      <i>",
"       Mayo Clin Proc",
"      </i>",
"      , 1999, 74(5):519-28.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/10/40102/abstract-text/10319086/pubmed\" id=\"10319086\" target=\"_blank\">",
"        10319086",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Farchione LA, &ldquo;Inactivation of Aminoglycosides by Penicillins,&rdquo;",
"      <i>",
"       J Antimicrob Chemother",
"      </i>",
"      , 1982, 8(Suppl A):27-36.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fuchs PC, Stickel S, Anderson PH, et al, &ldquo;",
"      <i>",
"       In Vitro",
"      </i>",
"      Inactivation of Aminoglycosides by Sulbactam, Other Beta-Lactams, and Sulbactam-Beta-Lactam Combinations,&rdquo;",
"      <i>",
"       Antimicrob Agents Chemother",
"      </i>",
"      , 1991, 35(1):182-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/10/40102/abstract-text/2014975/pubmed\" id=\"2014975\" target=\"_blank\">",
"        2014975",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Halstenson CE, Wong MO, Herman CS, et al, &ldquo;Effect of Concomitant Administration of Piperacillin on the Dispositions on Isepamicin and Gentamicin in Patients With End-Stage Renal Disease,&rdquo;",
"      <i>",
"       Antimicrob Agents Chemother",
"      </i>",
"      , 1992, 36(9):1832-36.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/10/40102/abstract-text/1416875/pubmed\" id=\"1416875\" target=\"_blank\">",
"        1416875",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hitt CM, Patel KB, Nicolau DP, et al, &ldquo;Influence of Piperacillin-Tazobactam on Pharmacokinetics of Gentamicin Given Once Daily,&rdquo;",
"      <i>",
"       Am J Health Syst Pharm",
"      </i>",
"      , 1997, 54(23):2704-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/10/40102/abstract-text/9408514/pubmed\" id=\"9408514\" target=\"_blank\">",
"        9408514",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Iseman MD, &ldquo;Treatment of Multidrug-Resistant Tuberculosis,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1993, 329(11):784-91.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/10/40102/abstract-text/8350889/pubmed\" id=\"8350889\" target=\"_blank\">",
"        8350889",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Konishi H, Goto M, Nakamoto Y, et al, &ldquo;Tobramycin Inactivation by Carbenicillin, Ticarcillin, and Piperacillin,&rdquo;",
"      <i>",
"       Antimicrob Agents Chemother",
"      </i>",
"      , 1983, 23(5):653-57.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/10/40102/abstract-text/6223576/pubmed\" id=\"6223576\" target=\"_blank\">",
"        6223576",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kristensen M, Molholm HJ, Kampmann J, et al, &ldquo;Letter: Drug Elimination and Renal Function,&rdquo;",
"      <i>",
"       J Clin Pharmacol",
"      </i>",
"      , 1974, 14(5-6):307-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/10/40102/abstract-text/4829522/pubmed\" id=\"4829522\" target=\"_blank\">",
"        4829522",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lau A, Lee M, Flascha S, et al, &ldquo;Effect of Piperacillin on Tobramycin Pharmacokinetics in Patients With Normal Renal Function,&rdquo;",
"      <i>",
"       Antimicrob Agents Chemother",
"      </i>",
"      , 1983, 24(4):533-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/10/40102/abstract-text/6651279/pubmed\" id=\"6651279\" target=\"_blank\">",
"        6651279",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Russoe ME and Atkins-Thor E, &ldquo;Gentamicin and Ticarcillin in Subjects With End-Stage Renal Disease. Comparison of Two Assay Methods and Evaluation of Inactivation Rate,&rdquo;",
"      <i>",
"       Clin Nephrol",
"      </i>",
"      , 1981, 15(4):175-80.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/10/40102/abstract-text/7237864/pubmed\" id=\"7237864\" target=\"_blank\">",
"        7237864",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Thompson MIB, Russo ME, Saxon BJ, et al, &ldquo;Gentamicin Inactivation by Piperacillin or Carbenicillin in Patients With End-Stage Renal Disease,&rdquo;",
"      <i>",
"       Antimicrob Agents Chemother",
"      </i>",
"      , 1982, 21(2):268-73.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/10/40102/abstract-text/6462107/pubmed\" id=\"6462107\" target=\"_blank\">",
"        6462107",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Viollier AF, Standiford HC, Drusano GL, et al, &ldquo;Comparative Pharmacokinetics and Serum Bactericidal Activity of Mezlocillin, Ticarcillin and Piperacillin, With and Without Gentamicin,&rdquo;",
"      <i>",
"       J Antimicrob Chemother",
"      </i>",
"      , 1985, 15(5):597-606.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/10/40102/abstract-text/4008387/pubmed\" id=\"4008387\" target=\"_blank\">",
"        4008387",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Vozeh S, Schmidlin O, and Taeschner W, &ldquo;Pharmacokinetic Drug Data,&rdquo;",
"      <i>",
"       Clin Pharmacokinetics",
"      </i>",
"      , 1988, 15(4):254-82.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/10/40102/abstract-text/3191648/pubmed\" id=\"3191648\" target=\"_blank\">",
"        3191648",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Walterspiel JN, Feldman S, Van R, et al, &ldquo;Comparative Inactivation of Isepamicin, Amikacin, and Gentamicin by Nine Beta-Lactams and Two Beta-Lactamase Inhibitors, Cilastatin and Heparin,&rdquo;",
"      <i>",
"       Antimicrob Agents Chemother",
"      </i>",
"      , 1991, 35(9):1875-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/10/40102/abstract-text/1952861/pubmed\" id=\"1952861\" target=\"_blank\">",
"        1952861",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Yasuhara H, Kobayashi S, Sakamoto K, et al, &ldquo;Pharmacokinetics of Amikacin and Cephalothin in Bedridden Elderly Patients,&rdquo;",
"      <i>",
"       J Clin Pharmacol",
"      </i>",
"      , 1982, 22(8-9):403-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/10/40102/abstract-text/7130429/pubmed\" id=\"7130429\" target=\"_blank\">",
"        7130429",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8587 Version 37.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-197.136.42.3-293D88DB16-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_10_40102=[""].join("\n");
var outline_f39_10_40102=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708960\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F185648\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F185622\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F185638\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F185623\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F185624\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16144918\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F185597\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F185582\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F185601\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F185654\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F185600\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F185656\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F185646\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F185604\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F185586\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299553\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F185591\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F185593\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F185607\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F185627\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F185608\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F185595\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F185598\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F185609\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F185585\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F185603\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8587\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8587|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?35/13/36051?source=related_link\">",
"      Kanamycin: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f39_10_40103="Uterine and hypogastric artery ligation";
var content_f39_10_40103=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F83009&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F83009&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Uterine and hypogastric artery ligation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 438px; height: 633px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Surgical treatment of atonic uterine hemorrhage.",
"    <br/>",
"    (A) Ligation of the uterine artery. The artery crosses over the ureter and is ligated beyond this point at the uterine corpus.",
"    <br/>",
"    (B) Hypogastric artery ligation. Ligation of the anterior division of the internal iliac artery is performed after careful identification and retraction of the ureter, which usually overlies the bifurcation of the iliac artery into the external and internal iliac branches.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Beckmann CRB, Ling FW, Laube DW, et al. Obstetrics and Gynecology, 4th ed, Lippincott Williams &amp; Wilkins, Baltimore 2002. Copyright &copy; 2002 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_10_40103=[""].join("\n");
var outline_f39_10_40103=null;
var title_f39_10_40104="Prevention of hepatitis B virus infection in the HIV-infected adult";
var content_f39_10_40104=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Prevention of hepatitis B virus infection in the HIV-infected adult",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/10/40104/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/10/40104/contributors\">",
"     Barbara H McGovern, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/10/40104/contributors\">",
"     Kenneth E Sherman, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/10/40104/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/10/40104/contributors\">",
"     David Thomas, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/10/40104/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/10/40104/contributors\">",
"     Allyson Bloom, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?39/10/40104/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 5, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H2121100\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;HIV-infected patients are at risk for hepatitis B virus (HBV) infection due to shared routes of transmission (eg, sexual transmission, injection drug use) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/10/40104/abstract/1\">",
"     1",
"    </a>",
"    ]. HIV-infected individuals are also less likely to clear acute HBV infection and are at increased risk of development of chronic infection, cirrhosis, and end-stage liver disease than HIV-seronegative patients who acquire HBV as adults [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/10/40104/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]. Routine screening and immunization is therefore recommended for all HIV-infected adults to prevent primary HBV infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/10/40104/abstract/5-9\">",
"     5-9",
"    </a>",
"    ]. However, the immune response to HBV vaccine is generally lower among HIV-infected patients compared with uninfected patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/10/40104/abstract/10-12\">",
"     10-12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic will address the prevention of hepatitis B and the various trials that have been conducted to optimize the immunogenicity of HBV vaccine in the HIV-infected host. The epidemiology, clinical manifestations, and evaluation for treatment in the",
"    <span class=\"nowrap\">",
"     HIV/HBV",
"    </span>",
"    coinfected patient are found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/51/16185?source=see_link\">",
"     \"Treatment of hepatitis B in the HIV-infected patient\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/55/7033?source=see_link\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of hepatitis B in the HIV-infected patient\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/63/44020?source=see_link\">",
"     \"Evaluation of chronic hepatitis B virus infection in the HIV-infected patient\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/22/37223?source=see_link\">",
"     \"Antiviral medications for the treatment of hepatitis B in the HIV-infected patient\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/62/6119?source=see_link\">",
"     \"Monitoring the HIV-infected patient with chronic hepatitis B virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9249266\">",
"    <span class=\"h1\">",
"     GENERAL BACKGROUND",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2121445\">",
"    <span class=\"h2\">",
"     Serologic screening",
"    </span>",
"    &nbsp;&mdash;&nbsp;All HIV-infected patients should have serologic testing for HBV infection and HBV vaccination should be offered to patients who have no evidence of prior exposure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/10/40104/abstract/5,13\">",
"     5,13",
"    </a>",
"    ]. Clinicians should obtain assays for hepatitis B surface antigen (HBsAg) and antibodies to hepatitis B surface antigen (anti-HBs). This serologic panel will identify most patients who have either chronic infection, resolved infection, or no evidence of prior infection. Some experts believe that important information can be obtained from testing for hepatitis B core antigen (anti-HBc) as well [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/10/40104/abstract/14\">",
"     14",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H307731\">",
"     'Management of patients with isolated anti-HB core antibody'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    HBsAg is the serologic hallmark of active HBV infection. Patients with concomitant IgM antibodies to core antigen have acute HBV infection (ie, anti-HBc IgM). Among patients who resolve their HBV infection spontaneously, the disappearance of HBsAg is followed by the appearance of hepatitis B core antibody (anti-HBc IgG) and hepatitis B surface antibody (anti-HBs). In contrast, persons who have evidence of HBsAg persisting for six months accompanied by anti-HBc IgG, with or without HBV DNA, have chronic HBV infection. Patients with chronic hepatitis should be fully evaluated. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/63/44020?source=see_link\">",
"     \"Evaluation of chronic hepatitis B virus infection in the HIV-infected patient\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    HIV-infected patients who have no evidence of these serologic markers are candidates for HBV immunization. Patients who are anti-HBc and anti-HBs-positive have resolved infection and do not need immunization against HBV infection. Patients who are anti-HBc-negative and anti-HBs-positive were vaccinated in the past. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/18/42279?source=see_link\">",
"     \"Serologic diagnosis of hepatitis B virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An anti-HBs level greater than 10",
"    <span class=\"nowrap\">",
"     IU/L",
"    </span>",
"    is consistent with seroprotection from prior immunization. (See",
"    <a class=\"local\" href=\"#H2121480\">",
"     'Surrogate markers of protection'",
"    </a>",
"    below.) Patients with a surface antibody less than 10",
"    <span class=\"nowrap\">",
"     IU/L",
"    </span>",
"    should be considered for a booster dose of HBV vaccine if risk exposures are anticipated. (See",
"    <a class=\"local\" href=\"#H16830405\">",
"     'Waning immunity'",
"    </a>",
"    below.) Detection of anti-HBs (without reporting a titer) does not confirm protection since some antibody assays detect levels less than 10",
"    <span class=\"nowrap\">",
"     IU/mL.",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H307083\">",
"    <span class=\"h2\">",
"     Isolated hepatitis B core antibody",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients whose only marker for HBV is anti-HBc have a serologic pattern referred to as &ldquo;isolated hepatitis B core antibody&rdquo;, which is discussed in detail below. (See",
"    <a class=\"local\" href=\"#H307731\">",
"     'Management of patients with isolated anti-HB core antibody'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H307075\">",
"    <span class=\"h2\">",
"     Testing for other hepatitis viruses",
"    </span>",
"    &nbsp;&mdash;&nbsp;HIV-infected patients should be tested for hepatitis A and hepatitis C antibodies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/10/40104/abstract/5\">",
"     5",
"    </a>",
"    ]. Patients who are not immune to hepatitis A (ie, anti-HAV IgG negative) should be immunized; patients who are HCV-seropositive should be evaluated for active liver disease. There is no available vaccine against hepatitis C infection. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/25/37273?source=see_link\">",
"     \"Immunizations in HIV-infected patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/36/11848?source=see_link\">",
"     \"Evaluation of the HIV-infected patient with chronic hepatitis C virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2121452\">",
"    <span class=\"h1\">",
"     VACCINE FORMULATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recombinant vaccines include Recombivax HB and Engerix-B (yeast-derived vaccines used mainly in the United States) and GenHevac B (mammalian cell-derived vaccine used mainly in Europe). The first two vaccines include the S antigen while the latter vaccine includes the S and pre-S2 antigens.",
"   </p>",
"   <p>",
"    The approved dosing schedules are the same and include three doses at 0, 1 and 6 months, which are given intramuscularly. The adult dosing formulations vary: the Recombivax HB dosage is 10",
"    <span class=\"nowrap\">",
"     mcg/mL;",
"    </span>",
"    the Engerix-B vaccine dosage is 20",
"    <span class=\"nowrap\">",
"     mcg/mL;",
"    </span>",
"    and the GenHevac B vaccine is 20",
"    <span class=\"nowrap\">",
"     mcg/mL.",
"    </span>",
"    The Energix-B vaccine is also available in a 40",
"    <span class=\"nowrap\">",
"     mcg/mL",
"    </span>",
"    dose, approved for use in renal dialysis patients in the US. If the combined hepatitis A and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/36/27207?source=see_link\">",
"     hepatitis B vaccine",
"    </a>",
"    (ie, Twinrix&reg;) is used, give three doses at zero, one, and six months; alternatively, a four-dose Twinrix&reg; schedule, administered on days 0, 7, and 21-30 followed by a booster dose at month 12 may be used.",
"   </p>",
"   <p>",
"    The efficacy of recombinant vaccines in HIV seronegative patients is greater than 90 percent, regardless of formulation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/10/40104/abstract/15-17\">",
"     15-17",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/60/31690?source=see_link\">",
"     \"Hepatitis B virus vaccination\"",
"    </a>",
"    .) By contrast, vaccine responses are generally suboptimal in HIV-infected patients. Thus, most studies have used formulations with 20",
"    <span class=\"nowrap\">",
"     mcg/mL",
"    </span>",
"    per dose. (See",
"    <a class=\"local\" href=\"#H4957169\">",
"     'Vaccine efficacy with standard dosing'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2121480\">",
"    <span class=\"h1\">",
"     SURROGATE MARKERS OF PROTECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A level of protective antibody (ie, anti-HBs) greater than 10",
"    <span class=\"nowrap\">",
"     IU/L,",
"    </span>",
"    is generally accepted as a surrogate marker of protection against HBV infection in the general population. However, higher antibody titers are generally desired since antibody levels decline over time and lower levels may negatively affect clinical outcomes among patients who do become infected after immunization.",
"   </p>",
"   <p>",
"    One observational study demonstrated the importance of this minimal threshold of protection in HIV-infected patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/10/40104/abstract/18\">",
"     18",
"    </a>",
"    ]. Among 409 vaccinees with anti-HBs less than 10",
"    <span class=\"nowrap\">",
"     IU/L,",
"    </span>",
"    46 (11 percent) developed acute HBV infection compared with 11 of 217 (5 percent) of vaccinees with HBsAb &ge;10",
"    <span class=\"nowrap\">",
"     IU/L",
"    </span>",
"    (hazard ratio 0.51; 95% CI 0.3-1.0). In addition, among participants who acquired acute HBV infection, 16 of 46 (35 percent) with anti-HBs levels of less than 10",
"    <span class=\"nowrap\">",
"     IU/L",
"    </span>",
"    developed chronic infection compared with 0 of 11 who had anti-HBs levels of greater than 10",
"    <span class=\"nowrap\">",
"     IU/L.",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4957169\">",
"    <span class=\"h1\">",
"     VACCINE EFFICACY WITH STANDARD DOSING",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, among healthy adults, HBV vaccine is immunogenic with seroconversion rates of &gt;90 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/10/40104/abstract/19\">",
"     19",
"    </a>",
"    ]. Compared with HIV-seronegative persons, HIV-infected patients have lower rates of seroconversion, lower titers of protective antibody, and faster rates of antibody declines after immunization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/10/40104/abstract/20-23\">",
"     20-23",
"    </a>",
"    ]. The immunogenicity of HBV vaccine has ranged widely from 18 to 72 percent among HIV-infected patients receiving a standard schedule of three doses of 20 mcg of antigen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/10/40104/abstract/20,24-26\">",
"     20,24-26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2121208\">",
"    <span class=\"h1\">",
"     RISK FACTORS FOR DECREASED VACCINE RESPONSE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H307282\">",
"    <span class=\"h2\">",
"     HIV status",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vaccine immunogenicity is directly affected by the patient&rsquo;s HIV status [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/10/40104/abstract/21,27\">",
"     21,27",
"    </a>",
"    ]. Several studies suggest that patients with ongoing HIV viremia and a CD4 cell count &lt;350",
"    <span class=\"nowrap\">",
"     cells/mm3",
"    </span>",
"    have lower seroconversion rates in response to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/36/27207?source=see_link\">",
"     hepatitis B vaccine",
"    </a>",
"    than those who have attained HIV RNA suppression on antiretroviral therapy (ART) with a robust immunologic recovery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/10/40104/abstract/24,27\">",
"     24,27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H307289\">",
"    <span class=\"h2\">",
"     Other factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Older age is also associated with lower immunologic responses. In one study of 437 HIV-infected patients, for every 10-year increase in age, the risk of not responding increased 30 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/10/40104/abstract/27\">",
"     27",
"    </a>",
"    ]. This observation has also been made among HIV seronegative persons receiving HBV vaccine who are over 40 years of age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/10/40104/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H307201\">",
"    <span class=\"h2\">",
"     Implications for timing of immunization",
"    </span>",
"    &nbsp;&mdash;&nbsp;In light of the impact of HIV parameters on vaccine immunogenicity, HBV vaccination should preferably occur before the CD4 cell count has declined (if the patient is not taking ART) or after HIV RNA suppression and immune recovery have been confirmed (in the patient starting ART).",
"   </p>",
"   <p>",
"    However, vaccination should not be deferred in the HBV-seronegative patient who is engaging in high-risk behaviors (eg, unprotected sex with a partner with chronic HBV infection) since some patients with advanced immunosuppression may still respond [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/10/40104/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H307208\">",
"    <span class=\"h2\">",
"     Effect of hepatitis C coinfection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who are HCV-seropositive have lower rates of seroconversion and lower geometric mean titers of anti-HBs after HBV vaccine compared with those who are not coinfected with hepatitis C virus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/10/40104/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. Similar observations have been made among HIV seronegative persons with occult HBV infection, which is defined as persons who have negative serologies for HBV with low levels of detectable HBV DNA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/10/40104/abstract/31\">",
"     31",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/18/42279?source=see_link&amp;anchor=H13#H13\">",
"     \"Serologic diagnosis of hepatitis B virus infection\", section on 'Occult HBV infection'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2121222\">",
"    <span class=\"h1\">",
"     STUDIES OF ALTERNATIVE VACCINE SCHEDULES",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of studies have compared alternative vaccination strategies to standard immunization in an effort to improve immunogenicity. Use of a double dose of vaccine at weeks 0, 4, 8, and 24 is associated with significantly increased immunogenicity, compared with standard dosing, as discussed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2122334\">",
"    <span class=\"h2\">",
"     Double-dose strategies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some studies in dialysis patients have suggested that a double-dose of vaccine may be more immunogenic than a standard dose in this patient population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/10/40104/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. A similar approach was undertaken in a randomized trial where 210 HIV-infected patients were assigned to the standard dosing arm (eg, Energix-B vaccine at 20 mcg at 0, 1 and 6 months) or an experimental arm of double-dose vaccine (ie, Energix-B at 40 mcg; given as two separate injections of 20 mcg) at 0, 1, and 6 months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/10/40104/abstract/25\">",
"     25",
"    </a>",
"    ]. A significantly higher seroconversion rate was seen among patients assigned to the double dose arm, but only in the subgroup of patients with a CD4 cell count of &gt;350",
"    <span class=\"nowrap\">",
"     cells/mm3.",
"    </span>",
"   </p>",
"   <p>",
"    A larger multicenter clinical trial in France was subsequently performed, which enrolled 437 HIV-infected patients with a CD4 cell count of &gt;200",
"    <span class=\"nowrap\">",
"     cells/mm3",
"    </span>",
"    to one of three arms of recombinant vaccine (GenHevac): a) three doses of standard intramuscular injections (ie, 20 mcg each) at weeks 0, 4, and 24; b) four intramuscular injections of high-dose vaccine (ie, 40 mcg each) at weeks 0, 4, 8, and 24; or c) four intradermal injections of low-dose vaccine (ie, 4 mcg) at weeks 0, 4, 8, and 24 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/10/40104/abstract/27\">",
"     27",
"    </a>",
"    ]. The following findings were observed:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The percentage of responders was significantly higher in the high-dose intramuscular and low-dose intradermal dosing arms than in the standard arm (82 and 77 percent with intramuscular and intradermal dosing, respectively, compared with 65 percent in the standard arm).",
"     </li>",
"     <li>",
"      At week 28, the geometric mean titer of antibody was significantly higher in the high-dose intramuscular and low-dose intradermal arms compared with the standard dosing arm (795",
"      <span class=\"nowrap\">",
"       mIU/mL",
"      </span>",
"      and 104",
"      <span class=\"nowrap\">",
"       mIU/mL",
"      </span>",
"      versus 55",
"      <span class=\"nowrap\">",
"       mIU/mL).",
"      </span>",
"     </li>",
"     <li>",
"      A significantly higher proportion of patients assigned to the intramuscular high-dose arm achieved early seroconversion by 12 weeks compared with the intradermal and the standard dose arms (72 percent compared with 45 and 25 percent, respectively).",
"     </li>",
"     <li>",
"      No safety concerns were raised for any of the HIV parameters studied (eg, CD4 cell count and HIV RNA).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition to earlier seroconversion, patients assigned to the high-dose intramuscular route also achieved higher levels of antibody titers; 74 percent of the patients in the high-dose intramuscular group had anti-HBs titers of 100",
"    <span class=\"nowrap\">",
"     mIU/mL",
"    </span>",
"    or greater compared with 53 percent in the intradermal arm and 40 percent in the standard arm. Higher levels of antibody after immunization are associated with greater duration of serologic protection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/10/40104/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Whether this immunization approach would be as effective in patients with HCV coinfection is unclear since only approximately 3 percent of the study population was HCV-seropositive. This vaccine strategy has also not been studied with the other available recombinant HBV vaccines.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2122218\">",
"    <span class=\"h1\">",
"     SAFETY AND ADVERSE EVENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common side effect of the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/36/27207?source=see_link\">",
"     hepatitis B vaccine",
"    </a>",
"    is discomfort at the injection site [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/10/40104/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Transient small increases in HIV RNA (eg, viral blips) have been reported with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/36/27207?source=see_link\">",
"     hepatitis B vaccine",
"    </a>",
"    and other general immunizations, such as influenza and pneumococcus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/10/40104/abstract/35\">",
"     35",
"    </a>",
"    ]; however, the clinical significance of transient viremia is unclear since clinical progression has not been reported after immunization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/10/40104/abstract/1,36\">",
"     1,36",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9459458\">",
"    <span class=\"h1\">",
"     SEROLOGIC TESTING AFTER IMMUNIZATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serologic testing, to determine if seroconversion has occurred, is not recommended in healthy individuals after HBV immunization. However, since the efficacy of HBV vaccine is impaired in HIV-infected patients, routine serologic testing after completion of the immunization series is recommended approximately two to four weeks after the last dose to assess whether the level of surface antibodies is protective (ie, &gt;10",
"    <span class=\"nowrap\">",
"     IU/L)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/10/40104/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16830405\">",
"    <span class=\"h2\">",
"     Waning immunity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Waning immunity is inferred through declining antibody titers, which are commonly seen in HIV-infected patients with immunosuppression and in other patient populations (eg, dialysis patients). In patients who have attained protective antibody titers, some specialists recommend yearly serologic testing, akin to the management of dialysis patients (who are given booster doses when anti-HBs titers decline to &lt;10",
"    <span class=\"nowrap\">",
"     IU/L).",
"    </span>",
"    Serologic testing of antibody titers is particularly important in the HIV-infected patient who:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Attains low levels of protective antibody after immunization (eg, just over 10",
"      <span class=\"nowrap\">",
"       IU/L)",
"      </span>",
"     </li>",
"     <li>",
"      Engages in high-risk behaviors (eg, shared needle use for injection drugs)",
"     </li>",
"     <li>",
"      Has a sexual partner with chronic HBV infection [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/10/40104/abstract/37\">",
"       37",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A single booster dose of vaccine may be sufficient to boost titers to protective levels in patients who were prior responders, but whose anti-HBs titer declined to &lt;10",
"    <span class=\"nowrap\">",
"     IU/L.",
"    </span>",
"    Antibody titers should be rechecked one month after a booster dose to determine efficacy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4995836\">",
"    <span class=\"h1\">",
"     LOW VACCINE COMPLETION RATES AMONG HIV-INFECTED PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several studies in outpatient clinics have confirmed low overall immunization rates against HBV infection among HIV-infected patients and low completion rates among those who do initiate a vaccine series [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/10/40104/abstract/1,38\">",
"     1,38",
"    </a>",
"    ]. In an illustrative study, of 1071 HIV-infected patients who were screened for hepatitis A or hepatitis B serologies, only a minority of eligible patients were subsequently vaccinated (ie, 23 percent and 32 percent, respectively) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/10/40104/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    To improve vaccination rates, one study evaluated an accelerated HBV immunization schedule (0, 1 and 3 weeks) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/10/40104/abstract/39\">",
"     39",
"    </a>",
"    ]. Patients (n = 761) were stratified according to their baseline CD4 cell count: &lt;200, 200-500, and &gt;500",
"    <span class=\"nowrap\">",
"     cells/mm3.",
"    </span>",
"    Although overall compliance was better in the accelerated vaccination arm, overall seroconversion rates were lower than in the standard arm (39 versus 50 percent). Predictors of response, independent of intervention arm, included the use of ART, HIV RNA suppression, and a high CD4 cell count. In fact, in the subset of patients with a CD4 cell count of &gt;500",
"    <span class=\"nowrap\">",
"     cells/mm3",
"    </span>",
"    (n = 364), similar rates of seroconversion were seen regardless of vaccine schedule. However, anti-HBs titers were only assessed at week 28; no long-term data are available on decay of antibody titers.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16830548\">",
"    <span class=\"h2\">",
"     Missed doses",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who missed doses of their primary series can receive another dose of HBV vaccine at any time. Surface antibody titers should be checked approximately two weeks after the vaccine dose has been administered. The immunization series can be considered complete if the anti-HBs titer is &gt;10",
"    <span class=\"nowrap\">",
"     IU/L.",
"    </span>",
"    The full immunization series can be given if a protective surface antibody response has not been attained.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H307675\">",
"    <span class=\"h1\">",
"     MANAGEMENT OF VACCINE NONRESPONDERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;No vaccination strategy has been consistently effective for HIV-infected patients who are nonresponders to a full series of HBV vaccine and many of the studies lack a comparative intervention arm. Methods that have been evaluated for boosting vaccine responses in HIV-infected patients have included doubling the dosage of vaccine, extending the number of doses, use of immunostimulatory adjuvants, or changing the route of administration (eg, intradermal versus intramuscular) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/10/40104/abstract/20,25,40-42\">",
"     20,25,40-42",
"    </a>",
"    ]. We suggest use of three injections of HBV vaccine with a double dose for patients who received standard dosing in the past.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H307703\">",
"    <span class=\"h2\">",
"     Increasing vaccine dosage",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a study of 144 patients with a history of vaccine failure, double-dose revaccination with a series of three monthly immunizations led to the development of protective anti-HBs titers in 51 percent of study participants [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/10/40104/abstract/42\">",
"     42",
"    </a>",
"    ]. The study design did not include a comparator arm.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H307710\">",
"    <span class=\"h2\">",
"     Increasing the number of injections",
"    </span>",
"    &nbsp;&mdash;&nbsp;Small observational studies have examined whether increasing the number of injections of HBV vaccine may improve overall immunogenicity. In a study of 63 prior vaccine nonresponders, seroconversion was seen in 16, 31, and 36 percent of patients after one, two, or three additional doses of vaccine, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/10/40104/abstract/43\">",
"     43",
"    </a>",
"    ]. In another study, increasing the number of doses of vaccine (eg, six injections total) in nine non-responders led to seroconversion in six patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/10/40104/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H307717\">",
"    <span class=\"h2\">",
"     Intradermal route",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among 12 HIV-infected patients who had failed a total of six intramuscular doses of HBV vaccine, four intradermal doses of HBV vaccine were administered over an eight-week period [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/10/40104/abstract/44\">",
"     44",
"    </a>",
"    ]. Although six patients did achieve seroconversion, antibody titers declined precipitously by 12 months of follow-up in five of the six patients to &lt;10",
"    <span class=\"nowrap\">",
"     IU/mL.",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H307724\">",
"    <span class=\"h2\">",
"     Studies of immunostimulatory adjuvants",
"    </span>",
"    &nbsp;&mdash;&nbsp;One",
"    study found that the use of a synthetic immunostimulatory adjuvant (CPG 7909) improved immunogenicity of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/36/27207?source=see_link\">",
"     hepatitis B vaccine",
"    </a>",
"    , including subjects with prior failure of immunization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/10/40104/abstract/40\">",
"     40",
"    </a>",
"    ]. However, this adjuvant is not available commercially.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H307731\">",
"    <span class=\"h1\">",
"     MANAGEMENT OF PATIENTS WITH ISOLATED ANTI-HB CORE ANTIBODY",
"    </span>",
"    &nbsp;&mdash;&nbsp;During serologic testing, some patients may have evidence of isolated anti-HBc. It is unclear as to whether immunization should be initiated among patients with this serologic profile since this serologic pattern may signify a false positive result or prior HBV infection in the distant past with loss of anti-HBs. Isolated anti-HBc may also be a marker of active occult HBV infection (as evidenced by presence of HBV DNA in serum in patients without HBsAg). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/18/42279?source=see_link\">",
"     \"Serologic diagnosis of hepatitis B virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    One way to differentiate between these possibilities is to immunize a patient with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/36/27207?source=see_link\">",
"     hepatitis B vaccine",
"    </a>",
"    to determine if an antibody response is elicited after only one dose; such a response would be consistent with an &ldquo;anamnestic&rdquo; response and prior infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/10/40104/abstract/45\">",
"     45",
"    </a>",
"    ]. However, studies of HIV-seronegative and HIV-seropositive patients with isolated anti-HBc demonstrate that immunization among patients with this serologic profile does not generally lead to an anamnestic response, but rather to a primary vaccine response [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/10/40104/abstract/29\">",
"     29",
"    </a>",
"    ]. Thus, the available evidence suggests that most HIV-infected patients with isolated anti-HBc should undergo a primary immunization series.",
"   </p>",
"   <p>",
"    At present, we suggest that HIV-infected patients who have isolated anti-HBc be fully vaccinated against HBV pending the results of larger studies. Alternatively, hepatitis B surface antibodies can be determined after one dose of vaccine to determine whether an anamnestic response has occurred. If surface antibodies are present after one dose, immunization can be considered complete.",
"   </p>",
"   <p>",
"    Prior to immunization, some specialists check for HBV DNA in patients with isolated anti-HBc to rule out occult HBV infection, which is defined as the presence of low-level viremia in patients without any laboratory markers of HBV infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/10/40104/abstract/5,31\">",
"     5,31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2121566\">",
"    <span class=\"h1\">",
"     THE ROLE OF ANTIRETROVIRAL THERAPY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H307953\">",
"    <span class=\"h2\">",
"     Prevention of HBV infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some antiretroviral medications have dual activity against HIV and HBV (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/15/5366?source=see_link\">",
"     emtricitabine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    ). It is unclear if inclusion of an HBV active antiviral medication may decrease the risk of acute HBV acquisition in an HIV-infected patient on ART after exposure to a person with chronic HBV infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/10/40104/abstract/1\">",
"     1",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H307968\">",
"    <span class=\"h2\">",
"     Response to HBV vaccine",
"    </span>",
"    &nbsp;&mdash;&nbsp;HIV RNA suppression and higher CD4 cell counts &gt;350",
"    <span class=\"nowrap\">",
"     cells/mm3",
"    </span>",
"    are associated with increased rates of seroconversion in response to HBV vaccine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/10/40104/abstract/25\">",
"     25",
"    </a>",
"    ]. Thus, it is preferable to immunize patients with no detectable HIV RNA and with a CD4 cell count above this threshold. However, if the patient is at increased risk for HBV acquisition (eg, having unprotected sex or actively using injection drugs), then immunization should be administered promptly since immunization may decrease the risk for severe hepatitis or chronicity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/10/40104/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2121527\">",
"    <span class=\"h1\">",
"     COUNSELING PATIENTS ABOUT AVOIDANCE OF HBV EXPOSURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients should be counseled regarding the need for safe sex, since HBV is effectively transmitted sexually, particularly among men who have sex with men (MSM). Patients should also be counseled regarding the need to avoid injection drug use completely or to reduce self harm by avoidance of sharing needles or other drug paraphernalia if continuing to inject. &nbsp;",
"   </p>",
"   <p>",
"    Avoidance of exposure to HBV should be emphasized during the vaccination period. Coincidental infection with HBV during the immunization period has been associated with a high rate of development of chronic HBV infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/10/40104/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2121546\">",
"    <span class=\"h1\">",
"     FUTURE TRENDS",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/36/27207?source=see_link\">",
"     Hepatitis B vaccine",
"    </a>",
"    is recommended for all children in the United States, Europe and in Asia. This vaccine initiative has already led to declines in chronic infection in endemic areas, such as Thailand. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/60/31690?source=see_link\">",
"     \"Hepatitis B virus vaccination\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It is possible that vaccine immune responses will be improved if most persons receive their immunizations in childhood before the onset of HIV infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/10/40104/abstract/1\">",
"     1",
"    </a>",
"    ]. However, HIV infection may lead to significant declines in antibody titers, leading to the need for booster injections.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here is the patient education article that is relevant to this topic. We encourage you to print or e-mail this topic to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?30/45/31447?source=see_link\">",
"       \"Patient information: Hepatitis B (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9249702\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      HIV-infected patients are at risk for hepatitis B virus (HBV) infection due to shared routes of transmission (eg, sexual transmission, injection drug use). HIV-infected individuals are also less likely to clear HBV DNA in the acute phase of infection and are at increased risk of developing chronic infection and cirrhosis compared with HIV-seronegative patients who acquire HBV as adults. (See",
"      <a class=\"local\" href=\"#H2121100\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      All HIV-infected patients should have serologic testing for HBV and vaccination should be offered to patients who have no evidence of prior HBV exposure. Laboratory evaluation should include assays for hepatitis B surface antigen and antibodies to hepatitis B surface antigen (anti-HBs). This serologic panel will identify most patients who have either chronic infection, resolved infection, or no evidence of prior infection. Some providers also order antibodies to hepatitis B core antigen (anti-HBc) to determine if the patient has isolated HB core antibody. (See",
"      <a class=\"local\" href=\"#H2121445\">",
"       'Serologic screening'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Recombinant vaccines include Recombivax HB and Engerix-B (yeast-derived vaccines used mainly in the United States) and GenHevac B (mammalian cell-derived vaccine used mainly in Europe). (See",
"      <a class=\"local\" href=\"#H2121452\">",
"       'Vaccine formulations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Compared with HIV-seronegative persons, HIV-infected patients have lower rates of seroconversion, lower titers of protective antibody, and faster rates of antibody declines after standard immunization. (See",
"      <a class=\"local\" href=\"#H4957169\">",
"       'Vaccine efficacy with standard dosing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Risk factors for lower seroconversion rates in response to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/36/27207?source=see_link\">",
"       hepatitis B vaccine",
"      </a>",
"      include advanced immunosuppression, detectable HIV viremia and chronic hepatitis C infection. (See",
"      <a class=\"local\" href=\"#H2121208\">",
"       'Risk factors for decreased vaccine response'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A level of anti-HBs greater than 10",
"      <span class=\"nowrap\">",
"       IU/L",
"      </span>",
"      is generally accepted as a surrogate marker of protection against HBV infection and should be routinely measured after completion of the vaccine series in HIV-infected patients. (See",
"      <a class=\"local\" href=\"#H9459458\">",
"       'Serologic testing after immunization'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In HIV-infected patients with a CD4 count of &gt;200",
"      <span class=\"nowrap\">",
"       cells/mm3,",
"      </span>",
"      we recommend immunization with a double dose of HBV vaccine (eg, 40 mcg intramuscularly) administered at baseline, one month, two months, and six months rather than standard dosing (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Although this vaccination strategy was specifically studied with a recombinant HBV vaccine available in Europe (ie, GenHevac B), a comparable recombinant vaccine formulation is available in the United States (ie, Energix-B). (See",
"      <a class=\"local\" href=\"#H2121222\">",
"       'Studies of alternative vaccine schedules'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      HIV-infected patients who are immunocompromised (eg, CD4 cell count &lt;200",
"      <span class=\"nowrap\">",
"       cells/mm3)",
"      </span>",
"      with poorly controlled HIV viremia usually have poor immunization responses to HBV vaccine. Efforts should be made to engage the patient into medical care and address other issues that may be interfering with adherence. However, vaccination should not be deferred in the HBV-seronegative patient who is engaging in high-risk behaviors (eg, unprotected sex with a partner with chronic HBV infection) since some patients with advanced immunosuppression may still respond. (See",
"      <a class=\"local\" href=\"#H307201\">",
"       'Implications for timing of immunization'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      No vaccination strategy has been consistently effective for HIV-infected patients who are nonresponders to HBV vaccine and many of the studies lack a comparative intervention arm. We suggest use of three injections of HBV vaccine with a double dose for patients who received standard dosing in the past (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H307675\">",
"       'Management of vaccine nonresponders'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      During serologic testing, some patients may have evidence of isolated anti-HB core antibody. It is unclear as to whether immunization should be initiated among patients with this serologic profile since this serologic pattern may signify a false positive result or prior HBV infection in the distant past with loss of anti-HBs, or it may occur in the setting of occult HBV infection. We suggest that HIV-infected patients who have a serologic pattern of &ldquo;isolated anti-HBc&rdquo; be vaccinated against HBV pending the results of larger studies (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H307731\">",
"       'Management of patients with isolated anti-HB core antibody'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/10/40104/abstract/1\">",
"      Kellerman SE, Hanson DL, McNaghten AD, Fleming PL. Prevalence of chronic hepatitis B and incidence of acute hepatitis B infection in human immunodeficiency virus-infected subjects. J Infect Dis 2003; 188:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/10/40104/abstract/2\">",
"      Hadler SC, Judson FN, O'Malley PM, et al. Outcome of hepatitis B virus infection in homosexual men and its relation to prior human immunodeficiency virus infection. J Infect Dis 1991; 163:454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/10/40104/abstract/3\">",
"      Walter SR, Thein HH, Amin J, et al. Trends in mortality after diagnosis of hepatitis B or C infection: 1992-2006. J Hepatol 2011; 54:879.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/10/40104/abstract/4\">",
"      Thio CL, Seaberg EC, Skolasky R Jr, et al. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet 2002; 360:1921.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/10/40104/abstract/5\">",
"      Kaplan JE, Benson C, Holmes KH, et al. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep 2009; 58:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/10/40104/abstract/6\">",
"      Advisory Committee on Immunization Practices. Recommended adult immunization schedule: United States, 2009*. Ann Intern Med 2009; 150:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/10/40104/abstract/7\">",
"      Brook G. Prevention of viral hepatitis in HIV co-infection. J Hepatol 2006; 44:S104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/10/40104/abstract/8\">",
"      Rockstroh JK, Bhagani S, Benhamou Y, et al. European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of chronic hepatitis B and C coinfection in HIV-infected adults. HIV Med 2008; 9:82.",
"     </a>",
"    </li>",
"    <li>",
"     file://aidsinfo.nih.gov/Guidelines/GuidelineDetail.aspx?MenuItem=Guidelines&amp;Search=Off&amp;GuidelineID=211&amp;ClassID=4 (Accessed on April 18, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/10/40104/abstract/10\">",
"      Collier AC, Corey L, Murphy VL, Handsfield HH. Antibody to human immunodeficiency virus (HIV) and suboptimal response to hepatitis B vaccination. Ann Intern Med 1988; 109:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/10/40104/abstract/11\">",
"      Keet IP, van Doornum G, Safary A, Coutinho RA. Insufficient response to hepatitis B vaccination in HIV-positive homosexual men. AIDS 1992; 6:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/10/40104/abstract/12\">",
"      Wong EK, Bodsworth NJ, Slade MA, et al. Response to hepatitis B vaccination in a primary care setting: influence of HIV infection, CD4+ lymphocyte count and vaccination schedule. Int J STD AIDS 1996; 7:490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/10/40104/abstract/13\">",
"      Rabeneck L, Risser JM, Murray NG, et al. Failure of providers to vaccinate HIV-infected men against hepatitis B: a missed opportunity. Am J Gastroenterol 1993; 88:2015.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/10/40104/abstract/14\">",
"      Vaccinia (smallpox) vaccine. Recommendations of the Immunization Practices Advisory Committee (ACIP). MMWR Recomm Rep 1991; 40:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/10/40104/abstract/15\">",
"      Mast EE, Weinbaum CM, Fiore AE, et al. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) Part II: immunization of adults. MMWR Recomm Rep 2006; 55:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/10/40104/abstract/16\">",
"      Corradi MP, Tata C, Marchegiano P, et al. Immunogenicity and safety of a recombinant hepatitis B vaccine produced in mammalian cells and containing the S and the preS2. Arch Virol Suppl 1992; 4:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/10/40104/abstract/17\">",
"      Douvin C, Simon D, Charles MA, et al. Hepatitis B vaccination in diabetic patients. Randomized trial comparing recombinant vaccines containing and not containing pre-S2 antigen. Diabetes Care 1997; 20:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/10/40104/abstract/18\">",
"      Landrum ML, Hullsiek KH, Ganesan A, et al. Hepatitis B vaccination and risk of hepatitis B infection in HIV-infected individuals. AIDS 2010; 24:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/10/40104/abstract/19\">",
"      Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2007; 45:507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/10/40104/abstract/20\">",
"      Rey D, Krantz V, Partisani M, et al. Increasing the number of hepatitis B vaccine injections augments anti-HBs response rate in HIV-infected patients. Effects on HIV-1 viral load. Vaccine 2000; 18:1161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/10/40104/abstract/21\">",
"      Laurence JC. Hepatitis A and B immunizations of individuals infected with human immunodeficiency virus. Am J Med 2005; 118 Suppl 10A:75S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/10/40104/abstract/22\">",
"      Chang JJ, Wightman F, Bartholomeusz A, et al. Reduced hepatitis B virus (HBV)-specific CD4+ T-cell responses in human immunodeficiency virus type 1-HBV-coinfected individuals receiving HBV-active antiretroviral therapy. J Virol 2005; 79:3038.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/10/40104/abstract/23\">",
"      Irungu E, Mugo N, Ngure K, et al. Immune response to hepatitis B virus vaccination among HIV-1 infected and uninfected adults in Kenya. J Infect Dis 2013; 207:402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/10/40104/abstract/24\">",
"      Overton ET, Sungkanuparph S, Powderly WG, et al. Undetectable plasma HIV RNA load predicts success after hepatitis B vaccination in HIV-infected persons. Clin Infect Dis 2005; 41:1045.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/10/40104/abstract/25\">",
"      Fonseca MO, Pang LW, de Paula Cavalheiro N, et al. Randomized trial of recombinant hepatitis B vaccine in HIV-infected adult patients comparing a standard dose to a double dose. Vaccine 2005; 23:2902.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/10/40104/abstract/26\">",
"      Shire NJ, Sherman KE. Management of hepatitis B virus in HIV-positive patients. Minerva Gastroenterol Dietol 2006; 52:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/10/40104/abstract/27\">",
"      Launay O, van der Vliet D, Rosenberg AR, et al. Safety and immunogenicity of 4 intramuscular double doses and 4 intradermal low doses vs standard hepatitis B vaccine regimen in adults with HIV-1: a randomized controlled trial. JAMA 2011; 305:1432.",
"     </a>",
"    </li>",
"    <li>",
"     file://aidsinfo.nih.gov/contentfiles/Adult_OI_041009.pdf (Accessed on April 22, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/10/40104/abstract/29\">",
"      Gandhi RT, Wurcel A, Lee H, et al. Response to hepatitis B vaccine in HIV-1-positive subjects who test positive for isolated antibody to hepatitis B core antigen: implications for hepatitis B vaccine strategies. J Infect Dis 2005; 191:1435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/10/40104/abstract/30\">",
"      Chakvetadze C, Bani-Sadr F, Le Pendeven C, et al. Serologic response to hepatitis B vaccination in HIV-Infected patients with isolated positivity for antibodies to hepatitis B core antigen. Clin Infect Dis 2010; 50:1184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/10/40104/abstract/31\">",
"      Shire NJ, Rouster SD, Stanford SD, et al. The prevalence and significance of occult hepatitis B virus in a prospective cohort of HIV-infected patients. J Acquir Immune Defic Syndr 2007; 44:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/10/40104/abstract/32\">",
"      Mitwalli A. Responsiveness to hepatitis B vaccine in immunocompromised patients by doubling the dose scheduling. Nephron 1996; 73:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/10/40104/abstract/33\">",
"      de Graeff PA, Dankert J, de Zeeuw D, et al. Immune response to two different hepatitis B vaccines in haemodialysis patients: a 2-year follow-up. Nephron 1985; 40:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/10/40104/abstract/34\">",
"      Potsch DV, Oliveira ML, Ginu&iacute;no C, et al. High rates of serological response to a modified hepatitis B vaccination schedule in HIV-infected adults subjects. Vaccine 2010; 28:1447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/10/40104/abstract/35\">",
"      Tasker SA, Wallace MR. Vaccination in HIV-infected Patients. Curr Infect Dis Rep 2000; 2:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/10/40104/abstract/36\">",
"      Wallace MR, Brandt CJ, Earhart KC, et al. Safety and immunogenicity of an inactivated hepatitis A vaccine among HIV-infected subjects. Clin Infect Dis 2004; 39:1207.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.cdc.gov/mmwr/PDF/rr/rr5416.pdf.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/10/40104/abstract/38\">",
"      Tedaldi EM, Baker RK, Moorman AC, et al. Hepatitis A and B vaccination practices for ambulatory patients infected with HIV. Clin Infect Dis 2004; 38:1478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/10/40104/abstract/39\">",
"      de Vries-Sluijs TE, Hansen BE, van Doornum GJ, et al. A randomized controlled study of accelerated versus standard hepatitis B vaccination in HIV-positive patients. J Infect Dis 2011; 203:984.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/10/40104/abstract/40\">",
"      Cooper CL, Davis HL, Angel JB, et al. CPG 7909 adjuvant improves hepatitis B virus vaccine seroprotection in antiretroviral-treated HIV-infected adults. AIDS 2005; 19:1473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/10/40104/abstract/41\">",
"      Cooper CL, Angel JB, Seguin I, et al. CPG 7909 adjuvant plus hepatitis B virus vaccination in HIV-infected adults achieves long-term seroprotection for up to 5 years. Clin Infect Dis 2008; 46:1310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/10/40104/abstract/42\">",
"      de Vries-Sluijs TE, Hansen BE, van Doornum GJ, et al. A prospective open study of the efficacy of high-dose recombinant hepatitis B rechallenge vaccination in HIV-infected patients. J Infect Dis 2008; 197:292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/10/40104/abstract/43\">",
"      Bloom A, Jackson K, Kiviat A, et al. Repeat hepatitis B vaccination may lead to seroprotection in HIV-infected patients who do not respond to an initial series. J Acquir Immune Defic Syndr 2009; 50:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/10/40104/abstract/44\">",
"      Shafran SD, Mashinter LD, Lindemulder A, et al. Poor efficacy of intradermal administration of recombinant hepatitis B virus immunization in HIV-infected individuals who fail to respond to intramuscular administration of hepatitis B virus vaccine. HIV Med 2007; 8:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/10/40104/abstract/45\">",
"      McIntyre A, Nimmo GR, Wood GM, et al. Isolated hepatitis B core antibody--can response to hepatitis B vaccine help elucidate the cause? Aust N Z J Med 1992; 22:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/10/40104/abstract/46\">",
"      Stramer SL, Wend U, Candotti D, et al. Nucleic acid testing to detect HBV infection in blood donors. N Engl J Med 2011; 364:236.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15807 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-122.72.76.133-F7344C3B4D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_10_40104=[""].join("\n");
var outline_f39_10_40104=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H9249702\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2121100\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9249266\">",
"      GENERAL BACKGROUND",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2121445\">",
"      Serologic screening",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H307083\">",
"      Isolated hepatitis B core antibody",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H307075\">",
"      Testing for other hepatitis viruses",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2121452\">",
"      VACCINE FORMULATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2121480\">",
"      SURROGATE MARKERS OF PROTECTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4957169\">",
"      VACCINE EFFICACY WITH STANDARD DOSING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2121208\">",
"      RISK FACTORS FOR DECREASED VACCINE RESPONSE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H307282\">",
"      HIV status",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H307289\">",
"      Other factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H307201\">",
"      Implications for timing of immunization",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H307208\">",
"      Effect of hepatitis C coinfection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2121222\">",
"      STUDIES OF ALTERNATIVE VACCINE SCHEDULES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2122334\">",
"      Double-dose strategies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2122218\">",
"      SAFETY AND ADVERSE EVENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9459458\">",
"      SEROLOGIC TESTING AFTER IMMUNIZATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16830405\">",
"      Waning immunity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4995836\">",
"      LOW VACCINE COMPLETION RATES AMONG HIV-INFECTED PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16830548\">",
"      Missed doses",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H307675\">",
"      MANAGEMENT OF VACCINE NONRESPONDERS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H307703\">",
"      Increasing vaccine dosage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H307710\">",
"      Increasing the number of injections",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H307717\">",
"      Intradermal route",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H307724\">",
"      Studies of immunostimulatory adjuvants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H307731\">",
"      MANAGEMENT OF PATIENTS WITH ISOLATED ANTI-HB CORE ANTIBODY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2121566\">",
"      THE ROLE OF ANTIRETROVIRAL THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H307953\">",
"      Prevention of HBV infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H307968\">",
"      Response to HBV vaccine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2121527\">",
"      COUNSELING PATIENTS ABOUT AVOIDANCE OF HBV EXPOSURE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2121546\">",
"      FUTURE TRENDS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9249702\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/22/37223?source=related_link\">",
"      Antiviral medications for the treatment of hepatitis B in the HIV-infected patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/55/7033?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of hepatitis B in the HIV-infected patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/63/44020?source=related_link\">",
"      Evaluation of chronic hepatitis B virus infection in the HIV-infected patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/36/11848?source=related_link\">",
"      Evaluation of the HIV-infected patient with chronic hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/60/31690?source=related_link\">",
"      Hepatitis B virus vaccination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/25/37273?source=related_link\">",
"      Immunizations in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/62/6119?source=related_link\">",
"      Monitoring the HIV-infected patient with chronic hepatitis B virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?30/45/31447?source=related_link\">",
"      Patient information: Hepatitis B (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/18/42279?source=related_link\">",
"      Serologic diagnosis of hepatitis B virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/51/16185?source=related_link\">",
"      Treatment of hepatitis B in the HIV-infected patient",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f39_10_40105="Cryptogenic stroke";
var content_f39_10_40105=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Cryptogenic stroke",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/10/40105/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/10/40105/contributors\">",
"     Shyam Prabhakaran, MD, MS",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/10/40105/contributors\">",
"     Mitchell SV Elkind, MD, MS, FAAN",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/10/40105/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/10/40105/contributors\">",
"     Scott E Kasner, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/10/40105/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/10/40105/contributors\">",
"     John F Dashe, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?39/10/40105/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 25, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of ischemic strokes are due to cardioembolism, large vessel atherothromboembolism, small vessel occlusive disease, or other unusual mechanisms. However, many ischemic strokes occur without a well-defined etiology and are labeled as cryptogenic. Other terms used in the literature to describe cryptogenic stroke include cryptogenous stroke and infarcts of unknown, uncertain, or undetermined cause. Cryptogenic stroke accounts for 30 to 40 percent of ischemic strokes in most modern stroke registries and databases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/10/40105/abstract/1-6\">",
"     1-6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic will provide an overview of the definition, epidemiology, pathophysiology, clinical features, diagnosis, treatment, and prognosis for cryptogenic stroke.",
"   </p>",
"   <p>",
"    A discussion of stroke classification and the clinical diagnosis of stroke subtypes is found separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/63/9208?source=see_link\">",
"     \"Etiology and classification of stroke\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/17/40216?source=see_link\">",
"     \"Clinical diagnosis of stroke subtypes\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The cryptogenic stroke category was devised first, for research purposes, in the NINDS Stroke Data Bank [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/10/40105/abstract/7,8\">",
"     7,8",
"    </a>",
"    ] and later modified in the TOAST trial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/10/40105/abstract/9\">",
"     9",
"    </a>",
"    ]. Classification along these lines has become increasingly used in clinical practice, as optimal management relates to the underlying mechanism. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/63/9208?source=see_link&amp;anchor=H13#H13\">",
"     \"Etiology and classification of stroke\", section on 'TOAST classification'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    By the TOAST classification, which is the most commonly used in clinical practice, cryptogenic stroke (or stroke of undetermined origin in TOAST terminology) is defined as brain infarction that is not attributable to a source of definite cardioembolism, large artery atherosclerosis, or small artery disease despite extensive vascular, cardiac, and serologic evaluation (",
"    <a class=\"graphic graphic_table graphicRef62571 \" href=\"mobipreview.htm?3/28/3531\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Ultimately, forced classification into one of the five subtypes can result in diagnostic misclassification and introduce heterogeneity among these subtypes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/10/40105/abstract/10\">",
"     10",
"    </a>",
"    ]. As an example, it is important to emphasize that the category of cryptogenic stroke as currently defined includes patients with less well-established potential causes of cardiac embolism, such as patent foramen ovale, aortic arch atheroma, and mitral valve strands, as well as potential prothrombotic disorders, such as those that may occur in association with antiphospholipid antibodies. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/31/23034?source=see_link\">",
"     \"Clinical manifestations of the antiphospholipid syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The TOAST classification also includes, as a separate category of cryptogenic stroke, those patients with two or more equally plausible etiologies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/10/40105/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY AND RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data on the incidence and prevalence of stroke subtypes vary based on the demographics of the study population, diagnostic definitions, extent of diagnostic evaluation, and methodology. Large epidemiologic studies have consistently reported that cryptogenic stroke accounts for about 30 to 40 percent of ischemic stroke [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/10/40105/abstract/1-4,11\">",
"     1-4,11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although risk factors often help unravel stroke mechanisms, the two are not always synonymous. Based on several large epidemiological stroke studies, it is possible to compare risk factors for cryptogenic stroke versus other subtypes. The comparison is, however, hindered in large part by definitional constraints. As an example, atrial fibrillation by definition will be rare in cryptogenic stroke because of the way in which the subtypes are defined. Similarly, risk factors that are important for extracranial atherosclerotic disease (hyperlipidemia, diabetes mellitus, etc.) may be underrepresented in patients with cryptogenic stroke.",
"   </p>",
"   <p>",
"    In the classification scheme, it is also conceivable that strokes of other",
"    <strong>",
"     determined",
"    </strong>",
"    cause (ie, migraine, dissection, vasculitis) might be erroneously represented in the",
"    <strong>",
"     undetermined",
"    </strong>",
"    category due to inadequate work-up or the limitations of diagnostic detection. However, given the rarity of these other causes in most registries (usually representing less than 5 percent of all strokes), this would not account for all cryptogenic strokes.",
"   </p>",
"   <p>",
"    Other risk factors that have been found in patients with cryptogenic stroke, including left ventricular thrombi after myocardial infarction, aortic atheroembolism or thromboembolism, and hypercoagulable states are addressed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/47/28410?source=see_link\">",
"     \"Overview of the evaluation of stroke\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/23/5497?source=see_link\">",
"     \"Left ventricular thrombus after acute myocardial infarction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/15/31994?source=see_link\">",
"     \"Embolism from atherosclerotic plaque: Atheroembolism (cholesterol crystal embolism)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/35/10809?source=see_link\">",
"     \"Embolism from aortic plaque: Thromboembolism\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/31/23034?source=see_link\">",
"     \"Clinical manifestations of the antiphospholipid syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Demographic factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of cryptogenic stroke may vary by",
"    <span class=\"nowrap\">",
"     race/ethnicity,",
"    </span>",
"    with higher incidence rates in blacks and Hispanics than in whites, but no clear association has been found for age and gender.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Age",
"    </span>",
"    &nbsp;&mdash;&nbsp;With the exception of the subtype of other determined causes (migraine, dissection, etc.), all stroke subtypes are rare in the young, and incidence rates rise dramatically with increasing age. While a few studies have reported that cryptogenic stroke disproportionately affects younger individuals, this has not been true in several other studies. In the Northern Manhattan Stroke Study (NOMASS, 1993 to 1996), 55 percent of strokes in the young (age &lt;45) were cryptogenic versus 42 percent in the age &gt;45 group [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/10/40105/abstract/12\">",
"     12",
"    </a>",
"    ]. However, other stroke registries all found lower rates (23 to 34 percent) similar to those in older age groups [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/10/40105/abstract/13-15\">",
"     13-15",
"    </a>",
"    ]. In a meta-analysis, young (defined as age &lt;50 years) age was inversely associated with cryptogenic stroke with a total OR of 0.6 (95% CI 0.4-1.0, p = 0.05) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/10/40105/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Gender",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cryptogenic stroke does not appear to differ by sex.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Race and ethnicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of cryptogenic stroke is higher in blacks and Hispanics and than in whites. In NOMASS, incidence rates of all ischemic stroke subtypes, including cryptogenic stroke, were higher in blacks and Hispanics than in whites [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/10/40105/abstract/16\">",
"     16",
"    </a>",
"    ]. In the Greater",
"    <span class=\"nowrap\">",
"     Cincinnati/Northern",
"    </span>",
"    Kentucky Stroke Study (GCNKSS), blacks had twice the annual incidence rate of cryptogenic stroke as whites (125 versus 65 per 100,000 persons), a result not confounded by differential testing patterns among black versus white patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/10/40105/abstract/17\">",
"     17",
"    </a>",
"    ]. In San Diego, an increased prevalence (nearly 46 percent) of cryptogenic stroke was seen in Mexican-American patients, a statistic again that was not explained by differences in diagnostic testing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/10/40105/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A transesophageal echocardiography study among 297 patients with cryptogenic stroke found racial differences in potential cardiac sources of embolism [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/10/40105/abstract/19\">",
"     19",
"    </a>",
"    ]. Blacks were less likely to have a potential source (particularly patent foramen ovale or atrial septal aneurysm) than whites but more likely to show evidence of left ventricular hypertrophy. The conclusion was that paradoxical embolism might play a lesser role in blacks compared with whites and that other processes associated with left ventricular hypertrophy, such as subclinical cerebral atherosclerosis, might be more important in this subgroup. Other studies have corroborated these findings [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/10/40105/abstract/20-22\">",
"     20-22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Other risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Evidence regarding the relationship of cryptogenic stroke with other potential risk factors is summarized in the sections that follow.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Atrial septal abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Atrial septal abnormalities, including patent foramen ovale, atrial septal aneurysm and atrial septal defect, have been associated with cryptogenic stroke, although the strength and clinical significance of this association is uncertain. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/48/39689?source=see_link&amp;anchor=H8#H8\">",
"     \"Atrial septal abnormalities (PFO, ASD, and ASA) and risk of cerebral emboli in adults\", section on 'Risk of embolic stroke'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Cardiac disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prevalence of cardiac disease among patients with cryptogenic stroke varies from 10 to 30 percent. In Rochester, coronary artery disease was less common in the undetermined (ie, cryptogenic) than in the large artery atherosclerosis subtype [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/10/40105/abstract/2\">",
"     2",
"    </a>",
"    ]. However, patients who had concurrent etiologies (ie, two or more probable stroke etiologies) in a German stroke study had a much higher prevalence of coronary and peripheral artery disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/10/40105/abstract/11\">",
"     11",
"    </a>",
"    ]. This concurrent etiology subgroup would be classified within the undetermined subgroup according to the TOAST criteria.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Diabetes",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prevalence of diabetes mellitus was similar across stroke subtypes in the Rochester and Bavarian population-based stroke studies, ranging from 15 to 30 percent in various populations and hospital-based studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/10/40105/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. In the Oxford meta-analysis of four population-based studies, the odds of diabetes occurring in patients with cryptogenic stroke were no different than for patients who had other stroke subtypes (OR 1.0, 95% CI 0.7-1.2) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/10/40105/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Family history",
"    </span>",
"    &nbsp;&mdash;&nbsp;The evidence regarding family history of stroke as a risk factor for cryptogenic stroke is conflicting. A case-control study of 421 Greek patients with acute stroke (including cerebral hemorrhage) and 239 matched controls showed that a family history of stroke was associated with large artery and small artery disease stroke subtypes, but not with cardioembolic or cryptogenic subtypes, after adjusting for known risk factors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/10/40105/abstract/23\">",
"     23",
"    </a>",
"    ]. A subsequent case-control study involving 600 consecutive Swedish patients with ischemic stroke and 600 matched controls found that a family history of stroke was associated with large artery, small vessel, and cryptogenic stroke subtypes (odds ratios 1.88, 1.79 and 1.70, respectively) but not cardioembolic stroke [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/10/40105/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Hypertension",
"    </span>",
"    &nbsp;&mdash;&nbsp;The proportion of cryptogenic stroke patients with hypertension ranges from 55 to 75 percent. Several studies have documented that hypertension is less common in cryptogenic stroke compared with other stroke subtypes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/10/40105/abstract/5,11,17,25\">",
"     5,11,17,25",
"    </a>",
"    ]. This observation was also supported by the Oxford meta-analysis, which found that the odds of hypertension in patients who had cryptogenic stroke was decreased compared with patients who had other stroke subtypes (OR 0.8, 95% CI 0.6-0.9) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/10/40105/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, patients with cryptogenic stroke may have an increased prevalence of hypertension compared with stroke-free controls, and one case-control study found that hypertension was associated with cryptogenic stroke (OR 4.5, 95% CI 1.5-13.2) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/10/40105/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Homocysteine",
"    </span>",
"    &nbsp;&mdash;&nbsp;While considered to be a risk factor for atherosclerosis and related stroke subtypes (large artery atherosclerosis and small artery disease), it is not clear if elevated homocysteine is a risk factor for cryptogenic stroke [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/10/40105/abstract/27-29\">",
"     27-29",
"    </a>",
"    ]. One case-control study found that mild hyperhomocysteinemia was independently associated with all subtypes including cryptogenic stroke [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/10/40105/abstract/30\">",
"     30",
"    </a>",
"    ]. The relationship of homocysteine with other stroke subtypes is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/61/30682?source=see_link&amp;anchor=H24#H24\">",
"     \"Secondary prevention of stroke: Risk factor reduction\", section on 'Hyperhomocysteinemia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The relationship of homocysteine with cardiovascular disease and stroke also is discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/37/19034?source=see_link&amp;anchor=H7#H7\">",
"     \"Overview of homocysteine\", section on 'Role in vascular disease'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Inflammatory and infectious causes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prospective studies have supported a potential role for inflammation and infection in stroke. While not specifically explored in patients with cryptogenic stroke, a proportion of such strokes may be accounted for by inflammatory or infectious factors.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Most [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/10/40105/abstract/31-33\">",
"       31-33",
"      </a>",
"      ] but not all [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/10/40105/abstract/34\">",
"       34",
"      </a>",
"      ] studies suggest that an elevated C-reactive protein (CRP) level is a risk factor for stroke.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      In a meta-analysis of 54 prospective studies and individual records from over 160,000 subjects without a history of vascular disease, CRP concentration was associated with the long-term risk of cardiovascular events, including ischemic stroke [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/10/40105/abstract/31\">",
"       31",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In the Physicians Health Study, CRP levels measured by high-sensitivity assays (hsCRP) independently predicted first ischemic stroke, with a relative risk of 1.9 for those in the highest quartile (hsCRP &gt;2.1) compared with those in the lowest quartile [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/10/40105/abstract/32\">",
"       32",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In the Framingham study, during over 10 years of follow-up, men in the highest quartile of hsCRP had twice the risk of stroke as those in the lowest, and women had three times the risk [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/10/40105/abstract/33\">",
"       33",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In the Northern Manhattan Study, among whites, blacks, and Hispanics, elevated hsCRP was",
"      <strong>",
"       not",
"      </strong>",
"      associated with an increased risk of stroke, though it was associated with a modest increased risk of myocardial infarction and death [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/10/40105/abstract/34\">",
"       34",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Elevated titers against C. pneumoniae may also be associated with risk of first stroke [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/10/40105/abstract/35,36\">",
"       35,36",
"      </a>",
"      ], although it is not clear that the risk is higher in those with cryptogenic stroke.",
"     </li>",
"     <li>",
"      The infectious burden index, a cumulative measure of exposure to different common infections, was associated with risk of stroke in the Northern Manhattan Study [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/10/40105/abstract/37\">",
"       37",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Lipids",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prevalence of hyperlipidemia in cryptogenic stroke patients ranges from 11 to 33 percent, and it is not clearly different among different stroke subtypes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/10/40105/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. In two hospital-based studies, cryptogenic stroke was characterized by a lower prevalence of hypercholesterolemia compared with large artery atherosclerosis and small artery disease but higher prevalence compared with cardioembolic stroke [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/10/40105/abstract/11,25\">",
"     11,25",
"    </a>",
"    ]. In a case-control study, there was no difference in total cholesterol, LDL, lipoprotein (a), and apolipoprotein E genotypes among those with cryptogenic stroke compared with controls. However, the lowest versus highest quartile of HDL was significantly associated with cryptogenic stroke (OR 5.36, 95% CI 1.1-12.2) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/10/40105/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Prior TIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;The proportion of cryptogenic stroke patients with prior TIA ranges from 10 to 20 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/10/40105/abstract/2-5,11\">",
"     2-5,11",
"    </a>",
"    ], which is less than large artery atherosclerosis stroke and similar to cardioembolic stroke.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Smoking",
"    </span>",
"    &nbsp;&mdash;&nbsp;The total odds ratio for the presence of smoking in the cryptogenic stroke subgroup from the Oxford meta-analysis was 0.8 (95% CI 0.6-1.0) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/10/40105/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;For the reasons given above, identifying a unifying theory and mechanism for cryptogenic stroke is likely to be difficult, if not impossible. The widespread use of modern technologies, including MRI, transesophageal echocardiography, and specific hematologic tests, has greatly enhanced the certainty of stroke subtype classification. Nevertheless, there remain many unanswered questions. The most pressing are those related to pathophysiologic mechanisms. Is cryptogenic stroke an early form of atherosclerotic stroke, a form of occult embolism, or a consequence of a hypercoagulable state? Are there some novel factors that are still lurking?",
"   </p>",
"   <p>",
"    Given these issues, it would be a mistake to presume that patent foramen ovale or any other single etiology is responsible for most or all cryptogenic strokes. Numerous mechanisms for cryptogenic stroke have been proposed.",
"   </p>",
"   <p>",
"    Several important mechanisms have been associated with cryptogenic stroke, including:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Occult cardiac embolism secondary to paroxysmal atrial fibrillation, aortic atheromatous disease, or other cardiac sources.",
"     </li>",
"     <li>",
"      Paradoxical embolism secondary to patent foramen ovale (PFO) or other atrial septal abnormalities. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?38/48/39689?source=see_link&amp;anchor=H8#H8\">",
"       \"Atrial septal abnormalities (PFO, ASD, and ASA) and risk of cerebral emboli in adults\", section on 'Risk of embolic stroke'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Thrombophilia (ie, hypercoagulable states including those related to antiphospholipid antibodies or to occult cancer with hypercoagulability of malignancy)",
"     </li>",
"     <li>",
"      Preclinical or subclinical cerebrovascular disease (ie, intracranial and extracranial vascular changes)",
"     </li>",
"     <li>",
"      Potentially inflammatory processes (eg, elevated C-reactive protein or chronic infections)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It is also conceivable that important but unidentified mechanisms exist, awaiting discovery.",
"   </p>",
"   <p>",
"    Several studies have tried to elucidate which mechanisms best explain cryptogenic stroke, as summarized in the sections that follow.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19246268\">",
"    <span class=\"h2\">",
"     Occult embolism from the heart or aorta",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the Stroke Data Bank, occult cardiac embolism was considered a major mechanism of cryptogenic stroke. In that report, there were 138 patients initially labeled as infarct of undetermined cause (ie, cryptogenic stroke) who had angiography within one week of symptom onset [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/10/40105/abstract/1\">",
"     1",
"    </a>",
"    ]. Of these, angiography was normal in 66 percent, supporting continued classification as cryptogenic. These infarcts were presumed to represent occult embolism. In an Italian study of 80 patients who had angiography within six hours and repeated within one week, 76 percent of cases had arterial occlusions on initial angiogram; of those who had repeat angiography, 70 percent showed recanalization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/10/40105/abstract/38\">",
"     38",
"    </a>",
"    ]. The authors implied that these represented embolic occlusions that underwent spontaneous thrombolysis. A large majority of cases (&gt;80 percent) were subsequently found to have potential embolic sources.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19246582\">",
"    <span class=\"h3\">",
"     Subclinical atrial fibrillation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Paroxysmal atrial fibrillation (AF), if transient, infrequent, and largely asymptomatic, may be undetected on standard cardiac monitoring such as continuous telemetry and 24 or 48-hour Holter monitors. In a study that assessed longer-term monitoring using an outpatient telemetry system for a median duration of 21 days among 56 patients with cryptogenic stroke, paroxysmal AF was detected in 13 patients (23 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/10/40105/abstract/39\">",
"     39",
"    </a>",
"    ]. The median time to detection of AF was seven days. The majority of patients with paroxysmal AF were asymptomatic during the fleeting episodes. Other reports using continuous cardiac telemetry, automated monitoring of continuous inpatient cardiac telemetry, ambulatory (Holter) electrocardiography, or transtelephonic monitoring of ECGs have noted that AF can be detected with longer duration of cardiac monitoring [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/10/40105/abstract/40-43\">",
"     40-43",
"    </a>",
"    ], and that precursors of AF such as frequent premature atrial contractions may predict those harboring paroxysmal AF [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/10/40105/abstract/44\">",
"     44",
"    </a>",
"    ]. The optimal monitoring method &ndash; continuous telemetry, ambulatory electrocardiography, serial electrocardiography, transtelephonic ECG monitoring, or implantable loop recorders &ndash; is uncertain, though longer durations of monitoring are likely to obtain the highest diagnostic yield [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/10/40105/abstract/45-47\">",
"     45-47",
"    </a>",
"    ] . (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/32/36361?source=see_link\">",
"     \"Ambulatory monitoring in the assessment of cardiac arrhythmias\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Additional evidence linking subclinical AF and cryptogenic stroke comes from a prospective study of 2580 subjects, age &ge;65 years, with hypertension and no history of AF who had recent implantation of a pacemaker or defibrillator [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/10/40105/abstract/48\">",
"     48",
"    </a>",
"    ]. At three months, subclinical atrial tachyarrhythmias detected by the implanted devices had occurred in 10 percent of patients, and were associated with an increased risk (at a mean of 2.5 years) for clinical AF (hazard ratio 5.6, 95% CI 3.8-8.2) and for the combined endpoint of ischemic stroke or systemic embolism (HR 2.5, 95% CI 1.3-4.9).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19246589\">",
"    <span class=\"h3\">",
"     Atrial septal abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;While retrospective data suggest that there is an increased prevalence of patent foramen ovale (PFO) and atrial septal aneurysm (ASA) in patients who have had a cryptogenic stroke, particularly in patients &lt;55 years old, population-based studies suggest that PFO and large PFO are not independent risk factors for stroke. In addition, prospective data suggest that PFO alone is not associated with a meaningfully increased risk of recurrent stroke or death in patients who have already had a cryptogenic stroke. These issues are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/48/39689?source=see_link&amp;anchor=H8#H8\">",
"     \"Atrial septal abnormalities (PFO, ASD, and ASA) and risk of cerebral emboli in adults\", section on 'Risk of embolic stroke'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19246596\">",
"    <span class=\"h3\">",
"     Aortic embolism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Besides proximal aortic atheromas, distal aortic sources of embolism have been proposed as a potential cause for cryptogenic stroke. One study using cardiac MRI suggested that complex atheromas in the descending aortic arch atheromas could lead to stroke via retrograde flow [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/10/40105/abstract/49\">",
"     49",
"    </a>",
"    ]. During diastole, retrograde flow in the descending aorta reached the great vessels supplying the brain in up to 24 percent of patients with cryptogenic stroke. This finding suggests that embolic material in the descending aortic arch could enter the cerebral vasculature during retrograde flow and cause ischemic stroke.",
"   </p>",
"   <p>",
"    The relationship of aortic embolism and stroke is reviewed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/63/9208?source=see_link&amp;anchor=H10#H10\">",
"     \"Etiology and classification of stroke\", section on 'Aortic atherosclerosis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/35/10809?source=see_link\">",
"     \"Embolism from aortic plaque: Thromboembolism\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19246254\">",
"    <span class=\"h2\">",
"     Large vessel disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Undetected large vessel disease could account for some cases of cryptogenic stroke. In 37 patients with stroke of no determined cause who were followed prospectively for one year in a South Korean study, 11 patients suffered recurrent ischemic stroke [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/10/40105/abstract/50\">",
"     50",
"    </a>",
"    ]. After stroke recurrence, six patients had evidence of large artery atherosclerosis, one was classified as cardioembolic (new onset atrial fibrillation), and four were still cryptogenic. The authors proposed that in their population, the predominant mechanism of cryptogenic stroke was progression of large vessel atherosclerosis or plaque instability.",
"   </p>",
"   <p>",
"    Data from autopsy studies suggest that ischemic stroke can be associated with lesser degrees of extracranial and intracranial large vessel stenosis (eg, 30 to 70 percent) or with vulnerable plaques without appreciable luminal compromise. Supporting evidence comes from the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a case-control study that included 259 patients with fatal ischemic stroke, intracranial atherosclerotic plaques (with or without stenosis) were noted in 62 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/10/40105/abstract/51\">",
"       51",
"      </a>",
"      ]. Furthermore, plaques with superimposed thrombi and stenosis of 30 to 70 percent were considered responsible for infarcts in four cases (1.5 percent), a group that would have been classified as cryptogenic in non-autopsy studies [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/10/40105/abstract/51\">",
"       51",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a subsequent study from the same investigators, plaques and stenoses involving the origin or proximal vertebral artery were present in more than twice as many patients with infarcts in posterior circulation as compared with anterior circulation infarcts (adjusted OR 2.10, 95% CI 1.01-4.38) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/10/40105/abstract/52\">",
"       52",
"      </a>",
"      ]. These lesions may be responsible for a larger proportion of strokes in the brainstem and posterior circulation than previously appreciated.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19246261\">",
"    <span class=\"h2\">",
"     Other causes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypercoagulable states have been proposed as a cause of cryptogenic stroke. However, studies assessing the prevalence of prothrombotic states and genetic polymorphisms predisposing individuals to thrombosis have",
"    <strong>",
"     not",
"    </strong>",
"    yielded convincing evidence that these are more common in patients with cryptogenic stroke than nonstroke controls [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/10/40105/abstract/53-55\">",
"     53-55",
"    </a>",
"    ]. Nevertheless, the available reports are small and not definitive.",
"   </p>",
"   <p>",
"    Unsuspected rare genetic conditions may present with stroke in the young. As an example, a prospective study assessing the prevalence of Fabry disease among 721 patients with cryptogenic stroke reported that significant alpha-galactosidase mutations were present in approximately 4 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/10/40105/abstract/56\">",
"     56",
"    </a>",
"    ]. Patients with these mutations had a disproportionate number of infarcts in the vertebrobasilar distribution and associated dolichoectasia of the basilar arteries, both known manifestations of cerebrovascular pathology in Fabry disease. Other reports suggest that the prevalence of unsuspected Fabry disease among patients with cryptogenic stroke is &lt;1 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/10/40105/abstract/57,58\">",
"     57,58",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cryptogenic stroke presents with superficial hemispheric infarction in 62 to 84 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/10/40105/abstract/1,19\">",
"     1,19",
"    </a>",
"    ]. In one study of patients with cryptogenic stroke, cortical signs were present in 27 percent, and abrupt onset occurred in 59 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/10/40105/abstract/59\">",
"     59",
"    </a>",
"    ]. Lacunar syndromes are rare, accounting for usually less than 5 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/10/40105/abstract/1,19\">",
"     1,19",
"    </a>",
"    ]. The severity of the initial presentation varies but, on average, tends to be milder than cardioembolic strokes and worse than lacunar strokes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/10/40105/abstract/11,19,50,59,60\">",
"     11,19,50,59,60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Superficial cerebral or cerebellar infarction involving the posterior division middle cerebral artery territory, distal posterior cerebral artery, anterior cerebral artery, superior cerebellar artery, and multiple territories are often considered markers of embolic events. A significant proportion of cryptogenic strokes adhere to embolic infarct topography on brain imaging (CT or MRI). Forty percent of cryptogenic strokes in the Stroke Data Bank were found to have cortical infarcts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/10/40105/abstract/1\">",
"     1",
"    </a>",
"    ]. Among 314 patients with cryptogenic stroke in the PFO-ASA study, 56 percent had superficial infarcts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/10/40105/abstract/59\">",
"     59",
"    </a>",
"    ]. The German Stroke Study found that parenchymal hemorrhagic transformation occurred in 2.4 percent of patients with stroke of unknown etiology in the first seven days, comparable to the percentage among cardioembolic stroke, suggesting an embolic mechanism [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/10/40105/abstract/11\">",
"     11",
"    </a>",
"    ]. Large subcortical strokes (&gt;15 mm) also tend to be either cryptogenic or cardioembolic in origin.",
"   </p>",
"   <p>",
"    Noninvasive vascular imaging typically does not identify a relevant vessel stenosis or occlusion in most patients with cryptogenic stroke, except the possibility of distal branch occlusion. However, in prospective data from the Stroke Data Bank, conventional angiography revealed large artery lesions in a significant minority of patients initially classified as having infarcts of undetermined cause [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/10/40105/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Transesophageal echocardiography (TEE) is often recommended in the evaluation of cryptogenic stroke, especially in the young (&lt;50 years) and in those with no or few stroke risk factors. The diagnostic yield of finding a potential source of embolism by TEE is appreciably greater than transthoracic echocardiography (TTE) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/10/40105/abstract/61-63\">",
"     61-63",
"    </a>",
"    ]. Though data on other imaging modalities such as cardiac MRI and multidetector CT of the heart and great vessels are emerging [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/10/40105/abstract/64,65\">",
"     64,65",
"    </a>",
"    ], it is not clear if these will supplant or complement TEE in the evaluation of cryptogenic stroke. Detected abnormalities on TEE that have been associated with cryptogenic stroke include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Atrial appendage thrombus",
"     </li>",
"     <li>",
"      Enlarged left atrium",
"     </li>",
"     <li>",
"      Spontaneous echo contrast",
"     </li>",
"     <li>",
"      Patent foramen ovale (PFO)",
"     </li>",
"     <li>",
"      Atrial septal aneurysm (ASA)",
"     </li>",
"     <li>",
"      Large thoracic aortic plaques",
"     </li>",
"     <li>",
"      Valvular strands",
"     </li>",
"     <li>",
"      Mitral valve prolapse",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In patients with cryptogenic stroke, the most frequently found abnormalities are PFO, ASA, and aortic atheromas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/10/40105/abstract/66,67\">",
"     66,67",
"    </a>",
"    ]. The timing of the TEE (&lt;72 hours versus &gt;72 hours) in relation to the index stroke does not appear to alter sensitivity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/10/40105/abstract/68\">",
"     68",
"    </a>",
"    ]. The clinical significance of most of these findings is still unclear, with conflicting studies on the relative risks and appropriate management.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cryptogenic stroke is a diagnosis of exclusion based on a thorough investigation for other potential etiologies. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/29/33242?source=see_link\">",
"     \"Initial assessment and management of acute stroke\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/47/28410?source=see_link\">",
"     \"Overview of the evaluation of stroke\"",
"    </a>",
"    .) Tests frequently performed to evaluate an ischemic stroke include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Brain imaging with CT or MRI, and neurovascular imaging with carotid duplex and transcranial Doppler, magnetic resonance angiography (MRA), CT angiography, or conventional angiography. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?16/56/17290?source=see_link\">",
"       \"Neuroimaging of acute ischemic stroke\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Cardiac and aortic evaluation including TTE and often TEE with saline contrast (or bubble) study, electrocardiogram, and prolonged (&ge;24 hours) continuous electrocardiographic monitoring to detect occult atrial fibrillation. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?12/4/12361?source=see_link\">",
"       \"Echocardiography in detection of intracardiac sources of embolism\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?10/35/10809?source=see_link\">",
"       \"Embolism from aortic plaque: Thromboembolism\"",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H19246582\">",
"       'Subclinical atrial fibrillation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Blood tests such as complete blood count, electrolytes, sedimentation rate, glucose, glycosylated hemoglobin, Venereal Disease Research Laboratory (VDRL) test, rapid plasma reagin (RPR) for syphilis, fasting lipids and homocysteine, and, in the appropriate clinical setting, lumbar puncture. In certain instances, such as cryptogenic stroke in the young, a search for rare genetic and acquired risk factors including prothrombotic states is warranted. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?27/47/28410?source=see_link\">",
"       \"Overview of the evaluation of stroke\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     NATURAL HISTORY AND PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Compared with other stroke subtypes, cryptogenic stroke tends to have a better prognosis at three months, six months, and one year. Approximately 50 to 60 percent score &lt;2 on the modified Rankin Scale (",
"    <a class=\"graphic graphic_table graphicRef75411 \" href=\"mobipreview.htm?22/32/23051\">",
"     table 2",
"    </a>",
"    ) at follow-up [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/10/40105/abstract/11,50,60,69\">",
"     11,50,60,69",
"    </a>",
"    ]. Mortality rates are lower than those for cardioembolic stroke but higher than those for small artery disease.",
"   </p>",
"   <p>",
"    Overall, the short-term risk of recurrent stroke after cryptogenic stroke is intermediate between the high early risk after large artery atherosclerosis stroke and low risk after small artery disease stroke. In the Oxford meta-analysis of four large population-based studies, the risks of recurrent stroke after cryptogenic stroke were 1.6 percent at seven days, 4.2 percent at one month, and 5.6 percent at three months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/10/40105/abstract/70\">",
"     70",
"    </a>",
"    ]. In the NINDS Stroke Data Bank, 3 percent of cryptogenic stroke patients had recurrent events at one month [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/10/40105/abstract/71\">",
"     71",
"    </a>",
"    ]. In the NOMASS study at three months, the risk of recurrence for the cryptogenic group was 3.7 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/10/40105/abstract/72\">",
"     72",
"    </a>",
"    ], slightly lower than those found in the Oxford meta-analysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/10/40105/abstract/70\">",
"     70",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    At two years, recurrence risk ranges from 14 to 20 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/10/40105/abstract/3,69,73\">",
"     3,69,73",
"    </a>",
"    ]. In the Stroke Data Bank, cryptogenic stroke had the lowest two-year recurrence risk and was an independent predictor of low recurrence risk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/10/40105/abstract/74\">",
"     74",
"    </a>",
"    ]. At five years, the long-term recurrence risk was 33.2 percent in Rochester, not significantly different from the other subtypes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/10/40105/abstract/69\">",
"     69",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     PREVENTION AND TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because the pathophysiology of cryptogenic stroke is heterogeneous, decisions regarding treatment for such patients are challenging. Nevertheless, there are no convincing data that acute management should differ by stroke subtype [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/10/40105/abstract/75\">",
"     75",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Randomized trial data show that intravenous thrombolysis with tPA (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/41/11929?source=see_link\">",
"     alteplase",
"    </a>",
"    ) is beneficial for eligible patients with ischemic stroke who can be treated within 4.5 hours of stroke onset. Acute management for patients with cryptogenic stroke who are not eligible for thrombolysis is also similar to patients with other ischemic stroke subtypes. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/8/41098?source=see_link\">",
"     \"Reperfusion therapy for acute ischemic stroke\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/60/31688?source=see_link\">",
"     \"Antithrombotic treatment of acute ischemic stroke and transient ischemic attack\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Secondary stroke prevention depends more directly on accurate ischemic stroke subtyping, with anticoagulation being the standard of care for most patients with definite cardioembolic etiology due to atrial fibrillation, and antiplatelet therapy for noncardioembolic strokes. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/17/40216?source=see_link\">",
"     \"Clinical diagnosis of stroke subtypes\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     Warfarin",
"    </a>",
"    -",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     Aspirin",
"    </a>",
"    Recurrent Stroke Study (WARSS) compared aspirin with warfarin in the prevention of recurrent ischemic stroke among noncardioembolic stroke patients and found no superiority of warfarin over aspirin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/10/40105/abstract/73\">",
"     73",
"    </a>",
"    ]. Among patients with cryptogenic stroke, the event rate (recurrent stroke or death) at two years was not significantly different for the warfarin-treated group compared with the aspirin-treated group (15.0 versus 16.5 percent, respectively).",
"   </p>",
"   <p>",
"    Based upon these findings and other data, current guidelines support the use of antiplatelet therapy with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    , or the combination aspirin-extended release",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/25/41366?source=see_link\">",
"     dipyridamole",
"    </a>",
"    over full-dose anticoagulation for the treatment of noncardioembolic stroke, including cryptogenic stroke [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/10/40105/abstract/76,77\">",
"     76,77",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/35/2618?source=see_link\">",
"     \"Antiplatelet therapy for secondary prevention of stroke\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A post-hoc analysis of WARSS data showed that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    therapy was associated with fewer recurrent strokes or deaths at two years compared with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    in selected subgroups of patients with cryptogenic stroke: those with mild stroke severity (NIH stroke scale score &le;5), those with posterior circulation infarcts sparing the brainstem, and those with no hypertension at baseline [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/10/40105/abstract/78\">",
"     78",
"    </a>",
"    ]. Since these results come from post-hoc analyses based on relatively small numbers of patients, they must be interpreted with great caution, and further prospective studies are needed to determine if warfarin is beneficial in specific subgroups of patients with cryptogenic stroke.",
"   </p>",
"   <p>",
"    There is a high degree of uncertainty regarding the optimal management of patent foramen ovale (PFO), atrial septal aneurysm (ASA), and atheromatous aortic disease. The management of specific coagulation disorders and the role of hematologic testing are also unclear at the moment. Therefore, for the majority of patients with cryptogenic stroke, antiplatelet therapy is recommended. Selected patients might benefit from anticoagulant therapy. The management of patients with cryptogenic stroke and atrial septal abnormalities is discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/63/14328?source=see_link\">",
"     \"Treatment of atrial septal abnormalities (PFO, ASD, and ASA) for prevention of stroke in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The management of individual risk factors associated with ischemic stroke and cryptogenic stroke is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/61/30682?source=see_link\">",
"     \"Secondary prevention of stroke: Risk factor reduction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For the vast majority of patients with cryptogenic stroke, antiplatelet therapy is recommended as the mainstay of antithrombotic therapy for secondary prevention [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/10/40105/abstract/76,77\">",
"     76,77",
"    </a>",
"    ]. This topic is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/35/2618?source=see_link\">",
"     \"Antiplatelet therapy for secondary prevention of stroke\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition, risk factor modification and other measures of secondary stroke prevention are applicable to most patients with cryptogenic stroke. These measures include control of hypertension and diabetes, smoking cessation, lipid lowering therapies, weight loss, moderate alcohol consumption, and adequate physical activity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/10/40105/abstract/76\">",
"     76",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/61/30682?source=see_link\">",
"     \"Secondary prevention of stroke: Risk factor reduction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cryptogenic stroke is defined as brain infarction that is not attributable to a source of definite cardioembolism, large artery atherosclerosis, or small artery disease despite extensive vascular, cardiac, and serologic evaluation. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Definition'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Cryptogenic stroke accounts for about 30 to 40 percent of ischemic stroke and the prevalence of cryptogenic stroke may be higher in blacks and Mexican-Americans compared with white populations in the United States. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Epidemiology and risk factors'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H7\">",
"       'Race and ethnicity'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The risk factors for cryptogenic stroke are not clearly different from the risk factors for other types of ischemic stroke, although hypertension may be less common in patients with cryptogenic stroke compared with other ischemic stroke types. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Other risk factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The pathophysiology of cryptogenic stroke is likely heterogeneous, and proposed mechanisms include occult cardiac embolism secondary to paroxysmal atrial fibrillation, aortic atheromatous disease or other cardiac sources, paradoxical embolism from atrial septal abnormalities such as patent foramen ovale, hypercoagulable states, preclinical or subclinical cerebrovascular disease, and inflammatory processes. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Pathophysiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Paroxysmal atrial fibrillation is present in approximately 25 percent of patients with cryptogenic stroke, depending on the method of detection. It may be undetected on standard cardiac monitoring such as continuous telemetry and 24 or 48-hour Holter monitors. The optimal monitoring method &ndash; continuous telemetry, ambulatory electrocardiography, serial electrocardiography, transtelephonic ECG monitoring, or implantable loop recorders &ndash; is uncertain, though longer durations of monitoring (eg, seven or more days) are likely to obtain the highest diagnostic yield. (See",
"      <a class=\"local\" href=\"#H19246268\">",
"       'Occult embolism from the heart or aorta'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      While retrospective data suggest that there is an increased prevalence of PFO and atrial septal aneurysm (ASA) in patients who have had a cryptogenic stroke, particularly in patients &lt;55 years old, population-based studies suggest that PFO and large PFO are not independent risk factors for stroke. In addition, prospective data suggest that PFO alone is not associated with a meaningfully increased risk of recurrent stroke or death in patients who have already had a cryptogenic stroke, although a small increase or decrease in risk cannot be excluded. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?38/48/39689?source=see_link&amp;anchor=H8#H8\">",
"       \"Atrial septal abnormalities (PFO, ASD, and ASA) and risk of cerebral emboli in adults\", section on 'Risk of embolic stroke'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Cryptogenic stroke presents with superficial hemispheric infarction in the majority of patients, and a significant proportion of cryptogenic strokes adhere to embolic infarct topography on brain imaging. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Cryptogenic stroke is a diagnosis of exclusion based on a thorough investigation for other potential etiologies. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The short-term risk of recurrent stroke after cryptogenic stroke is intermediate between the high early risk after large artery atherosclerosis stroke and low risk after small artery disease stroke. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Natural history and prognosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There are no convincing data that acute management of cryptogenic stroke should differ from other ischemic stroke subtypes. Clinical trial data show that intravenous thrombolysis with tPA (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?11/41/11929?source=see_link\">",
"       alteplase",
"      </a>",
"      ) is beneficial for eligible patients with ischemic stroke who can be treated within 4.5 hours of stroke onset. For most patients with cryptogenic stroke, antiplatelet therapy is recommended as the mainstay of antithrombotic therapy for secondary prevention. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Prevention and treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/10/40105/abstract/1\">",
"      Sacco RL, Ellenberg JH, Mohr JP, et al. Infarcts of undetermined cause: the NINCDS Stroke Data Bank. Ann Neurol 1989; 25:382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/10/40105/abstract/2\">",
"      Petty GW, Brown RD Jr, Whisnant JP, et al. Ischemic stroke subtypes: a population-based study of incidence and risk factors. Stroke 1999; 30:2513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/10/40105/abstract/3\">",
"      Kolominsky-Rabas PL, Weber M, Gefeller O, et al. Epidemiology of ischemic stroke subtypes according to TOAST criteria: incidence, recurrence, and long-term survival in ischemic stroke subtypes: a population-based study. Stroke 2001; 32:2735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/10/40105/abstract/4\">",
"      Schulz UG, Rothwell PM. Differences in vascular risk factors between etiological subtypes of ischemic stroke: importance of population-based studies. Stroke 2003; 34:2050.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/10/40105/abstract/5\">",
"      Schneider AT, Kissela B, Woo D, et al. Ischemic stroke subtypes: a population-based study of incidence rates among blacks and whites. Stroke 2004; 35:1552.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/10/40105/abstract/6\">",
"      Lee BI, Nam HS, Heo JH, et al. Yonsei Stroke Registry. Analysis of 1,000 patients with acute cerebral infarctions. Cerebrovasc Dis 2001; 12:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/10/40105/abstract/7\">",
"      Kunitz SC, Gross CR, Heyman A, et al. The pilot Stroke Data Bank: definition, design, and data. Stroke 1984; 15:740.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/10/40105/abstract/8\">",
"      Foulkes MA, Wolf PA, Price TR, et al. The Stroke Data Bank: design, methods, and baseline characteristics. Stroke 1988; 19:547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/10/40105/abstract/9\">",
"      Adams HP Jr, Bendixen BH, Kappelle LJ, et al. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke 1993; 24:35.",
"     </a>",
"    </li>",
"    <li>",
"     Mohr, JP, Choi, WC, Grotta, JC, et al. Stroke: Pathophysiology, diagnosis, and management, 4th Edition, Churchill Livingstone, New York 2004.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/10/40105/abstract/11\">",
"      Grau AJ, Weimar C, Buggle F, et al. Risk factors, outcome, and treatment in subtypes of ischemic stroke: the German stroke data bank. Stroke 2001; 32:2559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/10/40105/abstract/12\">",
"      Jacobs BS, Boden-Albala B, Lin IF, Sacco RL. Stroke in the young in the northern Manhattan stroke study. Stroke 2002; 33:2789.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/10/40105/abstract/13\">",
"      Adams HP Jr, Kappelle LJ, Biller J, et al. Ischemic stroke in young adults. Experience in 329 patients enrolled in the Iowa Registry of stroke in young adults. Arch Neurol 1995; 52:491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/10/40105/abstract/14\">",
"      Williams LS, Garg BP, Cohen M, et al. Subtypes of ischemic stroke in children and young adults. Neurology 1997; 49:1541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/10/40105/abstract/15\">",
"      Nedeltchev K, der Maur TA, Georgiadis D, et al. Ischaemic stroke in young adults: predictors of outcome and recurrence. J Neurol Neurosurg Psychiatry 2005; 76:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/10/40105/abstract/16\">",
"      White H, Boden-Albala B, Wang C, et al. Ischemic stroke subtype incidence among whites, blacks, and Hispanics: the Northern Manhattan Study. Circulation 2005; 111:1327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/10/40105/abstract/17\">",
"      Woo D, Gebel J, Miller R, et al. Incidence rates of first-ever ischemic stroke subtypes among blacks: a population-based study. Stroke 1999; 30:2517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/10/40105/abstract/18\">",
"      Zweifler RM, Lyden PD, Taft B, et al. Impact of race and ethnicity on ischemic stroke. The University of California at San Diego Stroke Data Bank. Stroke 1995; 26:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/10/40105/abstract/19\">",
"      Kizer JR, Silvestry FE, Kimmel SE, et al. Racial differences in the prevalence of cardiac sources of embolism in subjects with unexplained stroke or transient ischemic attack evaluated by transesophageal echocardiography. Am J Cardiol 2002; 90:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/10/40105/abstract/20\">",
"      Ward RP, Don CW, Furlong KT, Lang RM. Racial differences in aortic atheroma in patients undergoing transesophageal echocardiography for unexplained stroke or transient ischemic attack. Am J Cardiol 2004; 94:1211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/10/40105/abstract/21\">",
"      Di Tullio MR, Sacco RL, Gersony D, et al. Aortic atheromas and acute ischemic stroke: a transesophageal echocardiographic study in an ethnically mixed population. Neurology 1996; 46:1560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/10/40105/abstract/22\">",
"      Gupta V, Nanda NC, Yesilbursa D, et al. Racial differences in thoracic aorta atherosclerosis among ischemic stroke patients. Stroke 2003; 34:408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/10/40105/abstract/23\">",
"      Polychronopoulos P, Gioldasis G, Ellul J, et al. Family history of stroke in stroke types and subtypes. J Neurol Sci 2002; 195:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/10/40105/abstract/24\">",
"      Jood K, Ladenvall C, Rosengren A, et al. Family history in ischemic stroke before 70 years of age: the Sahlgrenska Academy Study on Ischemic Stroke. Stroke 2005; 36:1383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/10/40105/abstract/25\">",
"      Yip PK, Jeng JS, Lee TK, et al. Subtypes of ischemic stroke. A hospital-based stroke registry in Taiwan (SCAN-IV). Stroke 1997; 28:2507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/10/40105/abstract/26\">",
"      Karttunen V, Alfthan G, Hiltunen L, et al. Risk factors for cryptogenic ischaemic stroke. Eur J Neurol 2002; 9:625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/10/40105/abstract/27\">",
"      Eikelboom JW, Hankey GJ, Anand SS, et al. Association between high homocyst(e)ine and ischemic stroke due to large- and small-artery disease but not other etiologic subtypes of ischemic stroke. Stroke 2000; 31:1069.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/10/40105/abstract/28\">",
"      Wald DS, Law M, Morris JK. Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. BMJ 2002; 325:1202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/10/40105/abstract/29\">",
"      Yoo JH, Chung CS, Kang SS. Relation of plasma homocyst(e)ine to cerebral infarction and cerebral atherosclerosis. Stroke 1998; 29:2478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/10/40105/abstract/30\">",
"      Parnetti L, Caso V, Santucci A, et al. Mild hyperhomocysteinemia is a risk-factor in all etiological subtypes of stroke. Neurol Sci 2004; 25:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/10/40105/abstract/31\">",
"      Emerging Risk Factors Collaboration, Kaptoge S, Di Angelantonio E, et al. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet 2010; 375:132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/10/40105/abstract/32\">",
"      Ridker PM, Cushman M, Stampfer MJ, et al. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997; 336:973.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/10/40105/abstract/33\">",
"      Rost NS, Wolf PA, Kase CS, et al. Plasma concentration of C-reactive protein and risk of ischemic stroke and transient ischemic attack: the Framingham study. Stroke 2001; 32:2575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/10/40105/abstract/34\">",
"      Elkind MS, Luna JM, Moon YP, et al. High-sensitivity C-reactive protein predicts mortality but not stroke: the Northern Manhattan Study. Neurology 2009; 73:1300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/10/40105/abstract/35\">",
"      Elkind MS, Lin IF, Grayston JT, Sacco RL. Chlamydia pneumoniae and the risk of first ischemic stroke : The Northern Manhattan Stroke Study. Stroke 2000; 31:1521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/10/40105/abstract/36\">",
"      Elkind MS, Tondella ML, Feikin DR, et al. Seropositivity to Chlamydia pneumoniae is associated with risk of first ischemic stroke. Stroke 2006; 37:790.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/10/40105/abstract/37\">",
"      Elkind MS, Ramakrishnan P, Moon YP, et al. Infectious burden and risk of stroke: the northern Manhattan study. Arch Neurol 2010; 67:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/10/40105/abstract/38\">",
"      Fieschi C, Argentino C, Lenzi GL, et al. Clinical and instrumental evaluation of patients with ischemic stroke within the first six hours. J Neurol Sci 1989; 91:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/10/40105/abstract/39\">",
"      Tayal AH, Tian M, Kelly KM, et al. Atrial fibrillation detected by mobile cardiac outpatient telemetry in cryptogenic TIA or stroke. Neurology 2008; 71:1696.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/10/40105/abstract/40\">",
"      Gaillard N, Deltour S, Vilotijevic B, et al. Detection of paroxysmal atrial fibrillation with transtelephonic EKG in TIA or stroke patients. Neurology 2010; 74:1666.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/10/40105/abstract/41\">",
"      Sposato LA, Klein FR, J&aacute;uregui A, et al. Newly diagnosed atrial fibrillation after acute ischemic stroke and transient ischemic attack: importance of immediate and prolonged continuous cardiac monitoring. J Stroke Cerebrovasc Dis 2012; 21:210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/10/40105/abstract/42\">",
"      Bhatt A, Majid A, Razak A, et al. Predictors of occult paroxysmal atrial fibrillation in cryptogenic strokes detected by long-term noninvasive cardiac monitoring. Stroke Res Treat 2011; 2011:172074.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/10/40105/abstract/43\">",
"      Rizos T, G&uuml;ntner J, Jenetzky E, et al. Continuous stroke unit electrocardiographic monitoring versus 24-hour Holter electrocardiography for detection of paroxysmal atrial fibrillation after stroke. Stroke 2012; 43:2689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/10/40105/abstract/44\">",
"      Wallmann D, T&uuml;ller D, Wustmann K, et al. Frequent atrial premature beats predict paroxysmal atrial fibrillation in stroke patients: an opportunity for a new diagnostic strategy. Stroke 2007; 38:2292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/10/40105/abstract/45\">",
"      Seet RC, Friedman PA, Rabinstein AA. Prolonged rhythm monitoring for the detection of occult paroxysmal atrial fibrillation in ischemic stroke of unknown cause. Circulation 2011; 124:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/10/40105/abstract/46\">",
"      Bernstein RA. Detection of atrial fibrillation after cryptogenic stroke. Curr Treat Options Cardiovasc Med 2012; 14:298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/10/40105/abstract/47\">",
"      Kamel H. Tracking down atrial fibrillation in the stroke unit. Stroke 2012; 43:2541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/10/40105/abstract/48\">",
"      Healey JS, Connolly SJ, Gold MR, et al. Subclinical atrial fibrillation and the risk of stroke. N Engl J Med 2012; 366:120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/10/40105/abstract/49\">",
"      Harloff A, Simon J, Brendecke S, et al. Complex plaques in the proximal descending aorta: an underestimated embolic source of stroke. Stroke 2010; 41:1145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/10/40105/abstract/50\">",
"      Bang OY, Lee PH, Joo SY, et al. Frequency and mechanisms of stroke recurrence after cryptogenic stroke. Ann Neurol 2003; 54:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/10/40105/abstract/51\">",
"      Mazighi M, Labreuche J, Gongora-Rivera F, et al. Autopsy prevalence of intracranial atherosclerosis in patients with fatal stroke. Stroke 2008; 39:1142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/10/40105/abstract/52\">",
"      Mazighi M, Labreuche J, Gongora-Rivera F, et al. Autopsy prevalence of proximal extracranial atherosclerosis in patients with fatal stroke. Stroke 2009; 40:713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/10/40105/abstract/53\">",
"      Austin H, Chimowitz MI, Hill HA, et al. Cryptogenic stroke in relation to genetic variation in clotting factors and other genetic polymorphisms among young men and women. Stroke 2002; 33:2762.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/10/40105/abstract/54\">",
"      Calabr&ograve; RS, La Spina P, Serra S, et al. Prevalence of prothrombotic polymorphisms in a selected cohort of cryptogenic and noncryptogenic ischemic stroke patients. Neurol India 2009; 57:636.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/10/40105/abstract/55\">",
"      Belv&iacute;s R, Santamar&iacute;a A, Mart&iacute;-F&agrave;bregas J, et al. Diagnostic yield of prothrombotic state studies in cryptogenic stroke. Acta Neurol Scand 2006; 114:250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/10/40105/abstract/56\">",
"      Rolfs A, B&ouml;ttcher T, Zschiesche M, et al. Prevalence of Fabry disease in patients with cryptogenic stroke: a prospective study. Lancet 2005; 366:1794.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/10/40105/abstract/57\">",
"      Brouns R, Sheorajpanday R, Braxel E, et al. Middelheim Fabry Study (MiFaS): a retrospective Belgian study on the prevalence of Fabry disease in young patients with cryptogenic stroke. Clin Neurol Neurosurg 2007; 109:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/10/40105/abstract/58\">",
"      Wozniak MA, Kittner SJ, Tuhrim S, et al. Frequency of unrecognized Fabry disease among young European-American and African-American men with first ischemic stroke. Stroke 2010; 41:78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/10/40105/abstract/59\">",
"      Lamy C, Giannesini C, Zuber M, et al. Clinical and imaging findings in cryptogenic stroke patients with and without patent foramen ovale: the PFO-ASA Study. Atrial Septal Aneurysm. Stroke 2002; 33:706.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/10/40105/abstract/60\">",
"      Murat Sumer M, Erturk O. Ischemic stroke subtypes: risk factors, functional outcome and recurrence. Neurol Sci 2002; 22:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/10/40105/abstract/61\">",
"      Albers GW, Comess KA, DeRook FA, et al. Transesophageal echocardiographic findings in stroke subtypes. Stroke 1994; 25:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/10/40105/abstract/62\">",
"      Cujec B, Polasek P, Voll C, Shuaib A. Transesophageal echocardiography in the detection of potential cardiac source of embolism in stroke patients. Stroke 1991; 22:727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/10/40105/abstract/63\">",
"      Pearson AC, Labovitz AJ, Tatineni S, Gomez CR. Superiority of transesophageal echocardiography in detecting cardiac source of embolism in patients with cerebral ischemia of uncertain etiology. J Am Coll Cardiol 1991; 17:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/10/40105/abstract/64\">",
"      Zahuranec DB, Mueller GC, Bach DS, et al. Pilot study of cardiac magnetic resonance imaging for detection of embolic source after ischemic stroke. J Stroke Cerebrovasc Dis 2012; 21:794.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/10/40105/abstract/65\">",
"      Boussel L, Cakmak S, Wintermark M, et al. Ischemic stroke: etiologic work-up with multidetector CT of heart and extra- and intracranial arteries. Radiology 2011; 258:206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/10/40105/abstract/66\">",
"      Yahia AM, Shaukat AB, Kirmani JF, et al. Treatable potential cardiac sources of embolism in patients with cerebral ischemic events: a selective transesophageal echocardiographic study. South Med J 2004; 97:1055.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/10/40105/abstract/67\">",
"      Cerrato P, Imperiale D, Priano L, et al. Transoesophageal echocardiography in patients without arterial and major cardiac sources of embolism: difference between stroke subtypes. Cerebrovasc Dis 2002; 13:174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/10/40105/abstract/68\">",
"      Censori B, Colombo F, Valsecchi MG, et al. Early transoesophageal echocardiography in cryptogenic and lacunar stroke and transient ischaemic attack. J Neurol Neurosurg Psychiatry 1998; 64:624.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/10/40105/abstract/69\">",
"      Petty GW, Brown RD Jr, Whisnant JP, et al. Ischemic stroke subtypes : a population-based study of functional outcome, survival, and recurrence. Stroke 2000; 31:1062.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/10/40105/abstract/70\">",
"      Lovett JK, Coull AJ, Rothwell PM. Early risk of recurrence by subtype of ischemic stroke in population-based incidence studies. Neurology 2004; 62:569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/10/40105/abstract/71\">",
"      Sacco RL, Foulkes MA, Mohr JP, et al. Determinants of early recurrence of cerebral infarction. The Stroke Data Bank. Stroke 1989; 20:983.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/10/40105/abstract/72\">",
"      Moroney JT, Bagiella E, Paik MC, et al. Risk factors for early recurrence after ischemic stroke: the role of stroke syndrome and subtype. Stroke 1998; 29:2118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/10/40105/abstract/73\">",
"      Mohr JP, Thompson JL, Lazar RM, et al. A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke. N Engl J Med 2001; 345:1444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/10/40105/abstract/74\">",
"      Hier DB, Foulkes MA, Swiontoniowski M, et al. Stroke recurrence within 2 years after ischemic infarction. Stroke 1991; 22:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/10/40105/abstract/75\">",
"      Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med 1995; 333:1581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/10/40105/abstract/76\">",
"      Furie KL, Kasner SE, Adams RJ, et al. Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack: a guideline for healthcare professionals from the american heart association/american stroke association. Stroke 2011; 42:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/10/40105/abstract/77\">",
"      Lansberg MG, O'Donnell MJ, Khatri P, et al. Antithrombotic and thrombolytic therapy for ischemic stroke: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141:e601S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/10/40105/abstract/78\">",
"      Sacco RL, Prabhakaran S, Thompson JL, et al. Comparison of warfarin versus aspirin for the prevention of recurrent stroke or death: subgroup analyses from the Warfarin-Aspirin Recurrent Stroke Study. Cerebrovasc Dis 2006; 22:4.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1090 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-89.32.226.102-CCFD8525CC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_10_40105=[""].join("\n");
var outline_f39_10_40105=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H25\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EPIDEMIOLOGY AND RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Demographic factors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Age",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Gender",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Race and ethnicity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Other risk factors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Atrial septal abnormalities",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Cardiac disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Diabetes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Family history",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Hypertension",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Homocysteine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Inflammatory and infectious causes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Lipids",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Prior TIA",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Smoking",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19246268\">",
"      Occult embolism from the heart or aorta",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19246582\">",
"      - Subclinical atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19246589\">",
"      - Atrial septal abnormalities",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19246596\">",
"      - Aortic embolism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19246254\">",
"      Large vessel disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19246261\">",
"      Other causes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      NATURAL HISTORY AND PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      PREVENTION AND TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEURO/1090\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/1090|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?3/28/3531\" title=\"table 1\">",
"      TOAST classification",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?22/32/23051\" title=\"table 2\">",
"      Modified Rankin scale",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/32/36361?source=related_link\">",
"      Ambulatory monitoring in the assessment of cardiac arrhythmias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/35/2618?source=related_link\">",
"      Antiplatelet therapy for secondary prevention of stroke",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/60/31688?source=related_link\">",
"      Antithrombotic treatment of acute ischemic stroke and transient ischemic attack",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/48/39689?source=related_link\">",
"      Atrial septal abnormalities (PFO, ASD, and ASA) and risk of cerebral emboli in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/17/40216?source=related_link\">",
"      Clinical diagnosis of stroke subtypes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/31/23034?source=related_link\">",
"      Clinical manifestations of the antiphospholipid syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/4/12361?source=related_link\">",
"      Echocardiography in detection of intracardiac sources of embolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/35/10809?source=related_link\">",
"      Embolism from aortic plaque: Thromboembolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/15/31994?source=related_link\">",
"      Embolism from atherosclerotic plaque: Atheroembolism (cholesterol crystal embolism)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/63/9208?source=related_link\">",
"      Etiology and classification of stroke",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/29/33242?source=related_link\">",
"      Initial assessment and management of acute stroke",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/23/5497?source=related_link\">",
"      Left ventricular thrombus after acute myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/56/17290?source=related_link\">",
"      Neuroimaging of acute ischemic stroke",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/37/19034?source=related_link\">",
"      Overview of homocysteine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/47/28410?source=related_link\">",
"      Overview of the evaluation of stroke",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/8/41098?source=related_link\">",
"      Reperfusion therapy for acute ischemic stroke",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/61/30682?source=related_link\">",
"      Secondary prevention of stroke: Risk factor reduction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/63/14328?source=related_link\">",
"      Treatment of atrial septal abnormalities (PFO, ASD, and ASA) for prevention of stroke in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f39_10_40106="Pulmonary complications after allogeneic hematopoietic cell transplantation";
var content_f39_10_40106=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pulmonary complications after allogeneic hematopoietic cell transplantation",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/10/40106/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/10/40106/contributors\">",
"     Robert J Kaner, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/10/40106/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/10/40106/contributors\">",
"     Talmadge E King, Jr, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/10/40106/contributors\">",
"     Robert S Negrin, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/10/40106/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/10/40106/contributors\">",
"     Helen Hollingsworth, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?39/10/40106/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 29, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Allogeneic hematopoietic cell transplantation (HCT) is the treatment of choice for many hematologic disorders. Pulmonary complications are a common cause of morbidity and occasionally mortality following this procedure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/10/40106/abstract/1-3\">",
"     1-3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Certain aspects of the transplant procedure influence the later development of pulmonary disease; the pretransplant conditioning regimen and posttransplant immunosuppression contribute to direct lung toxicity and increase the risk of opportunistic infections.",
"   </p>",
"   <p>",
"    The pulmonary complications of allogeneic HCT will be reviewed here. The determination of eligibility for HCT, infectious complications of HCT, supportive care following HCT, and pulmonary complications of",
"    <strong>",
"     autologous",
"    </strong>",
"    HCT are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/50/22314?source=see_link\">",
"     \"Determining eligibility for allogeneic hematopoietic cell transplantation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/30/25066?source=see_link\">",
"     \"Overview of infections following hematopoietic cell transplantation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/39/29306?source=see_link\">",
"     \"Supportive care after hematopoietic cell transplantation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/25/14745?source=see_link\">",
"     \"Pulmonary complications after autologous hematopoietic cell transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     OVERVIEW AND DEFINITIONS",
"    </span>",
"   </p>",
"   <p>",
"    Hematopoietic cell transplantation (HCT) is a general term for a variety of procedures in which the patient is treated with chemotherapy",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    irradiation (ie, the &ldquo;preparative regimen&rdquo;) followed by the infusion of hematopoietic progenitor cells. Progenitor cells can come from a variety of sources (eg, bone marrow, peripheral blood, cord blood). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/49/38682?source=see_link\">",
"     \"Sources of hematopoietic stem cells\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H895198\">",
"    <span class=\"h2\">",
"     Allogeneic versus autologous HCT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Allogeneic HCT refers to the use of hematopoietic progenitor cells collected from a relative (which can be HLA identical, haploidentical, or mismatched) or an unrelated donor (volunteer or umbilical cord donor). Autologous HCT refers to collection of hematopoietic progenitor cells from the patient prior to the administration of high dose chemotherapy designed to target an underlying malignancy, followed by reinfusion of these cells.",
"   </p>",
"   <p>",
"    Many of the pulmonary complications of allogeneic HCT also occur with autologous HCT, but there are some important differences. Prevention of graft rejection and graft-versus-host disease (GVHD) in allogeneic HCT necessitates more intense immunosuppression than that required for autologous HCT, which does not have these complications. Allogeneic grafts may be associated with development of potentially detrimental GVHD. On the other hand, some allogeneic HCT patients may benefit from a graft-versus-tumor effect. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/43/44729?source=see_link\">",
"     \"Biology of the graft-versus-tumor effect following hematopoietic cell transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Autologous HCT is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/47/31482?source=see_link\">",
"     \"Autologous hematopoietic cell transplantation in multiple myeloma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/25/14745?source=see_link\">",
"     \"Pulmonary complications after autologous hematopoietic cell transplantation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/50/19241?source=see_link\">",
"     \"Determining eligibility for autologous hematopoietic cell transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H895213\">",
"    <span class=\"h2\">",
"     Preparative conditioning regimen",
"    </span>",
"    &nbsp;&mdash;&nbsp;Preparative conditioning regimens are designed to ablate or suppress the host bone marrow and thereby prevent graft rejection, but have the potential to cause pulmonary toxicity. Preparative regimens for HCT have been termed myeloablative (eg, total body irradiation &ge;5Gy, high dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/10/10408?source=see_link\">",
"     busulfan",
"    </a>",
"    ), nonmyeloablative (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9545?source=see_link\">",
"     fludarabine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    , antithymocyte globulin, irradiation &le;2Gy), and reduced intensity (eg, low dose busulfan,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/54/22376?source=see_link\">",
"     melphalan",
"    </a>",
"    ). The various preparative conditioning regimens are discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/34/25130?source=see_link\">",
"     \"Preparative regimens for hematopoietic cell transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H895392\">",
"    <span class=\"h2\">",
"     Engraftment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Engraftment after HCT is defined as the attainment of an absolute neutrophil count (ANC) of",
"    <span class=\"nowrap\">",
"     1000/microL,",
"    </span>",
"    or three consecutive days with a count greater than 500. Time to engraftment is variable, and dependent on multiple variables, including cell source, graft composition, and type of conditioning.",
"   </p>",
"   <p>",
"    At the time of engraftment of donor hematopoietic cells, patients may develop a cytokine-driven engraftment syndrome. (See",
"    <a class=\"local\" href=\"#H6458592\">",
"     'Engraftment syndrome'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H895268\">",
"    <span class=\"h2\">",
"     Maintenance immunosuppression",
"    </span>",
"    &nbsp;&mdash;&nbsp;After allogeneic HCT, maintenance immunosuppression is administered to prevent graft rejection and graft-versus-host disease (GVHD). A commonly used regimen is the combination of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    and a calcineurin inhibitor such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    ; alternative or additional agents include glucocorticoids,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil, and also agents targeting T cell depletion. These agents contribute to the risk of pulmonary toxicity and opportunistic infections. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/11/10425?source=see_link\">",
"     \"Prevention and treatment of acute graft-versus-host disease: Recommendations\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/13/24792?source=see_link\">",
"     \"Prevention of acute graft-versus-host disease: Trials of T cell depletion\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1426020\">",
"    <span class=\"h2\">",
"     Graft-versus-host disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Graft-versus-host disease (GVHD) occurs when immune cells transplanted from a non-identical donor (the graft) recognize the transplant recipient (the host) as foreign, thereby initiating an immune reaction that causes disease in the transplant recipient. Hyperacute GVHD, which is rare with current HLA typing, occurs in the first 14 days post HCT, acute GVHD in the first 100 days, and chronic GVHD after the first 100 days, although the specific timing is approximate. Despite preconditioning and maintenance immunosuppression to prevent GVHD, a substantial proportion of allogeneic HCT recipients are affected by GVHD. GVHD in turn may increase the risk of certain pulmonary complications, such as the idiopathic pneumonia syndrome, diffuse alveolar hemorrhage, bronchiolitis obliterans, and late-occurring infections.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14112523\">",
"    <span class=\"h1\">",
"     APPROACH TO THE PATIENT WITH RESPIRATORY SYMPTOMS OR SIGNS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The approach to evaluating pulmonary complications that occur after allogeneic HCT begins with considering the timing of onset of the pulmonary disease (eg, before or after engraftment), the appearance of the chest radiograph (eg, clear, focal opacities, diffuse opacities), and the following features:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The risk for certain infections can be predicted based on pretransplant serostatus (eg, cytomegalovirus, herpes simplex virus, HIV, varicella-zoster virus, Epstein-Barr virus, toxoplasmosis), prior exposures (eg, cats, birds, mycobacteria, endemic fungi) of the recipient and donor, and also the history of prophylaxis for infectious agents.",
"     </li>",
"     <li>",
"      History of timing, dose, and field of radiation therapy delivered to the chest to treat the underlying malignancy or as part of the conditioning regimen, as radiation pneumonitis is a potential cause of respiratory symptoms and signs. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?23/33/24090?source=see_link\">",
"       \"Radiation-induced lung injury\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Exposure to drugs that cause pulmonary or cardiac toxicity during the pretransplant treatment of the primary disease. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?13/42/13993?source=see_link\">",
"       \"Pulmonary toxicity associated with systemic antineoplastic therapy: Clinical presentation, diagnosis, and treatment\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?16/41/17050?source=see_link\">",
"       \"Pulmonary toxicity associated with antineoplastic therapy: Cytotoxic agents\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?40/46/41706?source=see_link\">",
"       \"Cardiotoxicity of anthracycline-like chemotherapy agents\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?39/12/40138?source=see_link\">",
"       \"Cardiotoxicity of nonanthracycline cancer chemotherapy agents\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Knowledge of the current and previous immunosuppressive and chemotherapeutic agents (eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/10/10408?source=see_link\">",
"       busulfan",
"      </a>",
"      , glucocorticoids) helps in assessing the risk of opportunistic infection and the likelihood of lung toxicity due to the agents given. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?13/42/13993?source=see_link\">",
"       \"Pulmonary toxicity associated with systemic antineoplastic therapy: Clinical presentation, diagnosis, and treatment\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The acuity of illness (eg, fever, tachypnea, hypoxemia, leukocyte counts) should guide the rapidity of the evaluation and the need for empiric antibiotics. Almost all febrile HCT recipients are treated empirically with broad-spectrum antibiotics, until a causative organism is identified or an alternate diagnosis is confirmed. The choice of empiric therapy should depend upon the risk for specific infections, the potential sites of infection and the susceptibility patterns at a given institution (",
"    <a class=\"graphic graphic_figure graphicRef52716 \" href=\"mobipreview.htm?8/10/8362\">",
"     figure 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/30/25066?source=see_link\">",
"     \"Overview of infections following hematopoietic cell transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H88599790\">",
"    <span class=\"h1\">",
"     CAUSES AND CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The types of pulmonary complications that occur following allogeneic HCT vary based on the time since the transplant occurred, although some complications can occur both early and late (",
"    <a class=\"graphic graphic_table graphicRef83194 \" href=\"mobipreview.htm?1/42/1709\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef83195 \" href=\"mobipreview.htm?16/20/16718\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H88599890\">",
"    <span class=\"h2\">",
"     Preengraftment period",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the preengraftment period from HCT up to engraftment (eg, about 0 to 30 days post HCT), the differential diagnosis of pulmonary complications includes infection, pulmonary edema due to cardiac and noncardiac causes such as sepsis syndrome or aspiration, and the engraftment syndrome (",
"    <a class=\"graphic graphic_table graphicRef83194 \" href=\"mobipreview.htm?1/42/1709\">",
"     table 1",
"    </a>",
"    ). Symptoms and signs are nonspecific and include fever, dyspnea, cough, and hypoxemia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H193827185\">",
"    <span class=\"h3\">",
"     Pulmonary infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infections due to aerobic gram positive and gram negative bacteria, fungi, and certain viruses occur in up to 10 percent of HCT recipients in the preengraftment phase (",
"    <a class=\"graphic graphic_figure graphicRef52716 \" href=\"mobipreview.htm?8/10/8362\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/10/40106/abstract/4-6\">",
"     4-6",
"    </a>",
"    ]. In addition to the effects of neutropenia, mucositis from the conditioning regimen contributes to the risk of infection via swallowing difficulties, aspiration, and possibly impaired mucociliary clearance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/10/40106/abstract/7-9\">",
"     7-9",
"    </a>",
"    ]. Distinguishing clinical, radiographic, and other diagnostic features of these infections are shown in the table (",
"    <a class=\"graphic graphic_table graphicRef83194 \" href=\"mobipreview.htm?1/42/1709\">",
"     table 1",
"    </a>",
"    ). A general approach to lung infection in immunocompromised patients and the spectrum of infections that complicate HCT is provided separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/51/25402?source=see_link\">",
"     \"Approach to the immunocompromised patient with fever and pulmonary infiltrates\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/30/25066?source=see_link\">",
"     \"Overview of infections following hematopoietic cell transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Among 427 consecutive allogeneic recipients, bacterial pneumonia developed in the first post-HCT month in 4 percent; fungal pneumonia in 9 percent, and viral pneumonia in 2 percent; 4 percent had suspected pneumonia without a specific organism being identified [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/10/40106/abstract/5\">",
"     5",
"    </a>",
"    ]. Pneumonia was a major contributor to mortality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/10/40106/abstract/5\">",
"     5",
"    </a>",
"    ]. The most common bacterial causes of pneumonia were Escherichia coli, Pseudomonas aeruginosa and Streptococcus pneumoniae.",
"   </p>",
"   <p>",
"    HCT recipients are at risk for serious lung infection due to respiratory virus infections, such as influenza A and B, parainfluenza viruses (PIV) especially PIV 3, respiratory syncytial virus (RSV) and human metapneumovirus (hMPV). Lymphopenia appears to be an important risk factor for respiratory virus infection. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/30/25066?source=see_link\">",
"     \"Overview of infections following hematopoietic cell transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Aspergillus pneumonia in neutropenic patients may present with the classic triad of fever, pleuritic chest pain, and hemoptysis, although this triad is frequently not present. The radiographic appearance is varied and includes single or multiple nodules with or without cavitation, patchy or segmental consolidation, or peribronchial opacities (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef70038 \" href=\"mobipreview.htm?41/33/42515\">",
"     image 1",
"    </a>",
"    ). A characteristic feature of aspergillus nodules in the neutropenic patient is a surrounding ground glass opacity (the halo sign) that reflects angioinvasion and hemorrhage into the surrounding tissue (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef56195 \" href=\"mobipreview.htm?41/47/42738\">",
"     image 2",
"    </a>",
"    ). However, the halo sign is not specific to aspergillus and can be seen with other fungi, such as Fusarium spp, agents of Mucormycosis , and Scedosporium spp. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/30/25066?source=see_link\">",
"     \"Overview of infections following hematopoietic cell transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Candida pneumonitis is rare due to the frequent use of prophylaxis with antifungal azole derivatives. In a case series of candida pneumonitis in HCT recipients, the typical presentation was fever unresponsive to board-spectrum antibiotics [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/10/40106/abstract/10\">",
"     10",
"    </a>",
"    ]. CT findings included multiple nodules ranging from 3 to 30 mm in diameter in 15 patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/10/40106/abstract/10\">",
"     10",
"    </a>",
"    ]. Air-space consolidation was present in 11 patients and in five, nodules were surrounded by discrete areas of ground-glass opacity (CT halo sign). In those patients with acute lung injury due to candida pneumonitis, the CT scan showed extensive ground glass opacities in addition to a focal area of consolidation. The bronchoalveolar lavage grew Candida in all patients. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/30/25066?source=see_link\">",
"     \"Overview of infections following hematopoietic cell transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H193827060\">",
"    <span class=\"h3\">",
"     Pulmonary edema",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pulmonary edema of cardiogenic or noncardiogenic origin can occur in the first month after HCT, sometimes complicating other processes such as pneumonia, sepsis, the engraftment syndrome, or hyperacute graft-versus-host-disease (GVHD). (See",
"    <a class=\"local\" href=\"#H6458592\">",
"     'Engraftment syndrome'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H193827192\">",
"     'Hyperacute and acute graft-versus-host disease'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Cardiac dysfunction can result from previous therapy for the primary disease with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    , anthracyclines, or external beam chest irradiation. Among patients with mild cardiac dysfunction, the administration of large volumes of intravenous fluids because of mucositis or antibiotic treatment for neutropenic fever can lead to pulmonary edema. The radiographic manifestations of cardiogenic pulmonary edema include interlobular septal thickening, cephalad vascular distribution, ground glass opacification (sometimes in a perihilar &ldquo;butterfly&rdquo; distribution) (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef58394 \" href=\"mobipreview.htm?5/36/5701\">",
"     image 3",
"    </a>",
"    ), pleural effusions, and sometimes cardiomegaly. The plasma brain natriuretic peptide (BNP) is usually elevated and the echocardiogram shows left ventricular dysfunction. The evaluation of cardiogenic pulmonary edema is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/23/7544?source=see_link\">",
"     \"Evaluation of acute decompensated heart failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    On the other hand, noncardiogenic pulmonary edema can be induced by sepsis, aspiration pneumonia, viral infection (eg, influenza) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/10/40106/abstract/11\">",
"     11",
"    </a>",
"    ], toxic effects of the conditioning regimen, or hyperacute GVHD. The evaluation of noncardiogenic pulmonary edema is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/57/1944?source=see_link\">",
"     \"Noncardiogenic pulmonary edema\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/22/25960?source=see_link&amp;anchor=H10#H10\">",
"     \"Clinical manifestations, diagnosis, and grading of acute graft-versus-host disease\", section on 'Hyperacute GVHD'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with severe hepatic veno-occlusive disease (another complication of HCT) can present with either cardiogenic or noncardiogenic pulmonary edema with pleural effusions. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/4/40009?source=see_link&amp;anchor=H2#H2\">",
"     \"Pathogenesis and clinical features of hepatic sinusoidal obstruction syndrome (veno-occlusive disease) following hematopoietic cell transplantation\", section on 'Clinical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6458592\">",
"    <span class=\"h3\">",
"     Engraftment syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;The engraftment syndrome is a noninfectious complication that is reported in 7 to 10 percent of autologous HCT, but only rarely following allogeneic HCT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/10/40106/abstract/12\">",
"     12",
"    </a>",
"    ]. It develops around 7 to 11 days following HCT during the time of neutrophil recovery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/10/40106/abstract/13\">",
"     13",
"    </a>",
"    ]. The engraftment syndrome usually causes only mild symptoms, but can result in dyspnea, fever &ge;38.3��C, an erythematous maculo-papular rash (not attributable to a drug), weight gain, hypoxemia, and diffuse pulmonary opacities consistent with noncardiogenic pulmonary edema [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/10/40106/abstract/14-20\">",
"     14-20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The pulmonary manifestations of the engraftment syndrome are felt to be due to diffuse capillary leakage. Findings on chest computed tomography include bilateral ground-glass opacification, hilar or peribronchial consolidation, and thickening of interlobular septa [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/10/40106/abstract/12,21,22\">",
"     12,21,22",
"    </a>",
"    ]. Pleural effusions were common in one series [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/10/40106/abstract/13,23\">",
"     13,23",
"    </a>",
"    ]. Bronchoalveolar lavage may show neutrophilia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/10/40106/abstract/13\">",
"     13",
"    </a>",
"    ]. In two patients who underwent lung biopsy, diffuse alveolar damage was noted.",
"   </p>",
"   <p>",
"    The presence of a skin rash raises the possibility that the engraftment syndrome is a manifestation of hyperacute GVHD. However, the exact findings on skin biopsy in patients with engraftment syndrome include mild edematous changes of the epidermal-dermal junction, absence of lymphocytic infiltration, presence of neutrophils in the lumen of small venules and capillaries [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/10/40106/abstract/19\">",
"     19",
"    </a>",
"    ]. In contrast, skin biopsy in acute GVHD typically shows interface dermatitis (vacuolization of the basal layer of the epidermis and a lymphocytic infiltrate in the superficial dermis) and epidermal apoptotic keratinocytes. However, the accuracy of differentiation of these processes by skin biopsy is unclear. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/5/42073?source=see_link&amp;anchor=H832193#H832193\">",
"     \"Cutaneous manifestations of graft-versus-host disease (GVHD)\", section on 'Skin biopsy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The evaluation and management of the engraftment syndrome are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/25/14745?source=see_link&amp;anchor=H15960344#H15960344\">",
"     \"Pulmonary complications after autologous hematopoietic cell transplantation\", section on 'Engraftment syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H193827192\">",
"    <span class=\"h3\">",
"     Hyperacute and acute graft-versus-host disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hyperacute and acute GVHD are the consequence of HLA mismatch between the donor and recipient. With accurate HLA typing using molecular methods, hyperacute GVHD is very rare.",
"   </p>",
"   <p>",
"    Hyperacute GVHD occurs in the first 14 days post transplant and is frequently (88 percent) associated with both skin involvement and noncardiogenic pulmonary edema. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/22/25960?source=see_link&amp;anchor=H3#H3\">",
"     \"Clinical manifestations, diagnosis, and grading of acute graft-versus-host disease\", section on 'Clinical and histological manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Acute graft-versus-host disease (GVHD) develops in the first 100 days following allogeneic HCT, although it is recognized that signs and symptoms can occur later in some patients&rsquo; acute GVHD. It rarely affects the lung directly, although it can be a risk factor for noncardiogenic pulmonary edema, diffuse alveolar hemorrhage, and later development of airflow obstruction. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Diffuse alveolar hemorrhage'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H193827060\">",
"     'Pulmonary edema'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H464750157\">",
"     'Airflow obstruction and bronchiolitis obliterans'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/22/25960?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and grading of acute graft-versus-host disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H88599909\">",
"    <span class=\"h2\">",
"     Post hematopoietic cell engraftment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The spectrum of pulmonary complications changes in the period after engraftment. Infections continue to be a significant cause of morbidity and mortality, although the specific organisms differ (",
"    <a class=\"graphic graphic_figure graphicRef52716 \" href=\"mobipreview.htm?8/10/8362\">",
"     figure 1",
"    </a>",
"    ). The idiopathic pneumonia syndrome, diffuse alveolar hemorrhage, and pulmonary alveolar proteinosis are infrequent, but can cause substantial pulmonary morbidity (",
"    <a class=\"graphic graphic_table graphicRef83195 \" href=\"mobipreview.htm?16/20/16718\">",
"     table 2",
"    </a>",
"    ). Noncardiogenic and cardiogenic pulmonary edema are more common preengraftment, but also occur postengraftment. Pulmonary thromboembolism has not specifically been associated with allogeneic HCT, but is a potential complication of hospitalization and severe medical illness.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H194946070\">",
"    <span class=\"h3\">",
"     Pulmonary infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the postengraftment period (ie, three weeks to three months), impaired cellular and humoral immunity are the main factors contributing to pulmonary infection. In the late postengraftment period (ie, more than three months after HCT), infectious complications are less common; the major risk factors for infection in this phase are chronic GVHD and its therapy. The organisms that cause lung infection in the post engraftment period are shown in the figure (",
"    <a class=\"graphic graphic_figure graphicRef52716 \" href=\"mobipreview.htm?8/10/8362\">",
"     figure 1",
"    </a>",
"    ) and are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/30/25066?source=see_link\">",
"     \"Overview of infections following hematopoietic cell transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The features related to postengraftment pulmonary infection are reviewed here:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Bacteria",
"      </strong>",
"      &ndash; Lung infection due to S. pneumoniae and H. influenzae, although less frequent than preengraftment, continues to occur in the first year post-HCT, largely associated with defects in cellular and humoral immunity. During this period, numerous other bacteria can cause infection, including Legionella, Nocardia, mycobacteria, and actinomycosis.",
"     </li>",
"     <li>",
"      <strong>",
"       Mycobacteria",
"      </strong>",
"      &ndash; Mycobacterial and atypical mycobacterial infections are occasionally reported after HCT [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/10/40106/abstract/24\">",
"       24",
"      </a>",
"      ]. The overall incidence of M. tuberculosis infections in allogeneic bone marrow transplant patients is 1 to 3 percent, except in Hong Kong where the incidence is reported to be &gt;5 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/10/40106/abstract/25\">",
"       25",
"      </a>",
"      ]. Total body irradiation and chronic GVHD (requiring enhanced immunosuppressive therapy) are associated with an increased risk of tuberculosis. Allogeneic HCT is associated with depressed delayed-type hypersensitivity reactions, so skin testing with purified protein derivative (PPD) is not likely to be helpful. Sputum samples are usually diagnostic. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?24/30/25066?source=see_link\">",
"       \"Overview of infections following hematopoietic cell transplantation\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      M. haemophilum and M. avium complex can be important pulmonary pathogens after HCT [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/10/40106/abstract/24,26,27\">",
"       24,26,27",
"      </a>",
"      ]. The diagnosis of M. haemophilum should be suspected in patients who have skin nodules or joint inflammation with or without pulmonary infiltrates. Confirmation of the diagnosis requires special culture conditions for isolation; thus, close communication with the microbiology laboratory is essential. Failure to recognize this treatable pathogen in a timely fashion can lead to a fatal outcome.",
"      <br/>",
"      <br/>",
"      The treatment of mycobacterial infections is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?19/21/19802?source=see_link\">",
"       \"Treatment of pulmonary tuberculosis in HIV-negative patients\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?2/24/2441?source=see_link\">",
"       \"Treatment of nontuberculous mycobacterial infections of the lung in HIV-negative patients\"",
"      </a>",
"      .) &nbsp;",
"     </li>",
"     <li>",
"      <strong>",
"       Cytomegalovirus",
"      </strong>",
"      &ndash; CMV pneumonitis rarely occurs during the preengraftment period, as the major risk involves cellular immunity. However, once engraftment occurs, it should be included in the differential diagnosis of cough, fever, or dyspnea, even in the absence of radiographic abnormalities. The risk is highest in seropositive recipients who receive marrow from a seronegative donor. Preemptive and prophylactic antiviral therapy has markedly reduced the incidence and severity of CMV disease and delayed its onset, although CMV must be considered in any allogeneic HCT recipient who is CMV seropositive or received hematopoietic cells from a seropositive donor [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/10/40106/abstract/28\">",
"       28",
"      </a>",
"      ]. Chest radiographs typically show patchy areas of ground glass or consolidation (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef74416 \" href=\"mobipreview.htm?12/24/12679\">",
"       image 4",
"      </a>",
"      ). High resolution computed tomography (HRCT) may show ground glass attenuation, parenchymal opacification, or innumerable small (&lt;5 mm) nodules [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/10/40106/abstract/29,30\">",
"       29,30",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      The diagnosis and treatment of CMV pneumonitis is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?24/30/25066?source=see_link\">",
"       \"Overview of infections following hematopoietic cell transplantation\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?8/25/8597?source=see_link\">",
"       \"Diagnosis of cytomegalovirus\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Respiratory viruses",
"      </strong>",
"      &ndash; Community-acquired infections with influenza, parainfluenza, respiratory syncytial virus, adenoviruses, and human metapneumovirus can occur during the postengraftment period (",
"      <a class=\"graphic graphic_figure graphicRef52716 \" href=\"mobipreview.htm?8/10/8362\">",
"       figure 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef83195 \" href=\"mobipreview.htm?16/20/16718\">",
"       table 2",
"      </a>",
"      ). Some specific details that pertain to postengraftment lung infection in HCT recipients are provided below. Viral infections following HCT are discussed in greater detail separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?24/30/25066?source=see_link\">",
"       \"Overview of infections following hematopoietic cell transplantation\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Influenza virus has the potential to cause serious lung infection and respiratory failure among HCT recipients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/10/40106/abstract/31\">",
"       31",
"      </a>",
"      ]. This was noted in particular with the 2009 pandemic influenza",
"      <span class=\"nowrap\">",
"       A/H1N1",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/10/40106/abstract/32\">",
"       32",
"      </a>",
"      ]. Infections with influenza tend to be seasonal, predominantly between November and April in North America. Progression to pneumonia is more likely among lymphopenic patients and thus is more common preengraftment than postengraftment [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/10/40106/abstract/31\">",
"       31",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Parainfluenza virus, a recognized cause of both upper and lower respiratory tract disease after HCT, affects 2 to 7 percent of HCT recipients and is seasonal. There are four serotypes, with type 3 being the most common cause of lung infection after HCT; the incubation period is one to four days. Upper respiratory tract symptoms may precede lower tract disease by several days, although pneumonia may occur without upper respiratory symptoms. Parainfluenza virus is also associated with asymptomatic shedding in HCT recipients.",
"      <br/>",
"      The HRCT findings in parainfluenza virus pneumonia include small peribronchial nodular opacities, ground glass opacities,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      air space consolidation (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef68781 \" href=\"mobipreview.htm?9/38/9830\">",
"       image 5",
"      </a>",
"      ). The evaluation and treatment of parainfluenza virus are discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?24/30/25066?source=see_link\">",
"       \"Overview of infections following hematopoietic cell transplantation\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?0/38/617?source=see_link&amp;anchor=H12#H12\">",
"       \"Parainfluenza viruses in adults\", section on 'Immunocompromised hosts'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Pneumonia due to respiratory syncytial virus (RSV) affects adult patients as well as children and has a high mortality after HCT [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/10/40106/abstract/33\">",
"       33",
"      </a>",
"      ]. There is a marked seasonal variation in incidence, with the peak between January and March. In addition, RSV can occur as a nosocomial outbreak [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/10/40106/abstract/34\">",
"       34",
"      </a>",
"      ]. The presence of concomitant otitis media or sinusitis should raise the suspicion for RSV infection. Diffuse ground glass opacities are the most common radiographic pattern associated with RSV pneumonitis. The diagnosis can be established by culture or rapid immunofluorescence of respiratory secretions, throat swabs, or nasopharyngeal washes. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?6/56/7050?source=see_link\">",
"       \"Respiratory syncytial virus infection: Clinical features and diagnosis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?37/27/38327?source=see_link\">",
"       \"Respiratory syncytial virus infection: Treatment\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Adenoviruses, which can be isolated in 3 to 5 percent of patients after HCT, should be considered in the differential diagnosis of pulmonary infection [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/10/40106/abstract/35\">",
"       35",
"      </a>",
"      ]. Affected patients present with pharyngitis, tracheitis, bronchitis, pneumonitis, enteritis, hemorrhagic cystitis, or disseminated disease and may progress to fatal pneumonia. The specific pattern of symptoms depends at least in part on the particular serotype and on the age of the recipient. Younger HCT recipients appear to be at risk for more severe infection. Asymptomatic shedding of adenovirus can often be detected in cultures from the pharynx, respiratory secretions, stool, or urine two to three months post-HCT [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/10/40106/abstract/36\">",
"       36",
"      </a>",
"      ]. The clinical manifestations, diagnosis, and management of adenovirus lung infection are discussed in detail separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?38/21/39257?source=see_link\">",
"       \"Epidemiology and clinical manifestations of adenovirus infection\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?36/40/37513?source=see_link&amp;anchor=H16#H16\">",
"       \"Diagnosis and treatment of adenovirus infection\", section on 'Treatment'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Human metapneumovirus is emerging as a pathogen affecting HCT recipients and is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?32/33/33304?source=see_link\">",
"       \"Human metapneumovirus infections\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Human herpes virus 6",
"      </strong>",
"      &ndash; Pneumonia due to human herpes virus-6 (HHV-6) has been reported after HCT, although active pneumonitis due to this virus appears uncommon [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/10/40106/abstract/37,38\">",
"       37,38",
"      </a>",
"      ]. HHV-6 reactivation occurs in approximately half of allogeneic HCT recipients and may account for some cases of pneumonitis previously considered to be idiopathic [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/10/40106/abstract/39\">",
"       39",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Idiopathic pneumonia syndrome'",
"      </a>",
"      below.) The clinical manifestations of HHV-6 infection are poorly described, and the prevalence of HHV-6 as a cause of interstitial pneumonia post-HCT remains to be determined. The diagnosis of HHV6 as a cause of pneumonitis has been drawn into question given that this virus is latent in lymphocytes, which complicates the interpretation of histopathology. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?10/1/10265?source=see_link\">",
"       \"Clinical manifestations, diagnosis, and treatment of human herpesvirus-6 infection in adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?24/30/25066?source=see_link\">",
"       \"Overview of infections following hematopoietic cell transplantation\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Fungal infection",
"      </strong>",
"      &ndash; During the postengraftment period, patients are at risk for infection with aspergillosis, other invasive molds, and Pneumocystis carinii (P. jirovecii) pneumonia (PCP) (",
"      <a class=\"graphic graphic_table graphicRef83195 \" href=\"mobipreview.htm?16/20/16718\">",
"       table 2",
"      </a>",
"      ). The median time of onset of Aspergillus infection is 100 days post-HCT; risk factors include older age, the presence and severity of GVHD, glucocorticoid therapy, and leukopenias. The radiographic features of Aspergillus infection are described above. (See",
"      <a class=\"local\" href=\"#H193827185\">",
"       'Pulmonary infections'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?24/30/25066?source=see_link\">",
"       \"Overview of infections following hematopoietic cell transplantation\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?33/51/34616?source=see_link&amp;anchor=H6#H6\">",
"       \"Epidemiology and clinical manifestations of invasive aspergillosis\", section on 'Pulmonary aspergillosis'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?3/52/3913?source=see_link&amp;anchor=H1064486416#H1064486416\">",
"       \"Diagnosis of invasive aspergillosis\", section on 'Diagnostic modalities'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?10/29/10712?source=see_link&amp;anchor=H773301049#H773301049\">",
"       \"Clinical manifestations and diagnosis of Fusarium infection\", section on 'Pneumonia'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Pneumocystis prophylaxis has reduced the risk of Pneumocystis pneumonia, which is a rare infection in patients who receive prophylaxis and take their medications. PCP is usually associated with diffuse radiographic opacities, but can occasionally present with focal opacities, cavitations, or a normal initial chest radiograph. Rarely, the conventional chest radiograph is normal in PCP, but high resolution computed tomography of the chest shows ground glass opacities. PCP is described in greater detail separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?24/30/25066?source=see_link\">",
"       \"Overview of infections following hematopoietic cell transplantation\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?22/8/22665?source=see_link\">",
"       \"Epidemiology, clinical manifestations, and diagnosis of Pneumocystis pneumonia in non-HIV-infected patients\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?9/4/9289?source=see_link\">",
"       \"Treatment and prevention of Pneumocystis pneumonia in non-HIV-infected patients\"",
"      </a>",
"      .).",
"     </li>",
"     <li>",
"      <strong>",
"       Toxoplasmosis",
"      </strong>",
"      &ndash; Reactivation of toxoplasmosis causing lung infection is rare following allogeneic HCT, particularly because most HCT candidates are tested for IgG and IgM antibodies to toxoplasmosis and, if positive, offered a course of therapy prior to HCT. The infection typically develops in the second month after transplantation in patients with a positive pretransplant serology who have not received preemptive treatment. The presence of neurologic toxoplasmosis should prompt assessment for disseminated disease. The radiographic presentation of toxoplasmosis is similar to that of Pneumocystis; Toxoplasma tachyzoites can be identified in BAL fluid. The clinical manifestations and diagnosis of toxoplasmosis are discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?24/30/25066?source=see_link\">",
"       \"Overview of infections following hematopoietic cell transplantation\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?32/22/33129?source=see_link&amp;anchor=H6#H6\">",
"       \"Toxoplasmosis in HIV-infected patients\", section on 'Clinical presentation'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?19/6/19559?source=see_link\">",
"       \"Diagnostic assays for toxoplasmosis infection\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Idiopathic pneumonia syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;The idiopathic pneumonia syndrome (IPS) is an important complication that develops in up to 10 percent of patients and generally occurs within four months after HCT, with a median time of onset of 19 days [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/10/40106/abstract/12,40-44\">",
"     12,40-44",
"    </a>",
"    ]. IPS may represent a heterogeneous group of disorders that result in the common pathologic findings of interstitial pneumonitis",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    diffuse alveolar damage.",
"   </p>",
"   <p>",
"    A consensus conference defined IPS as a clinical syndrome that fulfills the following criteria [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/10/40106/abstract/45\">",
"     45",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Widespread alveolar injury, defined as multilobar opacities on chest radiograph or CT scan PLUS signs and symptoms of pneumonia PLUS evidence of abnormal pulmonary physiology manifested by an increased alveolar-arterial oxygen gradient or the need for supplemental oxygen.",
"     </li>",
"     <li>",
"      Absence of lower respiratory tract infection, as determined by a negative bronchoalveolar lavage or lung biopsy, ideally followed by a second negative invasive test within two weeks.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The exact pathogenesis of IPS is not known, but the intensity of the preparative conditioning regimen has been implicated as a contributing factor. (See",
"    <a class=\"local\" href=\"#H895213\">",
"     'Preparative conditioning regimen'",
"    </a>",
"    above.) One retrospective study of 1100 patients found a lower incidence of IPS in patients treated with a nonmyeloablative versus a myeloablative regimen (2 versus 8 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/10/40106/abstract/41\">",
"     41",
"    </a>",
"    ]. A systematic analysis of 20 studies (1090 patients) found an association between the incidence of IPS and the use of high dose radiotherapy, high dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/10/10408?source=see_link\">",
"     busulfan",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/10/40106/abstract/46\">",
"     46",
"    </a>",
"    ]. Murine models suggest that these conditioning agents produce pulmonary epithelial injury followed by recruitment and activation of pulmonary macrophages and T-lymphocytes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/10/40106/abstract/44,47-49\">",
"     44,47-49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clinical manifestations include dyspnea, dry cough, hypoxemia, and diffuse radiographic opacities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/10/40106/abstract/45\">",
"     45",
"    </a>",
"    ]. The evaluation includes bronchoscopy with bronchoalveolar lavage and, if the patient will tolerate it, transbronchial biopsy. Surgical lung biopsy is occasionally performed if the transbronchial biopsy is contraindicated or inadequate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/10/40106/abstract/50\">",
"     50",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H14112893\">",
"     'Evaluation'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Optimal therapy of IPS in HCT recipients is uncertain but typically involves high dose glucocorticoids of 1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    or more, and prognosis is poor. In a series of approximately 81 patients who developed IPS after HCT, the disease progressed rapidly and the mortality rate was approximately 75 percent within 30 days of hospital discharge despite the use of high-dose glucocorticoid therapy in the majority of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/10/40106/abstract/41\">",
"     41",
"    </a>",
"    ]. Similar findings were noted in another study in which the mortality rate at one year was more than 85 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/10/40106/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The observation that certain cytokines (eg, interleukin [IL]-6, IL-8, tumor necrosis factor alpha) are increased in the bronchoalveolar lavage fluid of patients with IPS has led to studies of the combination of systemic glucocorticoids plus a tumor necrosis factor-alpha (TNF-alpha) inhibitor, such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/31/28151?source=see_link\">",
"     etanercept",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/10/40106/abstract/44,50-53\">",
"     44,50-53",
"    </a>",
"    ]. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a series of 15 patients with IPS who were treated with glucocorticoids plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/31/28151?source=see_link\">",
"       etanercept",
"      </a>",
"      (0.4",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      [maximum 25 mg]) twice weekly with a maximum of eight doses, 10 patients had a complete response within 3 to 18 days and the survival rate at 28 days was 73 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/10/40106/abstract/51\">",
"       51",
"      </a>",
"      ]. However, survival was only 20 percent at six months, a rate that persisted out to four years.",
"     </li>",
"     <li>",
"      Similar results were reported for a series of 11 patients with IPS; six received high-dose glucocorticoids alone and five also received",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/31/28151?source=see_link\">",
"       etanercept",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/6/28776?source=see_link\">",
"       infliximab",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/10/40106/abstract/52\">",
"       52",
"      </a>",
"      ]. The overall initial response rate was 81 percent; however, survival was only 30 percent at one year.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The safety and efficacy of TNF-alpha inhibitors for IPS are under investigation. Information about clinical trials for IPS is available on the NIH clinical trials web site (",
"    <a class=\"external\" href=\"file://clinicaltrials.gov/ct2/results?term=idiopathic+pneumonia+syndrome\">",
"     file://clinicaltrials.gov/ct2/results?term=idiopathic+pneumonia+syndrome",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Diffuse alveolar hemorrhage",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diffuse alveolar hemorrhage (DAH) occurs in less than 1 percent of HCT and is less common following allogeneic than autologous HCT (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef63710 \" href=\"mobipreview.htm?23/18/23845\">",
"     image 6",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef79321 \" href=\"mobipreview.htm?10/7/10353\">",
"     image 7",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/10/40106/abstract/54\">",
"     54",
"    </a>",
"    ]. However, among patients who undergo allogeneic HCT for an inherited metabolic storage disease, the risk of DAH is increased among those with mucopolysaccharidosis (19 percent), but not leukodystrophies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/10/40106/abstract/55\">",
"     55",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/25/14745?source=see_link&amp;anchor=H10#H10\">",
"     \"Pulmonary complications after autologous hematopoietic cell transplantation\", section on 'Diffuse alveolar hemorrhage'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    DAH following HCT is of unclear pathogenesis, but may be a consequence of factors such as infection, acute graft-versus-host-disease, or diffuse alveolar damage [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/10/40106/abstract/56\">",
"     56",
"    </a>",
"    ]. Mortality is high (&gt;80 percent) whether DAH is associated with infection or not [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/10/40106/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with DAH typically have patchy or diffuse opacities with air bronchograms on high resolution computed tomography. The diagnosis is typically made by bronchoalveolar lavage, which shows progressively hemorrhagic returns on sequential lavages in the same subsegment and hemosiderin-laden macrophages on cytologic analysis. The diagnostic evaluation of DAH is discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/61/23512?source=see_link\">",
"     \"The diffuse alveolar hemorrhage syndromes\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Treatment of DAH in the setting of allogeneic HCT depends on the underlying cause of DAH.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with infection-associated DAH, management includes treatment of the infection and general supportive care (eg, supplemental oxygen, mechanical ventilation). (See appropriate topic reviews.)",
"     </li>",
"     <li>",
"      For patients with DAH in the setting of acute GVHD, treatment is aimed at the acute GVHD with supportive care (eg, supplemental oxygen, mechanical ventilation) as necessary. Empiric antibiotics are often administered simultaneously. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?10/11/10425?source=see_link&amp;anchor=H13#H13\">",
"       \"Prevention and treatment of acute graft-versus-host disease: Recommendations\", section on 'Treatment'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For patients without evidence of infection or acute GVHD, systemic glucocorticoids are typically administered, despite the absence of formal data. In one report, four patients with DAH following allogeneic stem cell transplantation rapidly responded to glucocorticoids, although two of the patients ultimately died of multiple organ dysfunction [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/10/40106/abstract/57\">",
"       57",
"      </a>",
"      ]. Conversely, no significant response to glucocorticoids was noted in a small retrospective study of children who developed DAH following allogeneic stem cell transplantation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/10/40106/abstract/58\">",
"       58",
"      </a>",
"      ]. Similarly, in a larger retrospective series, there was no obvious survival benefit with glucocorticoid treatment [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/10/40106/abstract/59\">",
"       59",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Use of recombinant human Factor VII for refractory alveolar hemorrhage has been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/10/40106/abstract/60-63\">",
"     60-63",
"    </a>",
"    ]; the risks of fatal thrombotic events must be weighed if this therapy is considered.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6014419\">",
"    <span class=\"h3\">",
"     Connective tissue disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;A small number of patients have developed pulmonary involvement with autoimmune disease (eg, scleroderma, polymyositis, Sj&ouml;gren syndrome, antineutrophil cytoplasmic antibody-positive vasculitis) following allogeneic HCT; the mean onset is late, 31 months after HCT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/10/40106/abstract/64\">",
"     64",
"    </a>",
"    ]. The majority of these patients received a myeloablative conditioning regimen. A history of prior or current graft versus host disease (GVHD) was common.",
"   </p>",
"   <p>",
"    In a case series and literature review, the pulmonary manifestations of autoimmune disease included nonspecific interstitial pneumonia, lymphocytic pneumonia, diffuse alveolar damage, and bronchiolitis obliterans [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/10/40106/abstract/64\">",
"     64",
"    </a>",
"    ]. Autoantibodies, such as antinuclear antibody, anti-Scl70, antineutrophil cytoplasmic antibody (ANCA), anti-smooth muscle, and rheumatoid factor, were frequently noted. The patients described have had a poor prognosis, despite treatment with systemic glucocorticoids [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/10/40106/abstract/64\">",
"     64",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/25/23962?source=see_link&amp;anchor=H6225514#H6225514\">",
"     \"Clinical manifestations, diagnosis, and grading of chronic graft-versus-host disease\", section on 'Autoantibodies'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/25/409?source=see_link\">",
"     \"Lymphoid interstitial pneumonia in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/25/42393?source=see_link\">",
"     \"Nonspecific interstitial pneumonia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/16/22792?source=see_link\">",
"     \"Acute interstitial pneumonia (Hamman-Rich syndrome)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H193827199\">",
"    <span class=\"h3\">",
"     Organizing pneumonia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Organizing pneumonia (also known as bronchiolitis obliterans organizing pneumonia or BOOP) is reported following allogeneic HCT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/10/40106/abstract/65\">",
"     65",
"    </a>",
"    ] and may be idiopathic or related to lung irradiation, graft-versus host disease, or successful treatment of CMV pneumonitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/10/40106/abstract/66-68\">",
"     66-68",
"    </a>",
"    ], or chronic GVHD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/10/40106/abstract/69,70\">",
"     69,70",
"    </a>",
"    ]. Computed tomographic (CT) scans from patients with OP often reveal more extensive lung disease than expected from review of the plain chest radiograph. Radiographic patterns include patchy air-space consolidation, ground-glass opacities, small nodular opacities, and bronchial wall thickening with dilation. Patchy opacities occur most frequently in the periphery of the lung and at the lung bases. The diagnosis of OP is based upon the characteristic histopathologic pattern seen on surgical lung biopsy; treatment with systemic glucocorticoids is usually beneficial. The evaluation and management of organizing pneumonia is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/60/19402?source=see_link\">",
"     \"Cryptogenic organizing pneumonia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H193827206\">",
"    <span class=\"h3\">",
"     Malignancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The lungs can be the site of relapse of the underlying malignancy, development of a second cancer years after HCT, and secondary lymphoproliferative disease. Recurrence of the underlying malignancy in the lung is seen most commonly after allogeneic HCT for lymphoma. (See appropriate topic reviews for information about the pulmonary manifestations of the different types of lymphoma).",
"   </p>",
"   <p>",
"    Posttransplant lymphoproliferative disease (PTLD) developing after allogeneic HCT is thought to be a consequence of immunosuppression, which causes a deficiency in Epstein-Barr virus (EBV) specific cytotoxic T lymphocytes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/10/40106/abstract/71,72\">",
"     71,72",
"    </a>",
"    ]. The typical appearance of PTLD on chest CT is multiple pulmonary nodules with a peripheral or basal predominance; other patterns include patchy consolidation, mediastinal and hilar lymphadenopathy, pleural or chest wall masses and pleural effusion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/10/40106/abstract/73\">",
"     73",
"    </a>",
"    ]. Biopsy and histopathologic analysis are needed for diagnosis, which typically reveals EBV. While refractory to standard chemotherapy, post-HCT lymphoproliferative disease may respond to other treatment protocols, including",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    and reduced immunosuppression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/10/40106/abstract/74\">",
"     74",
"    </a>",
"    ]. The diagnosis and management of secondary lymphoproliferative disorders are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/50/23338?source=see_link\">",
"     \"Treatment and prevention of post-transplant lymphoproliferative disorders\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H193827213\">",
"    <span class=\"h3\">",
"     Pulmonary alveolar proteinosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pulmonary alveolar proteinosis (PAP) has been reported as a reversible cause of respiratory failure after allogeneic HCT for acute leukemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/10/40106/abstract/75\">",
"     75",
"    </a>",
"    ]. PAP presents with dyspnea and perihilar opacities in a &ldquo;bat-wing&rdquo; distribution on chest radiograph (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef62269 \" href=\"mobipreview.htm?9/10/9379\">",
"     image 8",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef58662 \" href=\"mobipreview.htm?40/17/41232\">",
"     image 9",
"    </a>",
"    ). The diagnosis is made by bronchoalveolar lavage; the BAL fluid has a characteristic milky appearance and stains positively for lipoproteins. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/62/8168?source=see_link\">",
"     \"Clinical manifestations and etiology of pulmonary alveolar proteinosis in adults\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H88600394\">",
"     'Bronchoscopy'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/6/7274?source=see_link\">",
"     \"Clinical features and diagnosis of the mucopolysaccharidoses\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1305415\">",
"    <span class=\"h3\">",
"     Pulmonary cytolytic thrombi",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pulmonary cytolytic thrombi (PCT) are an unusual complication of allogeneic HCT; PCT is without known etiology, although it may be a manifestation of acute and chronic GVHD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/10/40106/abstract/76,77\">",
"     76,77",
"    </a>",
"    ]. PCT is more common in children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/10/40106/abstract/50,77\">",
"     50,77",
"    </a>",
"    ]. The clinical presentation is fever, cough and dyspnea; conventional chest radiographs are usually clear, but HRCT shows numerous peripheral tiny pulmonary nodules. Peripheral nodular lesions have a broad differential in allogeneic HCT recipients, including aspergillus infection, organizing pneumonia, metastatic malignancy, or idiopathic interstitial pneumonia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/10/40106/abstract/77\">",
"     77",
"    </a>",
"    ]. As these processes require very different treatment, a definitive diagnosis is essential.",
"   </p>",
"   <p>",
"    A surgical lung biopsy is usually necessary to make the diagnosis of PCT and is performed after the usual blood and BAL studies to exclude infection fail to identify an infection. The histopathology of PCT reveals basophilic cytolytic thrombi in the small to medium distal pulmonary vessels with entrapped monocytes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/10/40106/abstract/78\">",
"     78",
"    </a>",
"    ]. Hemorrhagic infarcts are present, similar to those seen in invasive aspergillus infection, but stains and cultures for aspergillus are negative.",
"   </p>",
"   <p>",
"    The optimal treatment for PCT is not known, although systemic glucocorticoid therapy has been associated with successful outcomes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/10/40106/abstract/77,79\">",
"     77,79",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H193827220\">",
"    <span class=\"h3\">",
"     Pulmonary veno-occlusive disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pulmonary veno-occlusive disease (PVOD) occurs rarely after allogeneic HCT and may be a consequence of pre-transplant chemotherapy for the underlying malignancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/10/40106/abstract/80\">",
"     80",
"    </a>",
"    ]. It generally occurs late in the course, after the first 100 days, and should be suspected in patients with dyspnea, reduced diffusing capacity (DLCO), mild restriction on pulmonary function tests, and no evidence of infection.",
"   </p>",
"   <p>",
"    Chest radiographs often reveal a pleural effusion and Kerley B lines may be noted. Computed tomography (CT) may reveal septal thickening, diffuse or mosaic ground glass opacities with a centrilobular distribution, multiple small nodules, or alveolar consolidation. CT pulmonary angiography shows no evidence of pulmonary emboli. Doppler echocardiography shows pulmonary hypertension. Right-sided heart catheterization is necessary to document the combination of pulmonary hypertension and a normal pulmonary artery occlusion pressure. Occult alveolar hemorrhage may be found on BAL; lung biopsy is required for definitive confirmation of the diagnosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/10/40106/abstract/81\">",
"     81",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The diagnosis and treatment of PVOD are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/44/29385?source=see_link\">",
"     \"Pulmonary veno-occlusive disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H464750531\">",
"    <span class=\"h3\">",
"     Drug toxicity and radiation pneumonitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Allogeneic HCT recipients are at risk for lung toxicity due to the chemotherapeutic agents (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/10/10408?source=see_link\">",
"     busulfan",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/39/33399?source=see_link\">",
"     carmustine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    ) and radiation therapy used for preparative conditioning, or for treatment of the underlying disease prior to HCT. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/34/37415?source=see_link\">",
"     \"Busulfan-induced pulmonary injury\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/30/21990?source=see_link\">",
"     \"Cyclophosphamide pulmonary toxicity\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/42/28327?source=see_link\">",
"     \"Nitrosourea-induced pulmonary injury\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/5/9306?source=see_link\">",
"     \"Methotrexate-induced lung injury\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/9/17562?source=see_link&amp;anchor=H24#H24\">",
"     \"Mammalian target of rapamycin (mTOR) inhibitors in renal transplantation\", section on 'Respiratory system'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Acute radiation pneumonitis usually develops four to twelve weeks after irradiation, whereas symptoms of late or fibrotic radiation pneumonitis develop after 6 to 12 months. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/33/24090?source=see_link\">",
"     \"Radiation-induced lung injury\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Both drug toxicity and radiation pneumonitis usually present with dyspnea and a nonproductive cough; fever may also be present. Chest radiographs can show patchy or diffuse opacities with ground glass or consolidative attenuation. The evaluation and treatment of cytotoxic antineoplastic agent and irradiation-induced lung injury are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/30/21990?source=see_link\">",
"     \"Cyclophosphamide pulmonary toxicity\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/34/37415?source=see_link\">",
"     \"Busulfan-induced pulmonary injury\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/5/9306?source=see_link\">",
"     \"Methotrexate-induced lung injury\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/33/24090?source=see_link\">",
"     \"Radiation-induced lung injury\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H464750157\">",
"    <span class=\"h3\">",
"     Airflow obstruction and bronchiolitis obliterans",
"    </span>",
"    &nbsp;&mdash;&nbsp;Airflow obstruction developing after allogeneic HCT may be a consequence of HCT or may be due to bronchiolitis obliterans. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/53/4952?source=see_link\">",
"     \"Overview of pulmonary function testing in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Mild decrements in lung function are frequent following bone marrow transplantation, but are rarely symptomatic; chest radiographs are usually normal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/10/40106/abstract/82-84\">",
"     82-84",
"    </a>",
"    ]. As an example, one study of 52 patients who received allogeneic or autologous bone marrow transplants during childhood found that spirometry, lung volume, and diffusing capacity measurements were within normal limits in only 62 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/10/40106/abstract/85\">",
"     85",
"    </a>",
"    ]. However, none reported chronic respiratory symptoms. In a second study, airflow obstruction was present in 26 percent of patients after allogeneic HCT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/10/40106/abstract/82\">",
"     82",
"    </a>",
"    ]. Risk factors for the development of airflow obstruction included older age, a history of acute or chronic GVHD, and respiratory viral infections in the early post-transplant period. The pathophysiology of this mild airways obstruction is not well understood, but does not appear to be related to airway hyperresponsiveness [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/10/40106/abstract/86-88\">",
"     86-88",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast, moderate to severe airflow obstruction is usually a manifestation of bronchiolitis obliterans, which may be caused by chronic GVHD or certain viral infections. Chronic GVHD is a late (&gt;100 days) complication of allogeneic HCT and is thought to be similar to the bronchiolitis obliterans syndrome that is a manifestation of chronic rejection in lung transplant recipients (",
"    <a class=\"graphic graphic_picture graphicRef53459 graphicRef65164 \" href=\"mobipreview.htm?22/26/22954\">",
"     picture 1A-B",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/10/40106/abstract/89,90\">",
"     89,90",
"    </a>",
"    ]. Initially, patients with bronchiolitis obliterans often have a normal lung examination and a clear chest radiograph. As the disease progresses, the chest CT may show bronchiectasis and a mosaic pattern of ground glass opacities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/10/40106/abstract/91\">",
"     91",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Bronchiolitis obliterans due to chronic GVHD typically responds to glucocorticoids and increased immune suppression. Patients who respond poorly to treatment can progress to hypercapnia and death [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/10/40106/abstract/89,90,92-94\">",
"     89,90,92-94",
"    </a>",
"    ]. The diagnosis and treatment of bronchiolitis obliterans due to viral infection and lung transplant rejection are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/43/24247?source=see_link\">",
"     \"Bronchiolitis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/25/18841?source=see_link\">",
"     \"Chronic lung transplant rejection: Bronchiolitis obliterans\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14112893\">",
"    <span class=\"h1\">",
"     EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial evaluation of pulmonary complications of allogeneic HCT typically includes laboratory testing (eg, complete blood counts, blood cultures, peripheral blood and urine tests for viral, fungal, and imaging studies). Additional testing is based on the timing of symptom onset, acuity of illness, and the appearance of the chest radiograph.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H88600380\">",
"    <span class=\"h2\">",
"     Laboratory testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laboratory testing generally includes assessment of complete blood counts and differential to assess the severity of neutropenia and lymphocytopenia, and also the possibility that anemia is contributing to dyspnea. D-dimer and brain natriuretic peptide levels are sent when thromboembolism or cardiogenic pulmonary edema are suspected.",
"   </p>",
"   <p>",
"    Cytomegalovirus (CMV) pneumonitis is common in the postengraftment phase, so blood is tested for CMV replication (eg, viral load by PCR) in most patients with fever and radiographic opacities after engraftment. Serum assays for aspergillus galactomannan, &beta;-D-glucan, and cryptococcus antigen are obtained as well as urinary legionella antigen. Blood cultures are obtained for bacteria and fungi. A more detailed discussion of the evaluation for infection following HCT is provided separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/30/25066?source=see_link\">",
"     \"Overview of infections following hematopoietic cell transplantation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/52/3913?source=see_link\">",
"     \"Diagnosis of invasive aspergillosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/6/36966?source=see_link&amp;anchor=H7#H7\">",
"     \"Clinical manifestations and diagnosis of candidemia and invasive candidiasis in adults\", section on 'Non-culture methods'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Nasopharyngeal washings or swabs are sent for immunofluorescence antibody or multiplex polymerase chain reaction (PCR) testing for respiratory viruses and culture. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/25/5528?source=see_link&amp;anchor=H1018262449#H1018262449\">",
"     \"Diagnosis of seasonal influenza in adults\", section on 'Laboratory testing'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/38/617?source=see_link&amp;anchor=H14#H14\">",
"     \"Parainfluenza viruses in adults\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H88600387\">",
"    <span class=\"h2\">",
"     Imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;A conventional chest radiograph is obtained in virtually all HCT recipients with fever",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    pulmonary symptoms or signs, as the radiographic appearance can help guide the evaluation of pulmonary complications of HCT (",
"    <a class=\"graphic graphic_table graphicRef83194 \" href=\"mobipreview.htm?1/42/1709\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef83195 \" href=\"mobipreview.htm?16/20/16718\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    In addition, most patients undergo computed tomography (CT), which is more sensitive than a conventional chest radiograph and may identify subtle abnormalities missed on the conventional chest radiograph [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/10/40106/abstract/95\">",
"     95",
"    </a>",
"    ]. Chest CT is also used to characterize the patterns of abnormalities (eg, ground glass versus reticular, nodular versus diffuse) and the exact location. However, the specific radiographic pattern is rarely diagnostic and many of the pulmonary diseases that follow allogeneic HCT can have multiple radiographic appearances.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Diffuse pulmonary opacities ���",
"      </strong>",
"      After allogeneic HCT, diffuse pulmonary opacities can be caused by a broad spectrum of disease processes, including bacterial, viral (eg, CMV, influenza), or fungal (eg, Pneumocystis) infection, the engraftment syndrome, the idiopathic pneumonia syndrome, diffuse alveolar hemorrhage, interstitial pneumonia due to connective tissue disease, and pulmonary alveolar proteinosis (",
"      <a class=\"graphic graphic_table graphicRef83195 \" href=\"mobipreview.htm?16/20/16718\">",
"       table 2",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/10/40106/abstract/50,96\">",
"       50,96",
"      </a>",
"      ]. Many of these disorders are associated with diffuse ground glass opacities, although CMV, Aspergillus, Pneumocystis, organizing pneumonia, and pulmonary cytolytic thrombi can present with small nodular opacities.",
"     </li>",
"     <li>",
"      <strong>",
"       Focal pulmonary opacities &ndash;",
"      </strong>",
"      Focal or lobar opacities in febrile, allogeneic HCT recipients are often caused by bacterial or fungal infection, but can also be caused by pulmonary thromboembolism or organizing pneumonia. Invasive pulmonary fungal infection should be particularly suspected when there are nodular abnormalities on chest radiograph or computed tomograph (CT) scan [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/10/40106/abstract/97\">",
"       97",
"      </a>",
"      ]. Less common causes of focal radiographic opacities include organizing pneumonia, irradiation pneumonitis (localized to a field of treatment), and recurrent lymphoma.",
"     </li>",
"     <li>",
"      <strong>",
"       Clear chest radiograph &ndash;",
"      </strong>",
"      Following allogeneic HCT, the disease processes that cause dyspnea and a clear conventional chest radiograph include anemia, early Pneumocystis pneumonia, thromboembolic disease, cardiac dysfunction, and airways disease such as bronchiolitis obliterans [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/10/40106/abstract/98,99\">",
"       98,99",
"      </a>",
"      ]. Pneumocystis pneumonia and pulmonary veno-occlusive disease may present with a normal chest radiograph, but the chest CT is not normal. Pulmonary thromboembolism can present with a clear chest radiograph, but the presence of hypoxemia",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      or a positive D-dimer should lead to additional imaging studies. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?22/8/22665?source=see_link&amp;anchor=H13#H13\">",
"       \"Epidemiology, clinical manifestations, and diagnosis of Pneumocystis pneumonia in non-HIV-infected patients\", section on 'Radiographic findings'",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H193827220\">",
"       'Pulmonary veno-occlusive disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <strong>",
"       Additional imaging studies",
"      </strong>",
"      &ndash; When pulmonary thromboembolic disease or pulmonary veno-occlusive disease is suspected (eg, due to a positive D-dimer test, a characteristic pulmonary function test or radiographic pattern, or a degree of hypoxemia out of proportion to the radiographic opacities), either a computed tomography pulmonary angiogram (CTPA) or conventional pulmonary angiogram is obtained. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?5/57/6042?source=see_link&amp;anchor=H16#H16\">",
"       \"Diagnosis of acute pulmonary embolism\", section on 'Angiography'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?28/44/29385?source=see_link&amp;anchor=H11#H11\">",
"       \"Pulmonary veno-occlusive disease\", section on 'Radiographic findings'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?5/57/6042?source=see_link\">",
"       \"Diagnosis of acute pulmonary embolism\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14113095\">",
"    <span class=\"h2\">",
"     Pulmonary function testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;The evaluation of dyspnea in stable allogeneic HCT recipients without significant hypoxemia or radiographic opacities usually includes full pulmonary function testing with exercise oximetry",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    arterial blood gas analysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/10/40106/abstract/100\">",
"     100",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/53/4952?source=see_link\">",
"     \"Overview of pulmonary function testing in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/14/7400?source=see_link\">",
"     \"Diffusing capacity for carbon monoxide\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/32/9736?source=see_link\">",
"     \"Pulse oximetry\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The combination of a restrictive pattern with a gas transfer abnormality on pulmonary function testing suggests that interstitial lung disease may be present but too subtle to identify on a conventional chest radiograph. (See",
"    <a class=\"local\" href=\"#H88600387\">",
"     'Imaging'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The findings of normal lung volumes, but a pulse oxygen saturation and diffusing capacity (DLCO) that are lower than expected on the basis of the HRCT findings suggest idiopathic pneumonitis, thromboembolic disease or veno-occlusive disease.",
"   </p>",
"   <p>",
"    An obstructive pattern may be a nonspecific finding following HCT or may be a manifestation of bronchiolitis obliterans. (See",
"    <a class=\"local\" href=\"#H464750157\">",
"     'Airflow obstruction and bronchiolitis obliterans'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14113412\">",
"    <span class=\"h2\">",
"     Echocardiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;An echocardiogram is obtained when cardiac dysfunction is suspected (eg, diffuse opacities consistent with pulmonary edema) or to assess pulmonary artery pressures when pulmonary veno-occlusive disease is suspected. (See",
"    <a class=\"local\" href=\"#H193827220\">",
"     'Pulmonary veno-occlusive disease'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/53/14167?source=see_link\">",
"     \"Transthoracic echocardiography: Normal cardiac anatomy and tomographic views\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/45/7897?source=see_link\">",
"     \"Tissue Doppler echocardiography\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H88600394\">",
"    <span class=\"h2\">",
"     Bronchoscopy",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14112782\">",
"    <span class=\"h3\">",
"     Patients with diffuse pulmonary opacities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bronchoscopy with bronchoalveolar lavage (BAL) and bronchial brushing is usually performed when the patient has diffuse or widespread lung disease based on imaging studies, unless cardiogenic pulmonary edema is strongly suspected. At the time of bronchoscopy, endobronchial brushing samples are obtained to look for the cytologic changes typical of viral infections (eg, inclusion bodies in CMV), in addition to routine cytology.",
"   </p>",
"   <p>",
"    Bronchoalveolar lavage is performed in an area that appears involved based on the radiographic evaluation. To detect alveolar hemorrhage, three sequential lavages (30 to 60 mL aliquots) are obtained to look for progressively more hemorrhagic returns. Samples of BAL fluid and bronchial brushings are sent for immunofluorescence studies (eg, Pneumocystis, parainfluenza, influenza), stains (eg, gram, AFB), culture (eg, bacterial, mycobacterial, viral, fungal), a rapid shell-vial culture for CMV, Aspergillus galactomannan antigen, multiplex polymerase chain reaction (PCR) for respiratory viruses, and cytologic evaluation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/41/25239?source=see_link\">",
"     \"Basic principles and technique of bronchoalveolar lavage\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    With the shell-vial culture technique, the pellet from centrifuged BAL fluid is added to fibroblast monolayers, which are then immunohistochemically stained for expression of immediate-early viral antigens. Direct staining of BAL macrophages with monoclonal antibodies can also give results the same day with both high sensitivity and specificity for CMV pneumonitis.",
"   </p>",
"   <p>",
"    Polymerase chain reaction (PCR) testing of BAL fluid is another highly sensitive technique for identifying CMV, but may not be specific for active disease. However, combining PCR with immunostaining of alveolar cells using monoclonal antibodies to CMV may improve both specificity and positive predictive value (",
"    <a class=\"graphic graphic_picture graphicRef50365 \" href=\"mobipreview.htm?26/26/27048\">",
"     picture 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/10/40106/abstract/101\">",
"     101",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/30/25066?source=see_link\">",
"     \"Overview of infections following hematopoietic cell transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The additional diagnostic value of transbronchial lung biopsy (TBLB) in conjunction with BAL is controversial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/10/40106/abstract/102,103\">",
"     102,103",
"    </a>",
"    ]. We base the decision to obtain a TBLB on how well the patient is tolerating the bronchoscopy, whether they have risk factors for bleeding from a TBLB, and how well they would tolerate iatrogenic pneumothorax. Often, transbronchial biopsy cannot be performed due to thrombocytopenia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14112775\">",
"    <span class=\"h3\">",
"     Focal opacities",
"    </span>",
"    &nbsp;&mdash;&nbsp;For stable patients with focal opacities on lung imaging, bronchoscopic evaluation may be delayed pending the results of noninvasive cultures, laboratory tests, and empiric antibiotics directed at the most likely infection(s) based on the patient&rsquo;s post HCT phase (",
"    <a class=\"graphic graphic_figure graphicRef52716 \" href=\"mobipreview.htm?8/10/8362\">",
"     figure 1",
"    </a>",
"    ). If the initial cultures and other tests are negative and the patient hasn&rsquo;t responded to empiric therapy, bronchoscopy is usually performed to obtain BAL and brushing samples from the affected area for cultures, cytology, and possibly flow cytometry. The studies performed on the BAL fluid and endobronchial brushing samples are described above. (See",
"    <a class=\"local\" href=\"#H14112782\">",
"     'Patients with diffuse pulmonary opacities'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H88600929\">",
"    <span class=\"h2\">",
"     Lung biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;If the above blood, imaging, and bronchoscopic studies do not yield an explanation for diffuse pulmonary opacities and the patient is a surgical candidate, a surgical lung biopsy may be needed to secure a diagnosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/10/40106/abstract/96\">",
"     96",
"    </a>",
"    ]. Lung biopsy may be performed via video-assisted thoracoscopic surgery (VATS) or open thoracotomy. Samples are obtained from an area of disease activity, as determined by computed tomography and sent for histopathologic analysis and bacterial, mycobacterial, fungal, and viral culture. Special stains for mycobacteria and fungi are performed, and also in situ hybridization",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    immunohistochemistry to identify viral pathogens (",
"    <a class=\"graphic graphic_picture graphicRef50365 \" href=\"mobipreview.htm?26/26/27048\">",
"     picture 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/10/40106/abstract/104\">",
"     104",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/26/424?source=see_link&amp;anchor=H5#H5\">",
"     \"Role of lung biopsy in the diagnosis of interstitial lung disease\", section on 'Surgical lung biopsy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In a case series of 35 bone marrow recipients with diffuse pulmonary opacities who underwent open lung biopsy, the most common causes were idiopathic interstitial pneumonia (40 percent), cytomegalovirus pneumonia (20 percent), and organizing pneumonia (14 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/10/40106/abstract/96\">",
"     96",
"    </a>",
"    ]. Drug reactions were diagnosed in 30 percent, some of whom had organizing pneumonia. The idiopathic interstitial pneumonias found in these patients were diffuse alveolar damage (ie, acute interstitial pneumonia) or nonspecific interstitial pneumonia. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/16/22792?source=see_link\">",
"     \"Acute interstitial pneumonia (Hamman-Rich syndrome)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/25/42393?source=see_link\">",
"     \"Nonspecific interstitial pneumonia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For patients with lung toxicity due to chemotherapeutic agents or radiation therapy, biopsy findings are nonspecific and include diffuse alveolar damage, type II alveolar epithelial cell atypia and hyperplasia, interstitial pneumonitis, and thickening of the interstitium with early fibrosis. There is usually minimal acute inflammation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Several aspects of allogeneic hematopoietic cell transplantation (HCT) contribute to the development of pulmonary disease, including previous treatment of the underlying disease, the pretransplant conditioning regimen, engraftment of donor cells, graft-versus-host disease (GVHD), and ongoing immunosuppression. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H2\">",
"       'Overview and definitions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A prompt and thorough diagnostic approach is justified in the evaluation of pulmonary symptoms and signs after allogeneic HCT, because opportunistic infections are common and specific treatments are available. (See",
"      <a class=\"local\" href=\"#H14112523\">",
"       'Approach to the patient with respiratory symptoms or signs'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The pulmonary complications of allogeneic HCT include a broad spectrum of infectious, inflammatory, and neoplastic disorders (",
"      <a class=\"graphic graphic_table graphicRef83194 \" href=\"mobipreview.htm?1/42/1709\">",
"       table 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef83195 \" href=\"mobipreview.htm?16/20/16718\">",
"       table 2",
"      </a>",
"      ). The approach to evaluating these complications begins with considering the timing of onset of the pulmonary disease (eg, before or after engraftment), the appearance of the chest radiograph (eg, clear, focal opacities, diffuse opacities), and certain patient and donor specific features such as CMV serologic status, exposures to animals and endemic fungi, exposure to pneumotoxic drugs and radiation therapy, the underlying disease, and degree of immunosuppression. (See",
"      <a class=\"local\" href=\"#H14112523\">",
"       'Approach to the patient with respiratory symptoms or signs'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H88599790\">",
"       'Causes and clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The initial evaluation of pulmonary complications of allogeneic HCT typically includes laboratory testing (eg, complete blood counts, brain natriuretic protein (BNP), blood cultures, peripheral blood and urine tests for viral, fungal, and Legionella infection) and a chest radiograph. Additional testing is based on the timing of symptom onset, acuity of illness, and the appearance of the chest radiograph. (See",
"      <a class=\"local\" href=\"#H14112893\">",
"       'Evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with focal opacities on lung imaging, the most likely diagnosis is infection, although organizing pneumonia, radiation pneumonitis, and recurrent lymphoma are included in the differential. After noninvasive cultures and laboratory tests are obtained, empiric antibiotics are initiated based on the infections considered likely for that patient&rsquo;s post HCT phase (",
"      <a class=\"graphic graphic_figure graphicRef52716 \" href=\"mobipreview.htm?8/10/8362\">",
"       figure 1",
"      </a>",
"      ). If the initial cultures and other tests are negative and the patient hasn&rsquo;t responded to empiric therapy, bronchoscopy is usually performed to obtain cultures, cytology, and possibly flow cytometry from the affected area. (See",
"      <a class=\"local\" href=\"#H88600394\">",
"       'Bronchoscopy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients who have received cardiotoxic medications as therapy for their underlying disease, cardiac dysfunction can be a cause of dyspnea and diffuse radiographic opacities. Cardiac dysfunction may be suspected in the absence of fever, chills, or night sweats, but it can present concomitantly with infection. The evaluation typically includes measurement of brain natriuretic protein (BNP) and echocardiography. (See",
"      <a class=\"local\" href=\"#H193827060\">",
"       'Pulmonary edema'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For HCT recipients with diffuse radiographic opacities on lung imaging, bronchoscopy with bronchoalveolar lavage (BAL) is usually performed, preferably in an area of radiographic abnormality. Samples are obtained to look for alveolar hemorrhage, to identify potential infectious agents, and for cytologic analysis. Endobronchial brushing is also performed and samples sent for cytologic analysis. The additional diagnostic value of transbronchial biopsy in conjunction with BAL is controversial. (See",
"      <a class=\"local\" href=\"#H88600394\">",
"       'Bronchoscopy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with focal or diffuse radiographic opacities, if the diagnosis remains unclear after the above testing and the patient is not responding to empiric antimicrobial therapy, a surgical lung biopsy may be needed to secure a diagnosis. (See",
"      <a class=\"local\" href=\"#H88600929\">",
"       'Lung biopsy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with dyspnea and normal chest radiographs following allogeneic HCT may have anemia, pulmonary thromboembolic disease, bronchiolitis obliterans, pulmonary veno-occlusive disease, or cardiac dysfunction. Full pulmonary function testing with arterial blood gas analysis or exercise oximetry is helpful in guiding the evaluation. High resolution computed tomography of the chest is more sensitive than the plain chest radiograph and may detect subtle interstitial disease. Echocardiography is often performed to assess for cardiac dysfunction or evidence of pulmonary veno-occlusive disease. (See",
"      <a class=\"local\" href=\"#H464750157\">",
"       'Airflow obstruction and bronchiolitis obliterans'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H193827220\">",
"       'Pulmonary veno-occlusive disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Allogeneic HCT recipients who develop fever and radiographic lung opacities usually require empiric antibiotics, especially in the presence of neutropenia. Empiric antibiotics are chosen based on the patient&rsquo;s the risk for specific infections, the potential sites of infection, the susceptibility patterns at a given institution, and the cost of the various regimens (",
"      <a class=\"graphic graphic_figure graphicRef52716 \" href=\"mobipreview.htm?8/10/8362\">",
"       figure 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H14112523\">",
"       'Approach to the patient with respiratory symptoms or signs'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The treatment of pulmonary complications of allogeneic HCT depends on the specific cause (see appropriate topic reviews). Respiratory failure requiring prolonged mechanical ventilation after allogeneic HCT is generally associated with a very poor prognosis. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?43/35/44598?source=see_link&amp;anchor=H5#H5\">",
"       \"Intensive care for oncology patients: Short-term prognosis\", section on 'Bone marrow transplantation'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/10/40106/abstract/1\">",
"      Yen KT, Lee AS, Krowka MJ, Burger CD. Pulmonary complications in bone marrow transplantation: a practical approach to diagnosis and treatment. Clin Chest Med 2004; 25:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/10/40106/abstract/2\">",
"      Roychowdhury M, Pambuccian SE, Aslan DL, et al. Pulmonary complications after bone marrow transplantation: an autopsy study from a large transplantation center. Arch Pathol Lab Med 2005; 129:366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/10/40106/abstract/3\">",
"      Bhatia S, Francisco L, Carter A, et al. Late mortality after allogeneic hematopoietic cell transplantation and functional status of long-term survivors: report from the Bone Marrow Transplant Survivor Study. Blood 2007; 110:3784.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/10/40106/abstract/4\">",
"      Kotloff RM, Ahya VN, Crawford SW. Pulmonary complications of solid organ and hematopoietic stem cell transplantation. Am J Respir Crit Care Med 2004; 170:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/10/40106/abstract/5\">",
"      Aguilar-Guisado M, Jim&eacute;nez-Jambrina M, Espigado I, et al. Pneumonia in allogeneic stem cell transplantation recipients: a multicenter prospective study. Clin Transplant 2011; 25:E629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/10/40106/abstract/6\">",
"      Dettenkofer M, Wenzler-R&ouml;ttele S, Babikir R, et al. Surveillance of nosocomial sepsis and pneumonia in patients with a bone marrow or peripheral blood stem cell transplant: a multicenter project. Clin Infect Dis 2005; 40:926.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/10/40106/abstract/7\">",
"      Sisson JH, Reed EC, Robbins RA, et al. Impairment of nasal mucociliary clearance during bone marrow transplantation. University of Nebraska Medical Center bone Marrow Transplantation Pulmonary Study Group. Bone Marrow Transplant 1994; 13:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/10/40106/abstract/8\">",
"      Facchini L, Martino R, Ferrari A, et al. Degree of mucositis and duration of neutropenia are the major risk factors for early post-transplant febrile neutropenia and severe bacterial infections after reduced-intensity conditioning. Eur J Haematol 2012; 88:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/10/40106/abstract/9\">",
"      De Neve NY, Benoit DD, Depuydt PO, et al. Aspiration pneumonia: an underestimated cause of severe respiratory failure in patients with haematological malignancies and severe oral mucositis? Acta Clin Belg 2010; 65:416.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/10/40106/abstract/10\">",
"      Franquet T, M&uuml;ller NL, Lee KS, et al. Pulmonary candidiasis after hematopoietic stem cell transplantation: thin-section CT findings. Radiology 2005; 236:332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/10/40106/abstract/11\">",
"      Cost C, Brock E, Adams-Huet B, et al. 2009 pandemic influenza A (H1N1) virus infection in pediatric oncology and hematopoietic stem cell transplantation patients. Pediatr Blood Cancer 2011; 56:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/10/40106/abstract/12\">",
"      Franquet T, M&uuml;ller NL, Lee KS, et al. High-resolution CT and pathologic findings of noninfectious pulmonary complications after hematopoietic stem cell transplantation. AJR Am J Roentgenol 2005; 184:629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/10/40106/abstract/13\">",
"      Capizzi SA, Kumar S, Huneke NE, et al. Peri-engraftment respiratory distress syndrome during autologous hematopoietic stem cell transplantation. Bone Marrow Transplant 2001; 27:1299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/10/40106/abstract/14\">",
"      Mossad S, Kalaycio M, Sobecks R, et al. Steroids prevent engraftment syndrome after autologous hematopoietic stem cell transplantation without increasing the risk of infection. Bone Marrow Transplant 2005; 35:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/10/40106/abstract/15\">",
"      Schmid I, Stachel D, Pagel P, Albert MH. Incidence, predisposing factors, and outcome of engraftment syndrome in pediatric allogeneic stem cell transplant recipients. Biol Blood Marrow Transplant 2008; 14:438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/10/40106/abstract/16\">",
"      Foncillas MA, Diaz MA, Sevilla J, et al. Engraftment syndrome emerges as the main cause of transplant-related mortality in pediatric patients receiving autologous peripheral blood progenitor cell transplantation. J Pediatr Hematol Oncol 2004; 26:492.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/10/40106/abstract/17\">",
"      Dispenzieri A, Lacy MQ, Hayman SR, et al. Peripheral blood stem cell transplant for POEMS syndrome is associated with high rates of engraftment syndrome. Eur J Haematol 2008; 80:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/10/40106/abstract/18\">",
"      Akasheh M, Eastwood D, Vesole DH. Engraftment syndrome after autologous hematopoietic stem cell transplant supported by granulocyte-colony-stimulating factor (G-CSF) versus granulocyte-macrophage colony-stimulating factor (GM-CSF). Bone Marrow Transplant 2003; 31:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/10/40106/abstract/19\">",
"      Nishio N, Yagasaki H, Takahashi Y, et al. Engraftment syndrome following allogeneic hematopoietic stem cell transplantation in children. Pediatr Transplant 2009; 13:831.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/10/40106/abstract/20\">",
"      Spitzer TR. Engraftment syndrome following hematopoietic stem cell transplantation. Bone Marrow Transplant 2001; 27:893.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/10/40106/abstract/21\">",
"      Evans A, Steward CG, Lyburn ID, Grier DJ. Imaging in haematopoietic stem cell transplantation. Clin Radiol 2003; 58:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/10/40106/abstract/22\">",
"      Tanaka N, Kunihiro Y, Yujiri T, et al. High-resolution computed tomography of chest complications in patients treated with hematopoietic stem cell transplantation. Jpn J Radiol 2011; 29:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/10/40106/abstract/23\">",
"      Ravenel JG, Scalzetti EM, Zamkoff KW. Chest radiographic features of engraftment syndrome. J Thorac Imaging 2000; 15:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/10/40106/abstract/24\">",
"      Weinstock DM, Feinstein MB, Sepkowitz KA, Jakubowski A. High rates of infection and colonization by nontuberculous mycobacteria after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2003; 31:1015.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/10/40106/abstract/25\">",
"      Ip MS, Yuen KY, Woo PC, et al. Risk factors for pulmonary tuberculosis in bone marrow transplant recipients. Am J Respir Crit Care Med 1998; 158:1173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/10/40106/abstract/26\">",
"      Kiehn TE, White M, Pursell KJ, et al. A cluster of four cases of Mycobacterium haemophilum infection. Eur J Clin Microbiol Infect Dis 1993; 12:114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/10/40106/abstract/27\">",
"      Kiehn TE, White M. Mycobacterium haemophilum: an emerging pathogen. Eur J Clin Microbiol Infect Dis 1994; 13:925.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/10/40106/abstract/28\">",
"      de Medeiros CR, Moreira VA, Pasquini R. Cytomegalovirus as a cause of very late interstitial pneumonia after bone marrow transplantation. Bone Marrow Transplant 2000; 26:443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/10/40106/abstract/29\">",
"      Abe K, Suzuki K, Kamata N, et al. [High-resolution CT findings in cytomegalovirus pneumonitis after bone marrow transplantation]. Nihon Igaku Hoshasen Gakkai Zasshi 1998; 58:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/10/40106/abstract/30\">",
"      Leung AN, Gosselin MV, Napper CH, et al. Pulmonary infections after bone marrow transplantation: clinical and radiographic findings. Radiology 1999; 210:699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/10/40106/abstract/31\">",
"      Chemaly RF, Ghosh S, Bodey GP, et al. Respiratory viral infections in adults with hematologic malignancies and human stem cell transplantation recipients: a retrospective study at a major cancer center. Medicine (Baltimore) 2006; 85:278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/10/40106/abstract/32\">",
"      Renaud C, Campbell AP. Changing epidemiology of respiratory viral infections in hematopoietic cell transplant recipients and solid organ transplant recipients. Curr Opin Infect Dis 2011; 24:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/10/40106/abstract/33\">",
"      Englund JA, Sullivan CJ, Jordan MC, et al. Respiratory syncytial virus infection in immunocompromised adults. Ann Intern Med 1988; 109:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/10/40106/abstract/34\">",
"      Harrington RD, Hooton TM, Hackman RC, et al. An outbreak of respiratory syncytial virus in a bone marrow transplant center. J Infect Dis 1992; 165:987.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/10/40106/abstract/35\">",
"      La Rosa AM, Champlin RE, Mirza N, et al. Adenovirus infections in adult recipients of blood and marrow transplants. Clin Infect Dis 2001; 32:871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/10/40106/abstract/36\">",
"      Morris DJ, Corbitt G, Bailey AS, et al. Fatal disseminated adenovirus type 2 infection following bone marrow transplantation for Hurler's syndrome: a primary infection. J Infect 1993; 26:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/10/40106/abstract/37\">",
"      Carrigan DR, Drobyski WR, Russler SK, et al. Interstitial pneumonitis associated with human herpesvirus-6 infection after marrow transplantation. Lancet 1991; 338:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/10/40106/abstract/38\">",
"      Cone RW, Hackman RC, Huang ML, et al. Human herpesvirus 6 in lung tissue from patients with pneumonitis after bone marrow transplantation. N Engl J Med 1993; 329:156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/10/40106/abstract/39\">",
"      Buchbinder S, Elmaagacli AH, Schaefer UW, Roggendorf M. Human herpesvirus 6 is an important pathogen in infectious lung disease after allogeneic bone marrow transplantation. Bone Marrow Transplant 2000; 26:639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/10/40106/abstract/40\">",
"      Afessa B, Litzow MR, Tefferi A. Bronchiolitis obliterans and other late onset non-infectious pulmonary complications in hematopoietic stem cell transplantation. Bone Marrow Transplant 2001; 28:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/10/40106/abstract/41\">",
"      Fukuda T, Hackman RC, Guthrie KA, et al. Risks and outcomes of idiopathic pneumonia syndrome after nonmyeloablative and conventional conditioning regimens for allogeneic hematopoietic stem cell transplantation. Blood 2003; 102:2777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/10/40106/abstract/42\">",
"      Crawford SW, Longton G, Storb R. Acute graft-versus-host disease and the risks for idiopathic pneumonia after marrow transplantation for severe aplastic anemia. Bone Marrow Transplant 1993; 12:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/10/40106/abstract/43\">",
"      Crawford SW, Hackman RC. Clinical course of idiopathic pneumonia after bone marrow transplantation. Am Rev Respir Dis 1993; 147:1393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/10/40106/abstract/44\">",
"      Panoskaltsis-Mortari A, Griese M, Madtes DK, et al. An official American Thoracic Society research statement: noninfectious lung injury after hematopoietic stem cell transplantation: idiopathic pneumonia syndrome. Am J Respir Crit Care Med 2011; 183:1262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/10/40106/abstract/45\">",
"      Clark JG, Hansen JA, Hertz MI, et al. NHLBI workshop summary. Idiopathic pneumonia syndrome after bone marrow transplantation. Am Rev Respir Dis 1993; 147:1601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/10/40106/abstract/46\">",
"      Sampath S, Schultheiss TE, Wong J. Dose response and factors related to interstitial pneumonitis after bone marrow transplant. Int J Radiat Oncol Biol Phys 2005; 63:876.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/10/40106/abstract/47\">",
"      Panoskaltsis-Mortari A, Taylor PA, Yaeger TM, et al. The critical early proinflammatory events associated with idiopathic pneumonia syndrome in irradiated murine allogeneic recipients are due to donor T cell infusion and potentiated by cyclophosphamide. J Clin Invest 1997; 100:1015.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/10/40106/abstract/48\">",
"      Cooke KR, Krenger W, Hill G, et al. Host reactive donor T cells are associated with lung injury after experimental allogeneic bone marrow transplantation. Blood 1998; 92:2571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/10/40106/abstract/49\">",
"      Hildebrandt GC, Olkiewicz KM, Corrion LA, et al. Donor-derived TNF-alpha regulates pulmonary chemokine expression and the development of idiopathic pneumonia syndrome after allogeneic bone marrow transplantation. Blood 2004; 104:586.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/10/40106/abstract/50\">",
"      Afessa B, Peters SG. Noninfectious pneumonitis after blood and marrow transplant. Curr Opin Oncol 2008; 20:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/10/40106/abstract/51\">",
"      Yanik GA, Ho VT, Levine JE, et al. The impact of soluble tumor necrosis factor receptor etanercept on the treatment of idiopathic pneumonia syndrome after allogeneic hematopoietic stem cell transplantation. Blood 2008; 112:3073.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/10/40106/abstract/52\">",
"      Keates-Baleeiro J, Moore P, Koyama T, et al. Incidence and outcome of idiopathic pneumonia syndrome in pediatric stem cell transplant recipients. Bone Marrow Transplant 2006; 38:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/10/40106/abstract/53\">",
"      Gonzalez-Vicent M, Diaz MA, Sevilla J, Madero L. Cerebral toxoplasmosis following etanercept treatment for idiophatic pneumonia syndrome after autologous peripheral blood progenitor cell transplantation (PBPCT). Ann Hematol 2003; 82:649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/10/40106/abstract/54\">",
"      Majhail NS, Parks K, Defor TE, Weisdorf DJ. Diffuse alveolar hemorrhage and infection-associated alveolar hemorrhage following hematopoietic stem cell transplantation: related and high-risk clinical syndromes. Biol Blood Marrow Transplant 2006; 12:1038.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/10/40106/abstract/55\">",
"      Kharbanda S, Panoskaltsis-Mortari A, Haddad IY, et al. Inflammatory cytokines and the development of pulmonary complications after allogeneic hematopoietic cell transplantation in patients with inherited metabolic storage disorders. Biol Blood Marrow Transplant 2006; 12:430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/10/40106/abstract/56\">",
"      Agust&iacute; C, Ramirez J, Picado C, et al. Diffuse alveolar hemorrhage in allogeneic bone marrow transplantation. A postmortem study. Am J Respir Crit Care Med 1995; 151:1006.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/10/40106/abstract/57\">",
"      Raptis A, Mavroudis D, Suffredini A, et al. High-dose corticosteroid therapy for diffuse alveolar hemorrhage in allogeneic bone marrow stem cell transplant recipients. Bone Marrow Transplant 1999; 24:879.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/10/40106/abstract/58\">",
"      Ben-Abraham R, Paret G, Cohen R, et al. Diffuse alveolar hemorrhage following allogeneic bone marrow transplantation in children. Chest 2003; 124:660.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/10/40106/abstract/59\">",
"      Wanko SO, Broadwater G, Folz RJ, Chao NJ. Diffuse alveolar hemorrhage: retrospective review of clinical outcome in allogeneic transplant recipients treated with aminocaproic acid. Biol Blood Marrow Transplant 2006; 12:949.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/10/40106/abstract/60\">",
"      Pastores SM, Papadopoulos E, Voigt L, Halpern NA. Diffuse alveolar hemorrhage after allogeneic hematopoietic stem-cell transplantation: treatment with recombinant factor VIIa. Chest 2003; 124:2400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/10/40106/abstract/61\">",
"      Hicks K, Peng D, Gajewski JL. Treatment of diffuse alveolar hemorrhage after allogeneic bone marrow transplant with recombinant factor VIIa. Bone Marrow Transplant 2002; 30:975.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/10/40106/abstract/62\">",
"      Pihusch M, Bacigalupo A, Szer J, et al. Recombinant activated factor VII in treatment of bleeding complications following hematopoietic stem cell transplantation. J Thromb Haemost 2005; 3:1935.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/10/40106/abstract/63\">",
"      Blatt J, Gold SH, Wiley JM, et al. Off-label use of recombinant factor VIIa in patients following bone marrow transplantation. Bone Marrow Transplant 2001; 28:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/10/40106/abstract/64\">",
"      Bergeron A, Bengoufa D, Feuillet S, et al. The spectrum of lung involvement in collagen vascular-like diseases following allogeneic hematopoietic stem cell transplantation: report of 6 cases and review of the literature. Medicine (Baltimore) 2011; 90:146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/10/40106/abstract/65\">",
"      Daniels CE, Myers JL, Utz JP, et al. Organizing pneumonia in patients with hematologic malignancies: a steroid-responsive lesion. Respir Med 2007; 101:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/10/40106/abstract/66\">",
"      Mathew P, Bozeman P, Krance RA, et al. Bronchiolitis obliterans organizing pneumonia (BOOP) in children after allogeneic bone marrow transplantation. Bone Marrow Transplant 1994; 13:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/10/40106/abstract/67\">",
"      Palmas A, Tefferi A, Myers JL, et al. Late-onset noninfectious pulmonary complications after allogeneic bone marrow transplantation. Br J Haematol 1998; 100:680.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/10/40106/abstract/68\">",
"      Jinta M, Ohashi K, Ohta T, et al. Clinical features of allogeneic hematopoietic stem cell transplantation-associated organizing pneumonia. Bone Marrow Transplant 2007; 40:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/10/40106/abstract/69\">",
"      Freudenberger TD, Madtes DK, Curtis JR, et al. Association between acute and chronic graft-versus-host disease and bronchiolitis obliterans organizing pneumonia in recipients of hematopoietic stem cell transplants. Blood 2003; 102:3822.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/10/40106/abstract/70\">",
"      Thirman MJ, Devine SM, O'Toole K, et al. Bronchiolitis obliterans organizing pneumonia as a complication of allogeneic bone marrow transplantation. Bone Marrow Transplant 1992; 10:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/10/40106/abstract/71\">",
"      Micallef IN, Chhanabhai M, Gascoyne RD, et al. Lymphoproliferative disorders following allogeneic bone marrow transplantation: the Vancouver experience. Bone Marrow Transplant 1998; 22:981.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/10/40106/abstract/72\">",
"      Curtis RE, Travis LB, Rowlings PA, et al. Risk of lymphoproliferative disorders after bone marrow transplantation: a multi-institutional study. Blood 1999; 94:2208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/10/40106/abstract/73\">",
"      Scarsbrook AF, Warakaulle DR, Dattani M, Traill Z. Post-transplantation lymphoproliferative disorder: the spectrum of imaging appearances. Clin Radiol 2005; 60:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/10/40106/abstract/74\">",
"      Styczynski J, Einsele H, Gil L, Ljungman P. Outcome of treatment of Epstein-Barr virus-related post-transplant lymphoproliferative disorder in hematopoietic stem cell recipients: a comprehensive review of reported cases. Transpl Infect Dis 2009; 11:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/10/40106/abstract/75\">",
"      Cordonnier C, Fleury-Feith J, Escudier E, et al. Secondary alveolar proteinosis is a reversible cause of respiratory failure in leukemic patients. Am J Respir Crit Care Med 1994; 149:788.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/10/40106/abstract/76\">",
"      Morales IJ, Anderson PM, Tazelaar HD, Wylam ME. Pulmonary cytolytic thrombi: unusual complication of hematopoietic stem cell transplantation. J Pediatr Hematol Oncol 2003; 25:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/10/40106/abstract/77\">",
"      Gulbahce HE, Pambuccian SE, Jessurun J, et al. Pulmonary nodular lesions in bone marrow transplant recipients: impact of histologic diagnosis on patient management and prognosis. Am J Clin Pathol 2004; 121:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/10/40106/abstract/78\">",
"      Peters A, Manivel JC, Dolan M, et al. Pulmonary cytolytic thrombi after allogeneic hematopoietic cell transplantation: a further histologic description. Biol Blood Marrow Transplant 2005; 11:484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/10/40106/abstract/79\">",
"      Woodard JP, Gulbahce E, Shreve M, et al. Pulmonary cytolytic thrombi: a newly recognized complication of stem cell transplantation. Bone Marrow Transplant 2000; 25:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/10/40106/abstract/80\">",
"      Mandel J, Mark EJ, Hales CA. Pulmonary veno-occlusive disease. Am J Respir Crit Care Med 2000; 162:1964.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/10/40106/abstract/81\">",
"      Seguchi M, Hirabayashi N, Fujii Y, et al. Pulmonary hypertension associated with pulmonary occlusive vasculopathy after allogeneic bone marrow transplantation. Transplantation 2000; 69:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/10/40106/abstract/82\">",
"      Chien JW, Martin PJ, Gooley TA, et al. Airflow obstruction after myeloablative allogeneic hematopoietic stem cell transplantation. Am J Respir Crit Care Med 2003; 168:208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/10/40106/abstract/83\">",
"      Clark JG, Crawford SW, Madtes DK, Sullivan KM. Obstructive lung disease after allogeneic marrow transplantation. Clinical presentation and course. Ann Intern Med 1989; 111:368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/10/40106/abstract/84\">",
"      Kaplan EB, Wodell RA, Wilmott RW, et al. Chronic graft-versus-host disease and pulmonary function. Pediatr Pulmonol 1992; 14:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/10/40106/abstract/85\">",
"      Cerveri I, Zoia MC, Fulgoni P, et al. Late pulmonary sequelae after childhood bone marrow transplantation. Thorax 1999; 54:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/10/40106/abstract/86\">",
"      St John RC, Gadek JE, Tutschka PJ, et al. Analysis of airflow obstruction by bronchoalveolar lavage following bone marrow transplantation. Implications for pathogenesis and treatment. Chest 1990; 98:600.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/10/40106/abstract/87\">",
"      Barisione G, Bacigalupo A, Crimi E, et al. Changes in lung volumes and airway responsiveness following haematopoietic stem cell transplantation. Eur Respir J 2008; 32:1576.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/10/40106/abstract/88\">",
"      Barisione G, Bacigalupo A, Crimi E, Brusasco V. Acute bronchodilator responsiveness in bronchiolitis obliterans syndrome following hematopoietic stem cell transplantation. Chest 2011; 139:633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/10/40106/abstract/89\">",
"      Williams KM, Chien JW, Gladwin MT, Pavletic SZ. Bronchiolitis obliterans after allogeneic hematopoietic stem cell transplantation. JAMA 2009; 302:306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/10/40106/abstract/90\">",
"      Bacigalupo A, Chien J, Barisione G, Pavletic S. Late pulmonary complications after allogeneic hematopoietic stem cell transplantation: diagnosis, monitoring, prevention, and treatment. Semin Hematol 2012; 49:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/10/40106/abstract/91\">",
"      Song I, Yi CA, Han J, et al. CT findings of late-onset noninfectious pulmonary complications in patients with pathologically proven graft-versus-host disease after allogeneic stem cell transplant. AJR Am J Roentgenol 2012; 199:581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/10/40106/abstract/92\">",
"      Boas SR, Noyes BE, Kurland G, et al. Pediatric lung transplantation for graft-versus-host disease following bone marrow transplantation. Chest 1994; 105:1584.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/10/40106/abstract/93\">",
"      Rabitsch W, Deviatko E, Keil F, et al. Successful lung transplantation for bronchiolitis obliterans after allogeneic marrow transplantation. Transplantation 2001; 71:1341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/10/40106/abstract/94\">",
"      Pechet TV, de le Morena M, Mendeloff EN, et al. Lung transplantation in children following treatment for malignancy. J Heart Lung Transplant 2003; 22:154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/10/40106/abstract/95\">",
"      Graham NJ, M&uuml;ller NL, Miller RR, Shepherd JD. Intrathoracic complications following allogeneic bone marrow transplantation: CT findings. Radiology 1991; 181:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/10/40106/abstract/96\">",
"      Wang JY, Chang YL, Lee LN, et al. Diffuse pulmonary infiltrates after bone marrow transplantation: the role of open lung biopsy. Ann Thorac Surg 2004; 78:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/10/40106/abstract/97\">",
"      Mori M, Galvin JR, Barloon TJ, et al. Fungal pulmonary infections after bone marrow transplantation: evaluation with radiography and CT. Radiology 1991; 178:721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/10/40106/abstract/98\">",
"      Sharma S, Nadrous HF, Peters SG, et al. Pulmonary complications in adult blood and marrow transplant recipients: autopsy findings. Chest 2005; 128:1385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/10/40106/abstract/99\">",
"      Worthy SA, Flint JD, M&uuml;ller NL. Pulmonary complications after bone marrow transplantation: high-resolution CT and pathologic findings. Radiographics 1997; 17:1359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/10/40106/abstract/100\">",
"      Milburn HJ, Prentice HG, du Bois RM. Can lung function measurements be used to predict which patients will be at risk of developing interstitial pneumonitis after bone marrow transplantation? Thorax 1992; 47:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/10/40106/abstract/101\">",
"      Cathomas G, Morris P, Pekle K, et al. Rapid diagnosis of cytomegalovirus pneumonia in marrow transplant recipients by bronchoalveolar lavage using the polymerase chain reaction, virus culture, and the direct immunostaining of alveolar cells. Blood 1993; 81:1909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/10/40106/abstract/102\">",
"      Patel NR, Lee PS, Kim JH, et al. The influence of diagnostic bronchoscopy on clinical outcomes comparing adult autologous and allogeneic bone marrow transplant patients. Chest 2005; 127:1388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/10/40106/abstract/103\">",
"      Jain P, Sandur S, Meli Y, et al. Role of flexible bronchoscopy in immunocompromised patients with lung infiltrates. Chest 2004; 125:712.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/10/40106/abstract/104\">",
"      Barber&agrave; JA, Mart&iacute;n-Campos JM, Ribalta T, et al. Undetected viral infection in diffuse alveolar damage associated with bone marrow transplantation. Eur Respir J 1996; 9:1195.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4339 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-115.66.252.144-FC8D04C3D0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_10_40106=[""].join("\n");
var outline_f39_10_40106=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H21\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      OVERVIEW AND DEFINITIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H895198\">",
"      Allogeneic versus autologous HCT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H895213\">",
"      Preparative conditioning regimen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H895392\">",
"      Engraftment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H895268\">",
"      Maintenance immunosuppression",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1426020\">",
"      Graft-versus-host disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14112523\">",
"      APPROACH TO THE PATIENT WITH RESPIRATORY SYMPTOMS OR SIGNS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H88599790\">",
"      CAUSES AND CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H88599890\">",
"      Preengraftment period",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H193827185\">",
"      - Pulmonary infections",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H193827060\">",
"      - Pulmonary edema",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6458592\">",
"      - Engraftment syndrome",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H193827192\">",
"      - Hyperacute and acute graft-versus-host disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H88599909\">",
"      Post hematopoietic cell engraftment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H194946070\">",
"      - Pulmonary infections",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Idiopathic pneumonia syndrome",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Diffuse alveolar hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6014419\">",
"      - Connective tissue disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H193827199\">",
"      - Organizing pneumonia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H193827206\">",
"      - Malignancy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H193827213\">",
"      - Pulmonary alveolar proteinosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1305415\">",
"      - Pulmonary cytolytic thrombi",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H193827220\">",
"      - Pulmonary veno-occlusive disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H464750531\">",
"      - Drug toxicity and radiation pneumonitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H464750157\">",
"      - Airflow obstruction and bronchiolitis obliterans",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14112893\">",
"      EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H88600380\">",
"      Laboratory testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H88600387\">",
"      Imaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14113095\">",
"      Pulmonary function testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14113412\">",
"      Echocardiography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H88600394\">",
"      Bronchoscopy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14112782\">",
"      - Patients with diffuse pulmonary opacities",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14112775\">",
"      - Focal opacities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H88600929\">",
"      Lung biopsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/4339\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/4339|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?41/33/42515\" title=\"diagnostic image 1\">",
"      Aspergillus bronchiolitis and bronchopneumonia HRCT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?41/47/42738\" title=\"diagnostic image 2\">",
"      CT pulmonary aspergillosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?5/36/5701\" title=\"diagnostic image 3\">",
"      Pulmonary edema PA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?12/24/12679\" title=\"diagnostic image 4\">",
"      CMV pneumonia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?9/38/9830\" title=\"diagnostic image 5\">",
"      Parainfluenza pneumonia chest CT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?23/18/23845\" title=\"diagnostic image 6\">",
"      Diffuse alveolar hemorrhage PA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?10/7/10353\" title=\"diagnostic image 7\">",
"      DAH CT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?9/10/9379\" title=\"diagnostic image 8\">",
"      Alveolar proteinosis chest xray",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?40/17/41232\" title=\"diagnostic image 9\">",
"      Alveolar proteinosis CT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/4339|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?8/10/8362\" title=\"figure 1\">",
"      Infections after allogeneic HCT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/4339|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?3/49/3863\" title=\"picture 1A\">",
"      Oblit bronchiolitis BMT I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?3/42/3751\" title=\"picture 1B\">",
"      Oblit bronchiolitis BMT II",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?26/26/27048\" title=\"picture 2\">",
"      CMV pneumonitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/4339|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?1/42/1709\" title=\"table 1\">",
"      Pulmonary complications of allogeneic HCT - Preengraftment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/20/16718\" title=\"table 2\">",
"      Pulmonary complications of allogeneic HCT - Postengraftment",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/16/22792?source=related_link\">",
"      Acute interstitial pneumonia (Hamman-Rich syndrome)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/51/25402?source=related_link\">",
"      Approach to the immunocompromised patient with fever and pulmonary infiltrates",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/47/31482?source=related_link\">",
"      Autologous hematopoietic cell transplantation in multiple myeloma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/41/25239?source=related_link\">",
"      Basic principles and technique of bronchoalveolar lavage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/43/44729?source=related_link\">",
"      Biology of the graft-versus-tumor effect following hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/43/24247?source=related_link\">",
"      Bronchiolitis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/34/37415?source=related_link\">",
"      Busulfan-induced pulmonary injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/46/41706?source=related_link\">",
"      Cardiotoxicity of anthracycline-like chemotherapy agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/12/40138?source=related_link\">",
"      Cardiotoxicity of nonanthracycline cancer chemotherapy agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/25/18841?source=related_link\">",
"      Chronic lung transplant rejection: Bronchiolitis obliterans",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/6/7274?source=related_link\">",
"      Clinical features and diagnosis of the mucopolysaccharidoses",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/29/10712?source=related_link\">",
"      Clinical manifestations and diagnosis of Fusarium infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/6/36966?source=related_link\">",
"      Clinical manifestations and diagnosis of candidemia and invasive candidiasis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/62/8168?source=related_link\">",
"      Clinical manifestations and etiology of pulmonary alveolar proteinosis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/22/25960?source=related_link\">",
"      Clinical manifestations, diagnosis, and grading of acute graft-versus-host disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/25/23962?source=related_link\">",
"      Clinical manifestations, diagnosis, and grading of chronic graft-versus-host disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/1/10265?source=related_link\">",
"      Clinical manifestations, diagnosis, and treatment of human herpesvirus-6 infection in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/60/19402?source=related_link\">",
"      Cryptogenic organizing pneumonia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/5/42073?source=related_link\">",
"      Cutaneous manifestations of graft-versus-host disease (GVHD)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/30/21990?source=related_link\">",
"      Cyclophosphamide pulmonary toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/50/22314?source=related_link\">",
"      Determining eligibility for allogeneic hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/50/19241?source=related_link\">",
"      Determining eligibility for autologous hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/40/37513?source=related_link\">",
"      Diagnosis and treatment of adenovirus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/57/6042?source=related_link\">",
"      Diagnosis of acute pulmonary embolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/25/8597?source=related_link\">",
"      Diagnosis of cytomegalovirus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/52/3913?source=related_link\">",
"      Diagnosis of invasive aspergillosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/25/5528?source=related_link\">",
"      Diagnosis of seasonal influenza in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/6/19559?source=related_link\">",
"      Diagnostic assays for toxoplasmosis infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/14/7400?source=related_link\">",
"      Diffusing capacity for carbon monoxide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/21/39257?source=related_link\">",
"      Epidemiology and clinical manifestations of adenovirus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/51/34616?source=related_link\">",
"      Epidemiology and clinical manifestations of invasive aspergillosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/8/22665?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of Pneumocystis pneumonia in non-HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/23/7544?source=related_link\">",
"      Evaluation of acute decompensated heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/33/33304?source=related_link\">",
"      Human metapneumovirus infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/35/44598?source=related_link\">",
"      Intensive care for oncology patients: Short-term prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/25/409?source=related_link\">",
"      Lymphoid interstitial pneumonia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/9/17562?source=related_link\">",
"      Mammalian target of rapamycin (mTOR) inhibitors in renal transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/5/9306?source=related_link\">",
"      Methotrexate-induced lung injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/42/28327?source=related_link\">",
"      Nitrosourea-induced pulmonary injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/57/1944?source=related_link\">",
"      Noncardiogenic pulmonary edema",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/25/42393?source=related_link\">",
"      Nonspecific interstitial pneumonia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/30/25066?source=related_link\">",
"      Overview of infections following hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/53/4952?source=related_link\">",
"      Overview of pulmonary function testing in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/38/617?source=related_link\">",
"      Parainfluenza viruses in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/4/40009?source=related_link\">",
"      Pathogenesis and clinical features of hepatic sinusoidal obstruction syndrome (veno-occlusive disease) following hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/34/25130?source=related_link\">",
"      Preparative regimens for hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/11/10425?source=related_link\">",
"      Prevention and treatment of acute graft-versus-host disease: Recommendations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/13/24792?source=related_link\">",
"      Prevention of acute graft-versus-host disease: Trials of T cell depletion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/25/14745?source=related_link\">",
"      Pulmonary complications after autologous hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/41/17050?source=related_link\">",
"      Pulmonary toxicity associated with antineoplastic therapy: Cytotoxic agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/42/13993?source=related_link\">",
"      Pulmonary toxicity associated with systemic antineoplastic therapy: Clinical presentation, diagnosis, and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/44/29385?source=related_link\">",
"      Pulmonary veno-occlusive disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/32/9736?source=related_link\">",
"      Pulse oximetry",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/33/24090?source=related_link\">",
"      Radiation-induced lung injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/56/7050?source=related_link\">",
"      Respiratory syncytial virus infection: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/27/38327?source=related_link\">",
"      Respiratory syncytial virus infection: Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/26/424?source=related_link\">",
"      Role of lung biopsy in the diagnosis of interstitial lung disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/49/38682?source=related_link\">",
"      Sources of hematopoietic stem cells",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/39/29306?source=related_link\">",
"      Supportive care after hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/61/23512?source=related_link\">",
"      The diffuse alveolar hemorrhage syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/45/7897?source=related_link\">",
"      Tissue Doppler echocardiography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/22/33129?source=related_link\">",
"      Toxoplasmosis in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/53/14167?source=related_link\">",
"      Transthoracic echocardiography: Normal cardiac anatomy and tomographic views",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/4/9289?source=related_link\">",
"      Treatment and prevention of Pneumocystis pneumonia in non-HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/50/23338?source=related_link\">",
"      Treatment and prevention of post-transplant lymphoproliferative disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/24/2441?source=related_link\">",
"      Treatment of nontuberculous mycobacterial infections of the lung in HIV-negative patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/21/19802?source=related_link\">",
"      Treatment of pulmonary tuberculosis in HIV-negative patients",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f39_10_40107="Foods causing Salmonellosis";
var content_f39_10_40107=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F75035&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F75035&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    A short list of foods associated with salmonella outbreaks",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Salmonella serotype",
"       </td>",
"       <td class=\"subtitle1\">",
"        Food",
"       </td>",
"       <td class=\"subtitle1\">",
"        Cases",
"       </td>",
"       <td class=\"subtitle1\">",
"        Year",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Salmonella bareilly",
"       </td>",
"       <td>",
"        Ground tuna",
"       </td>",
"       <td>",
"        258 to date",
"       </td>",
"       <td>",
"        2012",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Salmonella agona",
"       </td>",
"       <td>",
"        Papayas",
"       </td>",
"       <td>",
"        106",
"       </td>",
"       <td>",
"        2011",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Salmonella typhimurium",
"       </td>",
"       <td>",
"        Peanut butter",
"       </td>",
"       <td>",
"        529",
"       </td>",
"       <td>",
"        2008",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Salmonella newport",
"       </td>",
"       <td>",
"        Mangoes",
"       </td>",
"       <td>",
"        78",
"       </td>",
"       <td>",
"        1999",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Salmonella muenchen",
"       </td>",
"       <td>",
"        Orange juice",
"       </td>",
"       <td>",
"        207",
"       </td>",
"       <td>",
"        1999",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Salmonella agona",
"       </td>",
"       <td>",
"        Dry cereal",
"       </td>",
"       <td>",
"        209",
"       </td>",
"       <td>",
"        1998",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Salmonella newport",
"       </td>",
"       <td>",
"        Sprouts",
"       </td>",
"       <td>",
"        135",
"       </td>",
"       <td>",
"        1996",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Salmonella poona",
"       </td>",
"       <td>",
"        Cantaloupes",
"       </td>",
"       <td>",
"        &gt;400",
"       </td>",
"       <td>",
"        1991",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_10_40107=[""].join("\n");
var outline_f39_10_40107=null;
var title_f39_10_40108="Selection of appropriate bronchoscopic diagnostic procedures";
var content_f39_10_40108=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F50508&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F50508&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Selection of appropriate bronchoscopic diagnostic procedures",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Brushing",
"       </td>",
"       <td class=\"subtitle1\">",
"        Broncho-alveolar lavage (BAL)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Washing",
"       </td>",
"       <td class=\"subtitle1\">",
"        Endobronchial biopsy (EBB)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Transbronchial biopsy (TBB)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Endobronchial needle aspiration (EBNA)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Transbronchial needle aspiration (TBNA)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Additional guidance",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Endoluminal lesion",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +++",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        +++",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        AFB or NBI if lesion is not distinct on routine examination",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Paratracheal mass, mediastinal or hilar lymphadenopathy",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        +++",
"       </td>",
"       <td>",
"        EBUS (radial or linear probe)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Peripheral lung mass or nodule",
"       </td>",
"       <td>",
"        +/-",
"       </td>",
"       <td>",
"        +/-",
"       </td>",
"       <td>",
"        +/-",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        ENB, EBUS (radial probe), XFL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Peripheral pulmonary infiltrate (localized)",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        ++",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        ++",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        +/-",
"       </td>",
"       <td>",
"        ENB or XFL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Diffuse pulmonary infiltrate",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +++",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        ++",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Cytological and microbiological specimens can be collected with all of the above procedures. Histological specimens can only be collected with endobronchial biopsy, transbronchial biopsy, or a needle core. If bronchoscopic procedure is not likely to yield diagnosis or is non-diagnostic, computed tomography (CT)-guided needle aspiration, mediastinoscopy, video-assisted thoracoscopic surgery (VATS), or thoracotomy may be indicated depending upon the location or size of the lesion or mass.",
"    <div class=\"footnotes\">",
"     -: unlikely to provide diagnostic information; +/-: uncertain diagnostic value; +: may provide diagnostic information; ++: more likely to provide diagnostic information; +++: most likely to provide diagnostic information; AFB: autofluorescence bronchoscopy; NBI: narrow band imaging; EBUS: endobronchial ultrasound; ENB: electromagnetic navigational bronchoscopy; XFL: x-ray fluoroscopy.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_10_40108=[""].join("\n");
var outline_f39_10_40108=null;
var title_f39_10_40109="LV filling pattern mortality MI";
var content_f39_10_40109=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F63794&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F63794&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    The effect of LV filling patterns on survival",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 386px; height: 306px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Among patients with a first myocardial infarction, mortality was significantly higher in patients with impaired relaxation (p = 0.02), pseudonormal filling (p &lt;0.00005) or restrictive filling (p &lt;0.00005) than in patients with a normal filling pattern. With a Cox analysis, a pseudonormal and restrictive filling pattern were independent predictors of mortality.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Moller JE, Sondergaard E, Poulsen SH, Egstrup K. J Am Coll Cardiol 2000; 36:1841.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_10_40109=[""].join("\n");
var outline_f39_10_40109=null;
var title_f39_10_40110="Heliox ventilator calibration";
var content_f39_10_40110=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F77384%7EPULM%2F74753&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=8\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F77384%7EPULM%2F74753&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=8\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Correction factors for inspiratory and expiratory volumes during use of Heliox",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        FiO",
"        <sub>",
"         2",
"        </sub>",
"        set",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        Veolar FT",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        Galileo",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        Servo 900C",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        Servo 300",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        VFi",
"       </td>",
"       <td class=\"subtitle2\">",
"        VFe",
"       </td>",
"       <td class=\"subtitle2\">",
"        VFi",
"       </td>",
"       <td class=\"subtitle2\">",
"        VFe",
"       </td>",
"       <td class=\"subtitle2\">",
"        VFi",
"       </td>",
"       <td class=\"subtitle2\">",
"        VFe",
"       </td>",
"       <td class=\"subtitle2\">",
"        VFi",
"       </td>",
"       <td class=\"subtitle2\">",
"        VFe",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        0.21",
"       </td>",
"       <td>",
"        1.68",
"       </td>",
"       <td>",
"        1.70",
"       </td>",
"       <td>",
"        1.68",
"       </td>",
"       <td>",
"        1.70",
"       </td>",
"       <td>",
"        1.38",
"       </td>",
"       <td>",
"        1.34",
"       </td>",
"       <td>",
"        1.00",
"       </td>",
"       <td>",
"        1.34",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        0.25",
"       </td>",
"       <td>",
"        1.60",
"       </td>",
"       <td>",
"        1.60",
"       </td>",
"       <td>",
"        1.60",
"       </td>",
"       <td>",
"        1.60",
"       </td>",
"       <td>",
"        1.36",
"       </td>",
"       <td>",
"        1.34",
"       </td>",
"       <td>",
"        1.00",
"       </td>",
"       <td>",
"        1.34",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        0.30",
"       </td>",
"       <td>",
"        1.51",
"       </td>",
"       <td>",
"        1.50",
"       </td>",
"       <td>",
"        1.51",
"       </td>",
"       <td>",
"        1.50",
"       </td>",
"       <td>",
"        1.35",
"       </td>",
"       <td>",
"        1.33",
"       </td>",
"       <td>",
"        1.00",
"       </td>",
"       <td>",
"        1.33",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        0.35",
"       </td>",
"       <td>",
"        1.44",
"       </td>",
"       <td>",
"        1.47",
"       </td>",
"       <td>",
"        1.44",
"       </td>",
"       <td>",
"        1.47",
"       </td>",
"       <td>",
"        1.33",
"       </td>",
"       <td>",
"        1.23",
"       </td>",
"       <td>",
"        1.00",
"       </td>",
"       <td>",
"        1.33",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        0.40",
"       </td>",
"       <td>",
"        1.37",
"       </td>",
"       <td>",
"        1.40",
"       </td>",
"       <td>",
"        1.37",
"       </td>",
"       <td>",
"        1.40",
"       </td>",
"       <td>",
"        1.31",
"       </td>",
"       <td>",
"        1.22",
"       </td>",
"       <td>",
"        1.00",
"       </td>",
"       <td>",
"        1.22",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        0.45",
"       </td>",
"       <td>",
"        1.31",
"       </td>",
"       <td>",
"        1.33",
"       </td>",
"       <td>",
"        1.31",
"       </td>",
"       <td>",
"        1.33",
"       </td>",
"       <td>",
"        1.29",
"       </td>",
"       <td>",
"        1.20",
"       </td>",
"       <td>",
"        1.00",
"       </td>",
"       <td>",
"        1.20",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        0.50",
"       </td>",
"       <td>",
"        1.28",
"       </td>",
"       <td>",
"        1.30",
"       </td>",
"       <td>",
"        1.28",
"       </td>",
"       <td>",
"        1.30",
"       </td>",
"       <td>",
"        1.26",
"       </td>",
"       <td>",
"        1.17",
"       </td>",
"       <td>",
"        1.00",
"       </td>",
"       <td>",
"        1.17",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        0.60",
"       </td>",
"       <td>",
"        1.20",
"       </td>",
"       <td>",
"        1.26",
"       </td>",
"       <td>",
"        1.20",
"       </td>",
"       <td>",
"        1.26",
"       </td>",
"       <td>",
"        1.24",
"       </td>",
"       <td>",
"        1.13",
"       </td>",
"       <td>",
"        1.00",
"       </td>",
"       <td>",
"        1.13",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1.00",
"       </td>",
"       <td>",
"        0.97",
"       </td>",
"       <td>",
"        1.01",
"       </td>",
"       <td>",
"        0.97",
"       </td>",
"       <td>",
"        1.01",
"       </td>",
"       <td>",
"        0.97",
"       </td>",
"       <td>",
"        1.09",
"       </td>",
"       <td>",
"        0.99",
"       </td>",
"       <td>",
"        1.09",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        FiO",
"        <sub>",
"         2",
"        </sub>",
"        set",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        Evita 2",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        Evita 4",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"4\">",
"        7200 series",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        VFi",
"       </td>",
"       <td class=\"subtitle2\">",
"        VFe",
"       </td>",
"       <td class=\"subtitle2\">",
"        VFi",
"       </td>",
"       <td class=\"subtitle2\">",
"        VFe",
"       </td>",
"       <td class=\"subtitle2\" colspan=\"2\">",
"        VFi",
"       </td>",
"       <td class=\"subtitle2\" colspan=\"2\">",
"        VFe",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        0.21",
"       </td>",
"       <td>",
"        1.83",
"       </td>",
"       <td>",
"        Inop",
"       </td>",
"       <td>",
"        NL",
"       </td>",
"       <td>",
"        Inop",
"       </td>",
"       <td colspan=\"2\">",
"        0.10",
"       </td>",
"       <td colspan=\"2\">",
"        Inop",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        0.25",
"       </td>",
"       <td>",
"        1.75",
"       </td>",
"       <td>",
"        Inop",
"       </td>",
"       <td>",
"        NL",
"       </td>",
"       <td>",
"        Inop",
"       </td>",
"       <td colspan=\"2\">",
"        0.14",
"       </td>",
"       <td colspan=\"2\">",
"        Inop",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        0.30",
"       </td>",
"       <td>",
"        1.73",
"       </td>",
"       <td>",
"        Inop",
"       </td>",
"       <td>",
"        NL",
"       </td>",
"       <td>",
"        Inop",
"       </td>",
"       <td colspan=\"2\">",
"        0.19",
"       </td>",
"       <td colspan=\"2\">",
"        Inop",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        0.35",
"       </td>",
"       <td>",
"        1.66",
"       </td>",
"       <td>",
"        Inop",
"       </td>",
"       <td>",
"        NL",
"       </td>",
"       <td>",
"        Inop",
"       </td>",
"       <td colspan=\"2\">",
"        0.25",
"       </td>",
"       <td colspan=\"2\">",
"        Inop",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        0.40",
"       </td>",
"       <td>",
"        1.60",
"       </td>",
"       <td>",
"        Inop",
"       </td>",
"       <td>",
"        NL",
"       </td>",
"       <td>",
"        Inop",
"       </td>",
"       <td colspan=\"2\">",
"        0.30",
"       </td>",
"       <td colspan=\"2\">",
"        Inop",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        0.45",
"       </td>",
"       <td>",
"        1.55",
"       </td>",
"       <td>",
"        Inop",
"       </td>",
"       <td>",
"        NL",
"       </td>",
"       <td>",
"        Inop",
"       </td>",
"       <td colspan=\"2\">",
"        0.35",
"       </td>",
"       <td colspan=\"2\">",
"        Inop",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        0.50",
"       </td>",
"       <td>",
"        1.48",
"       </td>",
"       <td>",
"        Inop",
"       </td>",
"       <td>",
"        NL",
"       </td>",
"       <td>",
"        Inop",
"       </td>",
"       <td colspan=\"2\">",
"        0.40",
"       </td>",
"       <td colspan=\"2\">",
"        Inop",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        0.60",
"       </td>",
"       <td>",
"        1.40",
"       </td>",
"       <td>",
"        Inop",
"       </td>",
"       <td>",
"        NL",
"       </td>",
"       <td>",
"        Inop",
"       </td>",
"       <td colspan=\"2\">",
"        0.50",
"       </td>",
"       <td colspan=\"2\">",
"        Inop",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1.00",
"       </td>",
"       <td>",
"        0.986",
"       </td>",
"       <td>",
"        1.093",
"       </td>",
"       <td>",
"        0.99",
"       </td>",
"       <td>",
"        1.093",
"       </td>",
"       <td colspan=\"2\">",
"        1.05",
"       </td>",
"       <td colspan=\"2\">",
"        1.05",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     Inop: inoperative; NL: nonlinear relationship; VFe: expiratory volume correction factor (VTe = VTe meas x VFe); VFi: inspiratory volume correction factor (VTdel = VTset x VFi).",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Tassaux D, Jolliet P, Thouret J, et al. Calibration of seven ICU ventilators for mechanical ventilation with helium-oxygen mixtures. Am J Respir Crit Care Med 1999; 160:22. Copyright &copy;1999 American Lung Association.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Delivered FIO2 during Heliox utilization",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        FIO",
"        <sub>",
"         2",
"        </sub>",
"        set",
"       </td>",
"       <td class=\"subtitle1\">",
"        Veolar FT",
"       </td>",
"       <td class=\"subtitle1\">",
"        Galileo",
"       </td>",
"       <td class=\"subtitle1\">",
"        Evita 2",
"       </td>",
"       <td class=\"subtitle1\">",
"        Evita 4",
"       </td>",
"       <td class=\"subtitle1\">",
"        Servo 900C",
"       </td>",
"       <td class=\"subtitle1\">",
"        Servo 300",
"       </td>",
"       <td class=\"subtitle1\">",
"        7200 series",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        0.21",
"       </td>",
"       <td>",
"        0.22",
"       </td>",
"       <td>",
"        0.22",
"       </td>",
"       <td>",
"        0.22",
"       </td>",
"       <td>",
"        0.22",
"       </td>",
"       <td>",
"        0.22",
"       </td>",
"       <td>",
"        0.22",
"       </td>",
"       <td>",
"        0.22",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        0.25",
"       </td>",
"       <td>",
"        0.25",
"       </td>",
"       <td>",
"        0.25",
"       </td>",
"       <td>",
"        0.24",
"       </td>",
"       <td>",
"        0.24",
"       </td>",
"       <td>",
"        0.25",
"       </td>",
"       <td>",
"        0.26",
"       </td>",
"       <td>",
"        0.56",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        0.3",
"       </td>",
"       <td>",
"        0.31",
"       </td>",
"       <td>",
"        0.31",
"       </td>",
"       <td>",
"        0.28",
"       </td>",
"       <td>",
"        0.27",
"       </td>",
"       <td>",
"        0.33",
"       </td>",
"       <td>",
"        0.33",
"       </td>",
"       <td>",
"        0.73",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        0.35",
"       </td>",
"       <td>",
"        0.37",
"       </td>",
"       <td>",
"        0.35",
"       </td>",
"       <td>",
"        0.31",
"       </td>",
"       <td>",
"        0.3",
"       </td>",
"       <td>",
"        0.35",
"       </td>",
"       <td>",
"        0.38",
"       </td>",
"       <td>",
"        0.83",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        04",
"       </td>",
"       <td>",
"        0.4",
"       </td>",
"       <td>",
"        0.41",
"       </td>",
"       <td>",
"        0.35",
"       </td>",
"       <td>",
"        0.34",
"       </td>",
"       <td>",
"        0.46",
"       </td>",
"       <td>",
"        0.43",
"       </td>",
"       <td>",
"        0.88",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        0.5",
"       </td>",
"       <td>",
"        0.51",
"       </td>",
"       <td>",
"        0.5",
"       </td>",
"       <td>",
"        0.42",
"       </td>",
"       <td>",
"        0.41",
"       </td>",
"       <td>",
"        0.51",
"       </td>",
"       <td>",
"        0.52",
"       </td>",
"       <td>",
"        0.95",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        0.6",
"       </td>",
"       <td>",
"        0.61",
"       </td>",
"       <td>",
"        0.6",
"       </td>",
"       <td>",
"        0.52",
"       </td>",
"       <td>",
"        0.5",
"       </td>",
"       <td>",
"        0.62",
"       </td>",
"       <td>",
"        0.63",
"       </td>",
"       <td>",
"        0.99",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1.0",
"       </td>",
"       <td>",
"        0.98",
"       </td>",
"       <td>",
"        1.0",
"       </td>",
"       <td>",
"        0.98",
"       </td>",
"       <td>",
"        0.97",
"       </td>",
"       <td>",
"        0.99",
"       </td>",
"       <td>",
"        0.99",
"       </td>",
"       <td>",
"        1.0",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Tassaux D, Jolliet P, Thouret J, et al. Calibration of seven ICU ventilators for mechanical ventilation with helium-oxygen mixtures. Am J Respir Crit Care Med 1999; 160:22. Copyright &copy;1999 American Lung Association.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_10_40110=[""].join("\n");
var outline_f39_10_40110=null;
var title_f39_10_40111="Adrenal mass CT";
var content_f39_10_40111=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F82224&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F82224&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Adrenal mass in disseminated histoplasmosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 307px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Adrenal CT shows a markedly enlarged left adrenal gland. This patient had disseminated histoplasmosis with involvement of the lungs, liver, and bone marrow, and had a painful tongue ulcer that on biopsy showed H. capsulatum on methenamine silver stain.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Carol A Kauffman, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_10_40111=[""].join("\n");
var outline_f39_10_40111=null;
